Skip to content


BMC Medical Genomics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

BMC Medical Genomics20092:2

Received: 02 September 2008

Accepted: 08 January 2009

Published: 08 January 2009



The production of peroxide and superoxide is an inevitable consequence of aerobic metabolism, and while these particular 'reactive oxygen species' (ROSs) can exhibit a number of biological effects, they are not of themselves excessively reactive and thus they are not especially damaging at physiological concentrations. However, their reactions with poorly liganded iron species can lead to the catalytic production of the very reactive and dangerous hydroxyl radical, which is exceptionally damaging, and a major cause of chronic inflammation.


We review the considerable and wide-ranging evidence for the involvement of this combination of (su)peroxide and poorly liganded iron in a large number of physiological and indeed pathological processes and inflammatory disorders, especially those involving the progressive degradation of cellular and organismal performance. These diseases share a great many similarities and thus might be considered to have a common cause (i.e. iron-catalysed free radical and especially hydroxyl radical generation).

The studies reviewed include those focused on a series of cardiovascular, metabolic and neurological diseases, where iron can be found at the sites of plaques and lesions, as well as studies showing the significance of iron to aging and longevity. The effective chelation of iron by natural or synthetic ligands is thus of major physiological (and potentially therapeutic) importance. As systems properties, we need to recognise that physiological observables have multiple molecular causes, and studying them in isolation leads to inconsistent patterns of apparent causality when it is the simultaneous combination of multiple factors that is responsible.

This explains, for instance, the decidedly mixed effects of antioxidants that have been observed, since in some circumstances (especially the presence of poorly liganded iron) molecules that are nominally antioxidants can actually act as pro-oxidants. The reduction of redox stress thus requires suitable levels of both antioxidants and effective iron chelators. Some polyphenolic antioxidants may serve both roles.

Understanding the exact speciation and liganding of iron in all its states is thus crucial to separating its various pro- and anti-inflammatory activities. Redox stress, innate immunity and pro- (and some anti-)inflammatory cytokines are linked in particular via signalling pathways involving NF-kappaB and p38, with the oxidative roles of iron here seemingly involved upstream of the IkappaB kinase (IKK) reaction. In a number of cases it is possible to identify mechanisms by which ROSs and poorly liganded iron act synergistically and autocatalytically, leading to 'runaway' reactions that are hard to control unless one tackles multiple sites of action simultaneously. Some molecules such as statins and erythropoietin, not traditionally associated with anti-inflammatory activity, do indeed have 'pleiotropic' anti-inflammatory effects that may be of benefit here.


Overall we argue, by synthesising a widely dispersed literature, that the role of poorly liganded iron has been rather underappreciated in the past, and that in combination with peroxide and superoxide its activity underpins the behaviour of a great many physiological processes that degrade over time. Understanding these requires an integrative, systems-level approach that may lead to novel therapeutic targets.

Background and preamble

The 'balkanisation' of the literature is in part due to the amount of it (some 25,000 journals with presently 2.5 million peer-reviewed papers per year, i.e. ~5 per minute [1]), with a number increasing by something approaching 2 per minute at PubMed/Medline alone. In addition, the disconnect between the papers in the literature (usually as pdf files) and the metadata describing them (author, journal, year, pages, etc) is acute and badly needs filling [2]. Without solving this problem, and without automation of the processes of reading, interpreting and exploiting this literature and its metadata in a digital format, we cannot make use of the existing tools for text mining and natural language processing (e.g. [35]), for joining disparate concepts [6], for literature-based discovery (e.g. [711], and for studies of bibliometrics [12, 13], literature dynamics [14], knowledge domains [15], detecting republication [16] and so on. Until we recognise these possibilities we are unlikely to seek to realise them.

The present article (and see [17] for a preprint) serves to show some of the benefits than can accrue from a more overarching view of the otherwise highly disparate literature in a particular domain (see also [18]), but was done 'the hard way', i.e. with a few bibliographic and bibliometric tools but without the kind of automation implied above. For the record, the main tools used (see a review in [2]) were Web of Knowledge and Scopus for literature and citation searching, supplemented by Google Scholar. Some use was also made of ARROWSMITH [6, 19, 20] and GOPubMed [21], as well as various workflows in the Taverna environment [2226], including the BioAID_DiseaseDiscovery workflow written by Marco Roos. Citations and attendant metadata were stored in Endnote (latterly version X).


Even under 'normal' conditions, as well as during ischaemia when tissue oxygenation levels are low, the redox poise of the mitochondrial respiratory chain is such that the normally complete four-electron reduction of dioxygen to water is also accompanied by the production, at considerable rates (ca 1–4% of O2 reduced), of partially reduced forms of dioxygen such as hydrogen peroxide and superoxide (e.g. [2745]). These 1- and 2-electron reductions of O2 are necessarily exacerbated when the redox poise of the b-type cytochromes is low, for instance when substrate supplies are in excess or when the terminal electron acceptor O2 is abnormally low due to hypoxia or ischaemia. Various other oxygenases, oxidases and peroxidases can also lead directly to the production of such 'reduced' forms of dioxygen in vivo (e.g. [4648]), with H2O2 from xanthine oxidase being especially implicated in ischaemia/reperfusion injury (e.g. [47, 4954]). These molecules (peroxide and superoxide) can cause or contribute to various kinds of oxidative stress. However, this is mainly not in fact because they can react directly with tissue components themselves, since they are comparatively non-toxic, cells have well-known means of dealing with them [55], and they are even used in cellular signalling (e.g. [5660]). Much more importantly, it is because they can react with other particular species to create far more reactive and damaging products such as hydroxyl radicals, with all these agents nevertheless being known collectively (and indiscriminately) as reactive oxygen species (ROSs). Possibly the commonest means by which such much more damaging species, in particular the hydroxyl radical, are created is by reaction with unliganded or incompletely liganded iron ions [6163]. The themes of this review are thus (i) that it is this combination of poorly liganded iron species, coupled to the natural production of ROSs, that is especially damaging, (ii) that the role of iron has received far less attention than has the general concept of ROSs, albeit the large literature that we review, and (iii) that this basic combination underpins a great many (and often similar) physiological changes leading to a variety of disease manifestations, and in particular those where the development of the disease is manifestly progressive and degenerative.

An overview of the structure of the review is given in Fig 1, in the form of a 'mind map' [64]. The main literature review for this meta-analysis was completed on June 30th, 2008, with some updates being added following the refereeing process.
Figure 1

An overview of this article, set out in the form of a 'mind map' [64].

Some relevant chemistry of iron and reduced forms of oxygen

While superoxide and peroxide are the proximate forms of incomplete O2 reduction in biology, a reaction catalysed by the enzyme superoxide dismutase [65] serves to equilibrate superoxide and peroxide:
Arguably the most important reaction of hydrogen peroxide with (free or poorly liganded) Fe(II) is the Fenton reaction [66], leading to the very reactive and damaging hydroxyl radical (OH)
Superoxide can also react with ferric iron in the Haber-Weiss reaction [67] to produce Fe(II) again, thereby effecting redox cycling:

Ascorbate can replace O2 •- within the cell for reducing the Fe(III) to Fe(II) [68]. Further reactions, that are not the real focus here, follow from the ability of hydroxyl radicals and indeed Fe(n) directly to interact with many biological macro- and small molecules, especially including DNA, proteins and unsaturated lipids. Thus [6973], Fe(II) and certain Fe(II) chelates react with lipid hydroperoxides (ROOH), as they do with hydrogen peroxide, splitting the O--O bond. This gives RO, an alkoxyl radical, which can also abstract H from polyunsaturated fatty acids and from hydroperoxides. The resulting peroxyl radicals ROO can continue propagation of lipid peroxidation. Oxidative stress also leads to considerable DNA damage [7476] and to the polymerisation and denaturation of proteins [7779] and proteolipids that can together form insoluble structures typically known as lipofucsin (see e.g. [80, 81]) or indeed plaques. Such plaques can also entrap the catalysts of their formation, and thereby point them up. Some of the evidence for these is described below. Many small molecule metabolic markers for this kind of oxidative stress induced by the hydroxyl radical and other 'reactive oxygen species' (ROSs) are known [43, 8289], and include 8-oxo-guanine [9094], 8-hydroxy guanine [95], 8-hydroxy-2'-deoxy-guanosine [96, 97], 8-oxo-GTP [98], 4-hydroxy-2-hexenal [99], 4-hydroxy-nonenal [100], 4-hydroperoxy-2-nonenal, various isoprostanes [101107], 7-keto-cholesterol [108], many other cholesterol derivatives [109], malondialdehyde [110], neopterin [111], nitrotyrosine [112115] and thymidine glycol [116, 117]. Note that the trivial names in common use for this kind of metabolite are not helpful and may even be ambiguous or misleading, and it is desirable (e.g. [118]) to refer to such molecules using terminology that relates them either to molecules identified in persistent curated datbases [119] such as ChEBI [120] or KEGG [121], or better to describe them via database-independent encodings such as SMILES [122] or InChI [123128] strings. (There are other oxidative markers that may be less direct, such as the ratio of 6-keto-prostaglandin F1α to thromboxane B2 [129], but these are not our focus here.)

Overall, it is in fact well established that the interactions between 'iron' sensu lato and partly reduced forms of oxygen can lead to the production of the very damaging hydroxyl radical (e.g. [43, 130139]), and that this radical in particular probably underpins or mediates many higher-level manifestations of tissue damage, disease, organ failure and ultimately death[36, 137, 140143]. While the role of ROSs generally in these processes has been widely discussed, the general recognition of the importance of inadequately liganded iron in each of them has perhaps been less than fully appreciated. One of our tasks here will therefore be to stress this role of 'iron', and to assess the various means of chelating 'iron' such that it does not in fact do this. (Throughout we use 'iron' to refer to forms of Fe(n, n > 0) with unspecified ligands, though we absolutely stress that it is the exact speciation and liganding that determines the reactivity of 'iron' in catalysing reactions such as that of hydroxyl radical formation, and indeed its bioavailability generally – inadequate liganding of iron in the required forms can be a cause of anaemia even if the total amount of 'iron' is plentiful.)

For completeness we note the reactions catalysed by superoxide dismutase
and by catalase

These together, were their activity in the relevant locations sufficiently great, might serve to remove (su)peroxide from cells completely.

In addition to reactive oxygen species there are ions such as the perferryl ion (Fe-O) [144] and reactive nitrogen species [60, 145147]. These latter are mainly formed from the natural radical NO, an important inflammatory mediator [148], with peroxynitrite production (from the reaction of NO and superoxide) [46, 149154] leading to nitrotyrosine [112], or nitro-fatty acid [155, 156] or protein cystein nitrosylation [157, 158] being a common means of their detection downstream. Other toxic products of the reactions of NO include NO2, N2O3, and S-nitrosothiols [159], and the sequelae of some of these may also involve iron [160].

Overall, we recognise that these kinds of inflammatory, oxidative stress-related reactions are accumulative and somewhat irreversible [161], that they are consequently age-related, and (see [162165] and later), and that most diseases and causes of mortality that are prevalent in the developed world are in this sense largely manifestations of this kind of aging.

Ligands and siderophores

As well as the reactions described above, ferrous ions will react with oxygen under aerobic conditions to produce ferric ions, and in natural environments there is little to stop this. Consequently, and because these reflect fundamental physicochemical properties of such ions, the problems of both solubility and toxicity were faced by bacteria (and indeed fungi [166169]) long ago in evolution, and were solved by their creation and excretion of (mainly ferric-)iron chelators known as siderophores [170189] (and for haemophores see [190]). These typically have extremely tight binding constants (Kf > 1030 [191]) and can solubilise and sequester iron such that it can be internalised via suitable transporter molecules within the bacterial plasma membrane [192]. Bacterial and fungal siderophores usually form hexadentate octahedral complexes with ferric iron and typically employ hydroxamates, α-hydroxycarboxylates and catechols as extremely effective Fe3+ ligands [182]. Since bacterial growth requires iron, it is unsurprising that siderophores are effectively virulence factors (e.g. [174, 193196]). While upwards of 500 microbial siderophores have been identified [182], with new ones still appearing (some via genomic analyses, e.g. [197]), and with the most common one in medical use, desferrioxamine or DFO, being such a bacterial product (see below), it is an astonishing fact that no human siderophore has been chemically identified, even though such activities were detected nearly 30 years ago [198, 199] (see also [200205]). As noted by Kaplan [206], "a discovery that mammals produce siderophores would lead to an epochal change in the paradigm of mammalian iron homeostasis." To this end, some recent events have begun to change matters, and our overall knowledge of the regulation of iron metabolism, considerably.

Mammalian iron metabolism

The total body iron in an adult male is 3000 to 4000 mg and the daily iron requirement for erythropoiesis, the major 'sink', is about 20 mg [207]. However, the loss of iron in a typical adult male is very small [208, 209] and can be met by absorbing just 1 – 2 mg of iron per day [210, 211]. The careful conservation and recycling of iron – mainly from degrading erythrocytes – is in fact essential because typical human diets contain just enough iron to replace the small losses, although when dietary iron is more abundant, absorption must be (and is) attenuated since higher levels than necessary lead to iron overload and many distressing sequelae contingent on the radical production described above.

A variety of aspects of mammalian iron metabolism have been reviewed in detail elsewhere (e.g. [134, 139, 195, 212241]), including a series on 'iron imports' [242248], and for our present purposes (Fig 2) mainly involves the intestinal (mainly duodenal) uptake of Fe(II) (produced from Fe(III) using a luminal ferrireductase) via a divalent metal ion transporter DMT1/DCT1/NRAMP [249, 250] and its subsequent binding as Fe(III) to transferrin (Tf). The intestinal uptake of haem (heme) occurs via the heme carrier protein-1 (HCP1) [251] and it is thereby internalized, while the iron in heme is liberated by heme oxygenase-1 (HO1) [252254]. Haem is synthesised in many tissues, especially liver and erythroid cells [255]. Vesicular routes of intestinal transfer may also occur [256, 257]. Low MW cytoplasmic chelators such as citrate can bind iron fairly weakly and thereby contribute to a labile iron pool (LIP) in the cytoplasm and especially the lysosomes and mitochondria (see [258262]), while ferritin [263] too can bind cytoplasmic iron (via a chaperone [264]) and is seen as a good overall marker of iron status [265267]. Iron(II) is subsequently exported through the basolateral membrane of the enterocyte by ferroportin-1 (FPN1) [268270]. Ferroportin may also contribute to uptake in enterocytes [271]. Fe(III) may then be produced by hephaestin (Hp) [272] before it is bound by transferrin (Tf), which is the main but not sole means of binding Fe(III) when it is transported through the circulation, with major iron storage taking place in the liver. Similar processes occur in the peripheral tissues, with significant transfer of iron from transferrin occurring via the transferrin receptor [273].
Figure 2

Schematic overview of the main elements considered to participate in mammalian iron metabolism.

'Free' haem appears in the circulation (it may have a signalling role [274]) and elsewhere largely because of erythrocyte degradation, and it can also greatly amplify the cellular damage caused by ROSs [275], and its degradation pathway via haem oxygenase [276, 277] to biliverdin and then using biliverdin reductase to form bilirubin generates 'free' (and potentially redox-active) iron. It would appear, not least because biliverdin has powerful antioxidant properties, that haem oxygenase is more protective than damaging [253, 278282], even though one of the products of its reaction is Fe that must eventually be liganded (or e.g. incorporated into ferritin). (Another product is the gas CO, that has been proposed as a measure of oxidative stress in the lung [283].)

All of the above obviously ignores both some important aspects of the speciation and liganding of iron, as well as the tissue distribution of the specific proteins involved – for which latter global information will shortly emerge [284] ( and see later). It also ignores any discussion on the genetic regulation of iron metabolism (e.g. [285288]), which is not our main focus.

However, one molecule in particular, hepcidin, has recently emerged as a 'master regulator' of regulation at the physiological level, and we describe some of these new developments.


In the liver and elsewhere, many aspects of iron metabolism are regulated by a recently discovered 25-amino acid polypeptide called hepcidin [207, 241, 245, 271, 289327] that acts in part as a negative regulator of iron efflux [328] by causing the internalisation of ferroportin [329333]. Hepcidin is produced, partly under the regulation of a receptor called hemojuvelin (e.g. [334]), via an 84-aa precursor called pre-pro-hepcidin and a 60 mer called pro-hepcidin [304, 335, 336] although the active agent is considered to be the 25 mer referred to above, and with the inactive precursors appearing not to be useful markers [337, 338].

Strikingly, anaemia and anoxia both suppress hepcidin production [245, 339, 340] (Fig 3), such that just while superoxide production is being enhanced by the anoxia there is more iron being absorbed from the intestine and effluxed into the circulation. In view of the inter-reactivity of superoxide and iron this could be anticipated to enhance free radical formation, leading to a positive feedback loop in which the problems are amplified: ischaemia/anoxia changes Fe(n) distribution leading to differential reactivity with the products of anoxia and thus further free radical production. However, hepcidin is overexpressed in inflammatory disease and is an early inflammatory marker [245, 341345]. Its expression is positively controlled inter alia by SMAD4, and loss of hepatic SMAD4 is thus associated with dramatically decreased expression of hepcidin in liver and increased duodenal expression of a variety of genes involved in intestinal iron absorption, including Dcytb, DMT1 and ferroportin, leading to iron overload [346]. STAT3 is another positive effector of hepcidin expression [347, 348], and ROSs inhibit this effect [349], thereby creating a link between ROSs and Fe metabolism. To understand the exact roles of hepcidin in iron metabolism, it is going to be especially important to understand where it is expressed; fortunately, such studies are beginning to emerge [350].
Figure 3

Some effects of hepcidin, summarizing the fact that hypoxic condition can suppress it and thus lead to hyperferraemia. Since hypoxic conditions can also lead to ROS production the hypoxia-mediated regulation of hepcidin can have especially damaging effects.

Overall there is a complex interplay between positive and negative regulation and the organismal distribution of iron caused by changes in hepcidin concentration [351], with in many cases the hypoxic response (decreased hepcidin) seeming to dominate that due to inflammation (increased hepcidin) even when iron levels are high [352, 353]. Specifically, lowered hepcidin causes hyperferraemia. Hepcidin is also activated by p53 [354], and may play a role in the degradation of atherosclerotic plaques [355]. Another recently discovered protein that is crucially involved in human iron metabolism is NGAL or siderocalin, and while there is some evidence for their co-regulation [356], they have normally been studied separately.

NGAL (also known as lipocalin-2 or siderocalin)

Lipocalins [357] are a diverse group of ligand-binding proteins that share a conserved structure even in the absence of significant sequence conservation. This core structure includes an eight-stranded anti- parallel β barrel that defines a calyx, or cup-shaped structure, enclosing the ligand binding site.

NGAL – neutrophil gelatinase-associated lipocalin – is a 21 kDal glycoprotein first isolated by Kjeldsen and colleagues in 1993 [358]. Synonyms include lipocalin 2, siderocalin, Lcn2, α2-microglobulin-related protein or neu-related lipocalin (in rats) [359, 360] and (in mice) 24p3 or uterocalin [361]. Although lipocalins are well known to be involved in the sequestration and transport of a variety of ligands, the natural ligand of NGAL (as is the case with many lipocalins) was not initially known even in terms of its chemical class. This changed with the seminal paper of Goetz and colleagues [362] (and see [206]) who purified recombinant NGAL from a particular strain of E. coli and found that its structure contained a negatively charged ferric siderophore with a subnanomolar dissociation constant that it had extracted from its bacterial host, and that the apo form of this molecule could also act as a potent bacteriostatic agent by sequestering iron (see also [363367]). A companion paper [368] showed that the iron-delivering activity was expressed in mammalian cells. The structure of NGAL is now known [369] and one of its interaction partners is a matrix metalloproteinase [370] to which it can presumably donate a metal ion and in the complex decrease its degradation [371].

The finding that NGAL was one of the most highly expressed proteins following ischaemia-reperfusion injury in kidney cells [372374], and prognostic of kidney damage long before the more traditional marker creatinine was raised significantly, has led to considerable interest in this protein, especially as a marker of renal injury [375389], and perhaps as a therapeutic [375]. Devireddy and colleagues [390] identified a receptor that internalizes 24p3, and internalization of iron bound to 24p3 prevents apoptosis. In contrast, internalization of the apo form of 24p3 that does not contain iron led to cellular iron efflux and apoptosis via the proapoptotic protein Bim [391]. In humans the megalin receptor can bind siderocalin (and its siderophore payload) and mediate its intracellular uptake [392]. Oxidative stress can also induce its expression [393], and it is protective against it [394].

Exogenously administered NGAL also markedly upregulates heme oxygenase-1, a proven multifunctional protective agent in experimental Acute Kidney Injury (AKI) that is thought to work by limiting iron uptake, promoting intracellular iron release, enhancing production of antioxidants such as biliverdin and carbon monoxide, and inducing the cell cycle regulatory protein p21 [279, 395, 396]. Because of this multifaceted protective action, NGAL has emerged as a prime therapeutic target in ischaemic AKI [379].

Structural and direct binding studies have suggested that siderocalin tends (although not exclusively) to bind catecholate-type ligands, rather than hydroxamate- or carboxylate-based siderophores, at least when tested with microbially derived siderophores [362, 363, 365] (but cf. [369] for claims, disputed [360] and not now accepted, as to the binding of bacterially derived formyl peptides!). The role of NGAL, as a siderophore-binding agent, is thus consistent with the widespread recognition that iron-induced radical generation is intimately involved in a variety of renal and other diseases [397, 398]. However, while it is certainly the case that siderocalin can reduce the virulence of bacteria when it binds the relevant bacterial siderophores [362367] and that bacteria can 'evade' this by synthesising siderophores that siderocalin cannot bind (e.g. [186, 187, 399401]), it is questionable whether the only role of siderocalin lies in fact in its antibacterial activity. Rather we would suggest that its main role is in sequestrating iron via a human siderophore to stop inappropriately liganded iron from producing damaging oxygen radicals. Consistent with this iron-liganding role for human biology is the fact that the tissue most highly expressing NGAL under normal conditions is bone marrow [360, 402], the site of erythropoiesis. The liganding can be extensive; as Goetz and colleagues [362] note, "During inflammation, concentrations of NGAL can increase to levels, with concentrations approaching 20–30 nM in the serum [403], presumably adequate to bind all available iron as ferric siderophore complexes".

Significant changes in NGAL expression have also been observed, for instance, during kinase-mediated signalling [404, 405], in cardiovascular disease [406409] and in cancer [410412].

These findings on the kidney and the role of NGAL, together with the important knowledge that its chief ligand is probably an unknown human siderophore (Figs 2, 4), thus lead us to consider the role of this system (and unliganded iron generally) in a whole series of other diseases that all share many characteristics of oxidative stress and inflammation (see also [413]). A similar thesis, albeit with comparatively little stress on iron, is the leitmotif of Finch's recent detailed monograph [163]. The theme of these sections is thus to stress the fact that while the role of ROSs in general in such syndromes has been pointed up previously, that of iron as a major culprit has not so generally yet been stressed, notwithstanding that there is in fact a great deal of pertinent literature that we here highlight as the focus of this review.
Figure 4

Overview of the roles of ischaemia, ROSs, poorly liganded iron and the iron metabolism regulators HGAL and hepicidin in effecting inflammation as a physiological level.

Some disease manifestations in which iron may be implicated

Preeclampsia (PE)

Another important disease that shares many of the same properties (or at least sequelae) of renal impairment, and may have the same fundamental aetiology, is pre-eclampsia. This is the most significant cause of morbidity and mortality in pregnant women [414]. The chief clinical manifestations at time of diagnosis are a raised blood pressure (hypertension) [415] and proteinuria, together with raised creatinine, consistent with the reversible existence (since it is relieved upon delivery of the baby) of renal impairment. However, prognostic markers that might manifest early in pregnancy are lacking, and would be highly desirable. There is widespread agreement [416] that a poor connection of the placenta to the uterus leads to ischaemia and thus oxidative stress, with a substantial involvement of apoptosis during the placental remodelling [417423]. Since preeclampsia-like syndromes can be induced in pregnant animals by surgical restriction of the uteroplacental blood supply [424], it is presumed that blood-borne agents arising from the ischaemic placenta are the cause of the generalized endothelial cell damage and inflammatory responses that give rise to the symptoms of hypertension, proteinuria, and sudden oedema characteristic of preeclampsia [70]. Indeed, many studies implicate oxidative stress as a substantial contributor to this [425489], while some have noted the importance of iron status [70, 133, 450, 490511], and so far as is known the transporters of iron in the placenta are similar to those in other cells [512]. Oxidative stress of this type is of course inflammatory in nature and inflammation is observed in PE [472, 476, 484, 486, 513519]. We suggest strongly that it is the combination of inadequately liganded Fe(II or III) and superoxide/peroxide leading to OH formation that is the chief mechanistic cause of the downstream events that manifest in PE, and that appropriate removal by liganding/chelation or otherwise of these ions would prove of therapeutic benefit. (Iron status has also been implicated in other pregnancy and neonatal disorders [520524].) There is evidence too for the involvement of the radical NO [456, 525].

We note that it is quite common nevertheless for iron to be prescribed during pregnancy, especially during its latter stages [526, 527], and that this does of course lead to oxidative stress [528, 529].

Oxidative stress is caused both by the initial rate of production of superoxide and the rate of their conversion into OH radicals. The former can be induced by hypoxic conditions such as occur at high altitude, and one prediction, that is borne out [487, 530], is that PE should therefore be more prevalent at high altitude. Erythropoietin may be a marker for oxidative stress in pre-eclampsia [531].

Regarding the second stage, predictions include that PE should be more common in those suffering from diseases of iron metabolism. Although such mothers are of course less well a priori, this prediction is borne out for α-thalassemia [532, 533] although not, interestingly, for haemochromatosis [534]. We note in this context that thalassaemia not only predisposes towards PE but is known in general to cause hepcidin to decrease and NGAL to increase [352, 353, 356, 535], with consequent and inevitable iron dysregulation.

Another prediction is then that hepcidin should be changed in pre-eclampsia. Although no serum measurements have been reported to date, it is of extreme interest that – while they took it to be an antimicrobial peptide rather than an iron regulator – a recent study by Knox and colleagues of placental gene expression in a mouse model of PE showed that hepcidin expression increased by a greater factor than that of any other gene save one [536], consistent with the view that major changes in the regulation of iron liganding and metabolism underpin PE.

Finally, we note that NGAL is significantly implicated in pregnancy, and was even named uterocalin in mice to reflect its high expression in the uterus [361, 537539]. A very recent study [540] suggests that it may be a useful second trimester biomarker for pre-eclampsia.


Type 2 diabetes and insulin resistance are known complications of pregnancy (e.g. [541545]), and also predispose towards PE. In a similar vein, various types of pregnancy-related intrauterine growth restriction predispose towards diabetes in later life [546, 547], pointing up the progressive nature of these syndromes. Metabolic biomarkers for the one can thus be predictive of the other [548], consistent with a common cause. Certainly ROSs are known to play a substantive role in both insulin resistance [549556] and in a variety of diabetic sequelae [95, 557559], and mitochondrial dysfunction may be an early step in this [560]. Some anti-diabetic drugs, such as the 'glitazones' that are considered to act on Peroxisome Proliferator Activated Receptor (PPAR)γ, may also act by decreasing ROS production (e.g. [561565]), and are even active aganst cerebral ischaemia and stroke [566569]. As with most if not all of the other diseases we review here, studies of pro-inflammatory markers (such as TNF-α, IL-1 and C-reactive protein [570]) during the development of diabetes show its aetiology to be inflammatory in nature [553, 571590]. Iron 'excess' is also a known feature of gestational diabetes [591593], and is a clear risk factor for the disease even in 'normal' populations [594603], and indeed diabetes is a classical consequence of iron overloading as seen in hereditary haemochromatosis [604]. Serum ferritin and body iron stores are strongly associated with diabetes [603, 605609], including prospectively [610], while changes in visfatin are also intimately involved in changes of iron metabolism (with pro-hepcidin being elevated) [611]. Most importantly, lipocalin 2 (siderocalin/NGAL) is strongly associated with the development of diabetes [612, 613]. Lowering iron improves insulin sensitivity [598, 614], and metallothionein is also protective [615619]. There seems little doubt that iron status is a major determinant of the development of type 2 diabetes [620].

Non-transferrin-bound iron is also considerably elevated in type 2 diabetes [621], and this too is exacerbated by vitamin C. Iron metabolism is substantially deranged in type 2 diabetes and the metabolism of glucose (a reducing sugar) interacts significantly with iron metabolism [598]. Iron is also strongly implicated in non-alcoholic steatohepatitis, considered an early marker of insulin resistance [622624]. Well-known diabetic complications include retinopathies, and it is noteworthy that elevated levels of ferritin can lead to cataract formation [625, 626].

The metabolic syndrome

Although some of its origins may be pre-natal [547], many of the features of these diseases are also seen in the (so-called) Metabolic Syndrome [627631]. Thus, serum ferritin is also related to insulin resistance [606, 632, 633] and iron levels are raised [624, 634, 635]. Of course diabetes and the Metabolic Syndrome are also closely coupled, so it is reasonable that features observed in the one may be observed during the development of the other. The metabolic syndrome is also an independent indicator for chronic kidney disease [636] and may be related to liver steatosis [637]. Metabolic disorders of this type too are closely intertwined with inflammation [575, 581, 587, 638], that is of course stimulated by ROSs whose generation is increased by high-fat diets [639]. Thus, our role here is to point up the existence of a considerable body of more-than-circumstantial evidence that here too the progressive and damaging nature of these diseases may be caused, in part, by inappropriately chelated iron.


"As previously pointed out by Booth et al. [640], 100% of the increase in the prevalence of Type 2 diabetes and obesity in the United States during the latter half of the 20th century must be attributed to a changing environment interacting with genes, because 0% of the human genome has changed during this time period." [629]

It is well known that there has been a staggering increase in the prevalence of obesity, diabetes, and especially type 2 diabetes, in the last 50 years or so, and that this increase is expected to continue (e.g. [641643] and Equally, it is now well known that obesity, metabolic syndrome, diabetes and cardiovascular diseases are all more or less related to each other [643], and the question arises here as to whether dysfunctional iron metabolism might be a feature of each of them. In the case of obesity per se, however, we see no major evidence as yet for a causative role of deranged iron metabolism or chelation in causing obesity. Indeed, while they are related [644], what little evidence there is [645, 646] suggests that the converse may be true, i.e. that changes in iron metabolism might be consequent upon obesity (possibly via peroxide generation [639]). Importantly, considerable evidence suggests that obesity and inflammation are significantly related [163, 486, 575, 581, 642, 647664], not least because adipocytes produce and release various adipokines including pro-inflammatory cytokines such as IL-6 and TNF-α [575, 649, 650, 665671]. It is likely that it is the combination of overfeeding-induced obesity and inflammation (partly induced by the obesity itself [672]) that leads to diabetes [673]. Certainly there is evidence for increased ROS production in obese mice, possibly mediated in part via the fatty acid-induced activation of NAPH oxidase [674], while obesity is linked [675, 676] to urinary levels of 8-epi-PGF, a well established marker of oxidative stress (qv). Fig 5 summarises the above in a manner that stresses the roles of iron, overfeeding and inflammation in the genesis of these processes, and notes that interference in several of these steps is likely to be required to limit their progression to best advantage.
Figure 5

Role of inflammation caused by hydroxyl radical formation in the interactive development of obesity, the metabolic syndrome and diabetes. Intervention at multiple steps is likely to be most beneficial in alleviating this kind of progression.


As well its significance in pre-eclampsia (see above), hypertension is a well known risk factor for many cardiovascular and related disease (e.g. [677]), and there is considerable evidence that its underlying cause is inflammatory in nature [678686], is related to the metabolic syndrome and obesity (e.g. [648, 687691]), and may be mediated mainly via ROSs [692]. There is evidence that some of its sequelae may be mediated via iron [693, 694].

Cardiovascular diseases

It is well known that elevated iron stores can predispose to coronary artery disease and thence myocardial infarction. The 'iron hypothesis' of the benefits of some iron depletion due to menstruation was devised to account for the lowering of heart-disease risk in young women (that disappears in those post-menopause) and was proposed by Jerome Sullivan in 1981 [695698] (and see also [699, 700]). (In this sense, the lack of menstruation during pregnancy would predispose to a comparative abundance of iron, as is indeed found – see above.) It is of particular interest that the well-known adverse vascular effects of homocysteine (in inhibiting flow-mediated dilatation) are in fact iron-dependent [701703], and that reducing homocysteine (e.g. by folate supplementation) in the absence of lowering iron has shown no clinical benefit to date [704], thereby suggestion iron mediation. By contrast, iron stores represent an established risk factor for cardiovascular disease [705].

Of course many factors such as lipid levels, stress, smoking and so are well-known risk factors for cardiovascular, coronary artery disease and related diseases. Indeed kidney disease is well established as a risk factor for cardiovascular disease [706708] (and indeed stroke [709]), all consistent with their having in part a common cause – we believe inflammation). Our purpose here, within the spirit of this review, is to indicate the evidence for the involvement of inappropriately chelated iron in cardiovascular diseases too. There is no doubt that the iron-mediated causal chain of ischaemia → (su)peroxide → OH radical formation occurs during the development of heart disease, especially during reperfusion injury [710713], and suitable iron chelators inhibit this [714, 715] (see also [716, 717], and for thalassaemia [718]). Iron is also involved in the protection that can be produced by ischaemic preconditioning [719, 720]. Erythropoietin, a hormone with multiple effects that may involve iron metabolism, is also protective [721, 722].

Heart failure

The sequelae of heart failure are complex, and involve a chronic and continuing worsening of a variety of physiological properties. ROSs are certainly involved here, since allopurinol (a potent inhibitor of xanthine oxidase) improves prognosis considerably [723], and uric acid is a well known biomarker for heart failure (see e.g. [724, 725]). Biopyrrins, degradation products of bilirubin and thus markers of oxidative stress are also considerably increased [726]. Anaemia is a common occurrence (and risk factor) in heart failure [727729], again implying a role for dysregulated iron metabolism and a need to understand the exact speciation of iron in chronic anaemias linked to inflammatory diseases [730].

It is next on the formation of atherosclerotic plaques that our attention is here focussed.


Atherosclerosis is a progressive inflammatory disease[731762] characterized by the accumulation of both oxidised lipids and various fibrous elements in arteries, often as plaques [763, 764]. Iron and oxidised lipids are both found in atherosclerotic lesions [141, 765777], and iron depletion by dietary or other means delays this [778782]. There is a correlation between iron status and atherosclerosis [766, 776, 783794], evidently caused in part by the known ability of poorly liganded iron to effect lipid [765, 784] and protein peroxidation, and by the effects of primed neutrophils [795] and transferrin [758]. In this context, exogenous ferric iron is deleterious to endothelial function [796], while iron chelation improves it [797800]. However, phlebotomy provided no clinical benefit here [801]. Note that iron levels in plaques correlate with the amount of oxidised proteins therein [771], and that in one study [767], the EPR-detectable iron (essentially Fe(III)) in atherosclerotic tissue was seventeen times greater than that in the equivalent healthy tissue; this is not a small effect. (Iron, as part of the general ROS cascade, has also been implicated in gallstone formation, where melatonin has proved protective [802, 803].)

Statins, typically developed on the basis of their ability to inhibit the enzyme HMG-CoA redutase and thus decrease serum cholesterol, are well established to have benefits in terms of decreasing the adverse events of various types of cardiovascular disease [804], albeit that in many populations (e.g. [805807]) cholesterol alone is a poor predictor of cardiovascular disease, especially in the normal range. However, a known target of statins different from HMGCoA reductase is the β2-integrin leukocyte function antigen-1 (LFA-1) [808, 809] and in this context, it is important to note that the clinical benefits of the statins are certainly not due solely to their cholesterol-lowering ability via the inhibition of HMG-CoA reductase (see e.g. [163, 281, 650, 807, 808, 810840]), and different statins can cause a variety of distinct expression profiles [841] that are inconsistent with a unitary mode of action. The apparent paradox [842] that lipid-lowering statins do indeed exhibit epidemiological disease-lowering benefit, while having little effect on plaques, is arguably well explained, especially within the context of the present review, via their additional anti-inflammatory effects [817, 819, 843863, 163, 807, 823825, 830, 836, 837, 864892], acting upstream of the nuclear transcription factor NF-κB (and see later). It is also extremely relevant, for instance, that some statins have metal chelating properties [893].

It has been pointed out that many measures of iron stress are inappropriate, since it is only the redox-active form of iron that is likely involved in oxidative stress. Serum ferritin is considered by some to be the most reliable marker of iron status in general [894], although it is not well correlated with iron distribution in the heart [895], for instance. What is clear, however, from the above is that deranged iron metabolism is intimately and causally involved in the formation of atherosclerotic lesions, and that appropriate iron chelation can help both to prevent and to reverse this.

Iron status is also closely involved in other chronic vascular diseases, and in the behaviour of wounds [896899].


Stroke is caused by ischaemia, leading to inflammation [900] and to the formation of ROS and other damaging free radicals [901] in the brain (which is high in metal ions [902]), and is exacerbated by existing inflammation – see e.g. [903, 904]. Thus, another prediction is that iron excess should also aggravate the sequelae of stroke, and that appropriate chelation or free radical trapping agents should mitigate these effects. These predictions are indeed borne out [138, 905914]. It is also of considerable interest that plasma NGAL levels are increased in stroke [406]; it is noteworthy that this can be seen in plasma despite the localised origin of the disease.

A variety of other studies have shown the beneficial treatments in stroke models of anti-inflammatory and antioxidant treatment, i.e. treatments that lower the amount of ROSs (e.g. [915922]), as well as of preconditioning [923]. Given its role in iron metabolism, it is of considerable interest that erythropoietin also seems to be very effective in protecting against brain ischaemia/reperfusion injury and stroke [924939], by a mechanism independent of erythropoiesis [940942], and one that appears to involve anti-inflammatory activity [943].

Alzheimer's, Parkinson's and other major neurodegenerative diseases

Oxidative stress and inflammation are early events of neurodegenerative diseases [920, 944957] such as Alzheimer's disease (e.g. [958973]), where plaque formation precedes neurodegeneration [974]. Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases [944, 981, 945, 958, 982985, 962, 986989, 950, 9901021, 917, 10221034, 278, 10351055, 43, 10561059, 285, 1060, 972, 10611065, 141, 975, 10661087].

Indeed Thompson and colleagues comment [136] that "The underlying pathogenic event in oxidative stress is cellular iron mismanagement" and stress that "Multiple lines of evidence implicate redox-active transition metals, such as iron and copper, as mediators of oxidative stress and ROS production in neurodegenerative diseases". There is also ample evidence for its presence in the plaques characteristic of Alzheimer's disease [1004, 1013, 1027, 1088], just as in those of atherosclerosis (see above). Note too that iron can catalyse the oxidation of dopamine to a quinine form that can bind covalently to and then aggregate proteins 1089. Kostoff 1090 has used a very interesting literature-based discovery approach to highlight the role of oxidative stress in the development of Parkinson's disease.

Other papers highlight the role of iron in multiple sclerosis [899, 991, 10911098] and in prion diseases [967, 1099, 1100]. However, a particularly clear example of iron-mediated neurodegeneration is given by the sequelae consequent upon lesions in a protein known as frataxin involved in the disease Friedreich's ataxia (FA).

Friedreich's ataxia

A number of repiratory chain components contain non-heme iron, and the question arises as to how they acquire it 1101. Frataxin is a mitochondrial iron chaperone protein [11021109], involved in the safe insertion of Fe(II) during the production of Fe-S centres in the mitochondrial respiratory chain 1110. As are some other aspects of iron metabolism 1111, it is highly conserved in eukaryotes from yeast to humans [1112, 1113], a fact that made the unravelling of its function considerably easier [11141123]. Friedreich's ataxia (FA) is a neurodegenerative disorder that arises from a genetic deficit of frataxin activity, whether by a missense mutation or, much more commonly, via the addition of GAA trinucleotide repeats [1107, 11241127]. As well as the neurodegeneration and measurable iron deposition, clinical symptoms include cardiac hypertrophy 1128 and (pre-)diabetes 1129, consistent with the general thesis described here that all are in part manifestations of iron dysregulation, and in which suitable chelation may be beneficial [1130, 1131] (but cf. 1132).

ROSs are undoubtedly involved in FA [1133, 1134], specifically via Fenton chemistry [1135, 1136], since the attenuation of H2O2 production (but not of superoxide) 1110 ameliorates the disease 1137. The deficit in frataxin causes both an increase in ROS (H2O2) production via the mitochondrial electron transport deficiency 1138 as well as a dysregulation in iron metabolism, potentially a very damaging synergistic combination (see later). Elements of its (in)activity that are seen as paradoxical 1139 are in fact easily explained when one recognises that it is the combination of free iron with H2O2 that is especially damaging. The neonatally lethal GRACILE syndrome is also caused by a failure of iron chaperoning into mitochondrial complex III due to mutations in the BCS1L gene [1140, 1141].

Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease

ALS is another progressive inflammatory 1142 disease in which motor neuron death causes irreversible wasting of skeletal muscles. It has largely defied efforts to uncover the genetic basis of any predisposition 1143, save for a very clear association with defects in a Cu/Zn superoxide dismutase [33, 11441146] that can obviously lead to an increase in the steady-state levels of superoxide (and hence hydroxyl radical formation). There is also significant evidence for the involvement of iron [1147, 1148]. Drug therapies have to date shown rather limited benefits, and more in mouse models of Cu/Zn SOD deficiencies than in humans, though iron chelation therapy does not seem to have figured heavily, and it is recognised that combination therapies might offer better prognoses 1149.


Aging or senescence is defined as a decline in performance and fitness with advancing age 1150. Iron stores tend to increase with age [11511155], partly due to dietary reasons 1156 (and see [1157, 1158]), as does anaemia [1159, 1160]. So too does the expression of NGAL/Lcn2/siderocalin, a process that can be reversed by melatonin 1161. Mainstream theories of aging [163, 165, 11621180] recognise the relationship between progressive inflammation, cellular damage and repair and the higher-level manifestations of the aging process, and ('the free radical theory of aging' [1163, 1181]) ROSs are of course strongly implicated as partial contributors to the aging process (e.g. [31, 43, 980, 1163, 11821206]). Needless to say, not least because of the low steady-state net rate of generation of the various ROSs 1207, few studies have managed to be very specific mechanistically 1208, but it should be clear that all ROSs are not created equal and we need here to concentrate mainly on the 'nasty' parts of ROS metabolism, and in particular on the hydroxyl radical as generated via poorly liganded iron and on peroxynitrite, and to have the greatest effects we need to inhibit both their generation and their reactivity (see Systems Biology section, below). The iron content of cells also increases as cells age normally 1209. As many diseases increase with age, probably via mechanisms highlighted herein, treating aging can thereby treat disease [162], and it is important to recognise that most 'diseases' are in fact consequences of aging (despite the considerably greater historical focus on the former).


One issue of aging is not that just it happens but that it can manifest in a series of essentially undesirable physiological changes, referred to as frailty 1210, in which ROSs have also been strongly implicated. Indeed, there are many parts of physiology and metabolism that lose functionality during aging (e.g. the cardiovascular system 1211 and of course cognitive function 1212), and iron metabolism is known to change considerably as humans age [980, 1213], with anaemia a typical accompaniment of aging 1214. The question then arises as to how much of this deranged iron metabolism is causal in accelerated aging, and this is not easy to state at this time. However, lowering iron does increase the lifespan of Drosophila 1215 and yeast 1105. At all events, the purpose of this rather brief section is to point out to researchers in aging, frailty and gerontology generally the relevance of inadequately controlled iron metabolism as a major part of ROS-induced injuries that may accelerate the aging process.


Although aging and longevity are not of course the same thing, and longevity is not a 'disease', studies of aging are often performed with the intention of improving our understanding of longevity 1216, and certainly longevity is linked to age-related disease 1217. However, the longevity of many organisms can be varied by the manipulation of any number of diseases or processes. This said, caloric or dietary restriction is a well-known contributor to longevity (indeed the only reliable one in pretty well all species [12181223] – although possibly not H. sapiens 1180), and appears to act at the root of the processes involved 1224. Caloric restriction appears to be associated with a considerably lowered rate of production of ROSs and accrual of ROS-induced damage [1207, 12251228], and this is to be expected on general grounds in that a restriction of substrate supply will make the redox poise of mitochondria 1229 more oxiding and thereby minimise the amount of 1- and 2-electron reductions of O2 to form peroxide and superoxide. It is therefore also of great interest that caloric restriction also benefits iron status 1230 and that it is this improved iron status that in part promotes longevity 1231. Caloric restriction has also been shown to effect a differential stress response between normal and tumour cells 1232, although this study did not look at relative iron status.

Antioxidants can also influence lifespan. Thus (rather high doses of) melatonin extended the lifespan (and stress resistance) of Drosophila [1191, 12331235] while that of Caenorhadbitis elegans could be extended by mimics 1236 of SOD and catalase 1187, and by a variety of antioxidant and other pharmacological agents 1237.

As an example, let us consider C. elegans. Mutants with a decreased activity of the insulin-like growth factor signalling pathway (e.g. daf2 mutants that have a greater amount of the DAF16 FOXO-like transcription factor) can live for nearly twice as long as wild types [1238, 1239] and produce more catalase, superoxide dismutase (sod-3) 1240 and glutathione-S-transferase.

Overall, it is the potent combination of oxidative stress, already leading to damaging peroxides and radicals, and its catalysis and further reactions caused by inappropriately chelated iron, that causes a 'double whammy'. Indeed, iron, copper and H2O2 have been referred to as the 'toxic triad' 1032. While there is comparatively little that we can do about the production of superoxide and peroxide, we can (by pharmacological or dietary means) try and improve the speciation of iron ions.

Rheumatoid arthritis

One disease whose aetiology is well known to be bound up with ROSs is rheumatoid arthritis (RA) [36, 12411246]. What is known of the role of iron metabolism? Generally an overall low iron status – anaemia – is a characteristic of rheumatoid arthritis [12471251], whereas by contrast iron is elevated in the synovial fluid of arthritic joints [12521255]. This suggests a significant derangement of iron metabolism in RA as well, and a mechanism [12561259] in which elevated superoxide liberates free iron from ferritin in synovial fluid (and elsewhere 1260), thereby catalysing further the damaging production of hydroxyl radicals. This autocatalytic process (Fig 6) is, even in principle, especially destructive (and may account for species differences in sensitivity to iron loading 1261). Note that erythrocytes when oxidized can also release free iron [524]. Natural antioxidants such as vitamin E are also lowered 1262. There is some evidence that appropriate iron chelators can ameliorate the symptoms of RA 1263, though membrane-impermeant chelators such as desferroxamine cannot 1264.
Figure 6

Catalysis and autocatalysis in the Haber-Weiss and Fenton reactions leading to the production of the hydroxyl radical, including the liberation by superoxide of free iron from ferritin.

One interesting feature of RA is that in 75% of women it is strongly ameliorated during pregnancy [12651267]; although the multifactorial nature of this observation has made a mechanistic interpretation difficult, from everything that we have seen so far it would be surprising if changes in iron metabolism were not strongly involved.

An interesting related feature is the 'restless legs syndrome' [12681270], that is often associated with iron deficiency and pregnancy. Serum transferrin receptor seems to be a rather sensitive measure of this iron deficiency [273, 1271, 1272]. There are relationships with other syndromes that we discuss here, such as cardiovascular disease 1273, but in the present review it is of especial interest that a dysregulation of iron metabolism appears to play a significant role 1274

Lupus (Systemic Lupus Erythematosus)

Lupus, or Systemic Lupus Erythematosus (SLE) [1275, 1276] describes a syndrome, somewhat related to arthritis and rheumatism, of broadly auto-immunological or inflammatory origin, and with a large variety of manifestations (e.g. [12771285]), but characterised in particular by fatigue 1286, often as a result of anaemia. This of course points to a certain level of iron dysregulation (of any number of causes), and there is certain some evidence for this [1274, 1287]. Thus, while anaemia is a feature of the disease, serum ferritin may be raised in SLE 1288, and some of the usual lipid markers of oxidative stress (that can be a result of hydroxyl radical production catalysed by poorly liganded iron) are also present 1289.

There is also a very interesting linkage between SLE and vitamin D metabolism 1290, something that has also come up in relation to the statins and atherosclerosis ([832, 1291], but cf. 1292), and indeed it there is evidence that statins may be of benefit in the treatment and even reversal of lupus [1293, 1294]. Indeed, from a much more general point of view, there is precedent for these kinds of linkages being used to uncover unknown mediators in disease states that may be worth pursuing (e.g. [6, 19, 20, 1295, 1296]).


Asthma is a well-known inflammatory disease, and has been linked with ROS generation 1297 catalysed by iron [276, 12981300].

Inflammatory bowel diseases (IBD)

By definition, IBD such as Crohn's disease and ulcerative colitis are inflammatory diseases, and while the inflammation and ROS production are well established here, their origins are somewhat uncertain [13011304]. They are frequently accompanied by anaemia, implying a derangement in iron absorption and/or metabolism [1305, 1306], and very probably absorption [1307, 1308]. The anaemia may be monitored by ferritin and transferrin receptor levels, and its correction is possible by iron supplementation plus erythropoietin [13091315]. One may suppose that some of the issues here relate to iron speciation, that is usually not measured in these studies.

Age-related macular degeneration

Age-related macular degeneration (AMD) 1316 is now the leading cause of blindness and visual disability in the elderly in developed countries [13171320]. Many components of atherosclerotic plaques have also been demonstrated in drusen 1321, a characteristic of AMD and, as here, it is reasonable to propose a common mechanism of pathogenesis between AMD and atherosclerosis. Retinal iron levels increase with age 1322, iron is significantly implicated in AMD [13231329], and iron chelation may help to reverse the process 1330. Dietary antioxidants are also protective 1331. The source of the iron appears to be excess angiogenesis and leakage from blood vessels catalysed by VEGF, and a PEGylated aptamer [13321334] against VEGF (pegaptanib) or a monoclonal antibody (ranibizumab) have shown significant promise in the treatment of macular degeneration [13351340]. Plausibly a combination therapy with one of these plus a suitable iron chelator might be even more effective.


Psoriasis is an anflammatory disease in which the production of free radicals and ROSs are strongly implicated [13411343]. Here too there is clear evidence for the involvement of a deranged iron metabolism [13431345]. Early attempts at therapy with a series of unusual iron chelators (that unfortunately had side effects) 1346 do not seem to have been followed up.


Gout is another important inflammatory disease, characterised by the accumulation of uric acid 1347. There is considerable evidence that this too is a disease of iron overload, and that uric acid accumulation – as both an antioxidant and an iron chelator 1348 – is in response to the iron overload [1349, 1350] and with highly beneficial remission of gouty symptoms occurring on depletion of iron by phlebotomy 1351.

Alcoholic and other forms of liver disease

It is known that with chronic excess, either iron or alcohol alone may individually injure the liver and other organs, and that in combination, each exaggerates the adverse effects of the other. Specifically, in alcoholic liver disease, both iron and alcohol contribute to the production of hepatic fibrosis [13521358]. Iron overload is well known to lead to hepatotoxicity [13591362] and liver cancer [1363, 1364], and lowering or chelating it is protective [1365, 1366]. Hepcidin may be involved here 1367.

Chronic obstructive pulmonary disorder (COPD) and related lung diseases

Chronic obstructive pulmonary disease (COPD) is a progressive and chronic disease which is characterised by an apparently inexorable decline in respiratory function, exercise capacity, and health status. It is also characterised by periods in which the symptoms are considerably exacerbated [13681371]. Such an acute exacerbation of COPD (AECOPD) is defined 1372 as "a sustained worsening of the patient's condition from the stable state and beyond normal day to day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD". Smoking is a major source of free radicals (and indeed metals 1373), and is a major cause of COPD. Consequently, there is considerable evidence for the evidence for the involvement of inflammation and ROSs in both the 'stable' and 'exacerbated' stages [13741381].

Needless to say, there is also considerable evidence for the significance of exposure to iron 1382 (as well as exposure to other toxic metals 1383) in the development of COPD and other lung diseases 1384. Haem oxygenase also appears to be a significant culprit [280], and lung (lavage) iron is increased 1385 while transferrin levels can be considerably lower 1386.

Other lung diseases in which ROS and iron have been implicated include Adult Respiratory Distress Syndrome [13871390] and cystic fibrosis 1391.


Tobacco smoke contains many unpleasant and carcinogenic compounds, and that tobacco smoking is a leading cause of carcinoma of the lung and indeed of other organs has become well known since the pioneering epidemiological studies of Doll, Peto and colleagues (e.g. [13921395]). Our purpose here is to point out that many of the particles associated with smoking (and also ingested from other sources) are heavily laden with micro-particulate iron, which, as a major catalyst of hydroxyl radical production, undoubtedly is a substantial contributor as well (see e.g. [1373, 1384, 13961400]).

Cancer and oncology

In addition to the issues of smoking, the development of cancer can certainly contain an inflammatory component (e.g. [14011425]), and indeed the long-term use of prophylactic anti-inflammatory aspirin lowers colon cancer incidence by 40% (age-adjusted relative risk = 0.6) 1426 (though note that this may have other side-effects 1427). (The well-known association between infectious agents such as H. pylori [14281430] and e.g. bowel cancer is probably initiated by chronic inflammation.) Given that cells require iron, restricting its supply can also limit the growth of cells, including tumour cells [14311442]. Conversely the iron carrier NGAL is overexpressed in tumours [410, 411, 1443], a process mediated via NF-κB 1444 (and see later). Further, the roles of iron, not least in the mutagenic effects of metal-catalysed Fenton chemistry, are also of significance in promoting oncogenesis [14451461]. Iron chelators [1438, 1462] are thus a doubly attractive component of anti-cancer therapeutics. The mutagenic, carcinogenic and disease-causing actions of asbestos and related fibres may also be due in significant measure to the ability of the Fe(n) that they contain to catalyse hydroxyl radical production [14631475], while there seem to be complex relations between the likelihood of apoptosis and the differential concentrations of superoxide and H2O2 [1476, 1477]. Overall, it is becoming increasingly widely recognised that anti-inflammatory agents have a role to play in the treatment of cancers; we would suggest that iron chelation may be a useful component of such treatments.


Just as do tumour cells, the malarial parasite Plasmodium falciparum requires considerable iron for growth, and there is evidence that lowering the amount of available iron provides a promising route to antimalarials (e.g. [14781494], but cf. 1495). Note in this context that iron-catalysed radical formation is also significantly involved in the antimalarial (i.e. cytotoxic) mode of action of artemisinin [1494, 14961504], and this reaction is in fact inhibited by iron chelators 1505 such that a combined artemisinin-chelator therapy would be contraindicated.


Lower down the evolutionary scale, and as presaged earlier in the section on bacterial siderophores, microbes require iron for growth, its presence may be limiting even at the scale of global CO2 fixation [15061509], its excess can in some circumstances 1510 correlate with infectivity or virulence (see above and e.g. [180, 193, 1493, 15111531]), and its chelation in a form not available to bacteria offers a route to at least a bacteriostatic kind of antibiotic or to novel therapies based on the lowering of iron available to microbes by using hepcidin 1532 or NGAL 1533. Iron chelators are also inhibitory to trypanosomes [1534, 1535], and changes in iron metabolism are also associated with viral infections 1536.

Sepsis leading to organ failure and death: severe inflammatory response syndrome

It is well known that one consequence of bacterial infection (sepsis) can be septic shock, that this can be mimicked by the Gram-negative bacterial outer membrane component LPS (lipopolysaccharide), and that in the worst cases this leads via multiple organ failure to death. However, whatever LPS does it is quite independent of the present of viable (i.e. growing or culturable – see [1537, 1538]) bacteria as the same phenomena leading to multiple organ failure (MOF) are seen without infection [1539, 1540]. Consequently, the recognition of a series of symptoms contingent on this initial inflammatory response has led to the development of the idea of a Systemic Inflammatory Response Syndrome (SIRS) [15411551] that leads to the MOF, both via apoptosis 1552 and necrosis [1553, 1554]. There is by now little doubt that these phenomena too are associated with the hyperproduction of ROSs [1546, 1551, 15551570]. Circulating free iron is raised in sepsis and related conditions [1400, 15711573]. Direct assays of oxidant induced cell death indicate that most 'free' iron is concentrated in lysosomes [15741577], that its decompartmentation is substantially involved 1570, and that its chelation can thus prevent cell death [15781581].

Many circulating inflammatory factors have been identified as important in the development of septic shock, including cytokines such as Tissue Necrosis Factor (TNF) 1582, and cellular responses via the Toll-Like Receptor are clearly involved in this process [1583, 1584]. However, we would argue that since antibodies against TNF do not inhibit the sequelae of septic shock such as multiple organ failure, the truly damaging agents are caused elsewhere and are likely to involve the iron-mediated production of damaging hydroxyl radicals (see also 1563).

In this regard, it is especially interesting that the antioxidant melatonin is particularly effective in preventing septic shock [15851587], and a variety of suitable antioxidants have shown potential here [1573, 15881591], notably in combination with iron chelators [1592, 1593] (and see also [1594, 1595]). As with quite a number of the indications given above, a further link with Fe metabolism is seen in the protective effects of erythropoietin [1596, 1597].

Pro- and anti-oxidants and their contributions to cellular physiology

A very great many cellular metabolites are redox active within the range of redox potentials realistically accessible to biology (including some molecules such as proline 1598 that are not commonly considered to be redox-active), and it is not our purpose here to list them extensively. Not only their redox potential and status but even their absolute amounts can have profound effects on metabolism 1599). Our chief point here is that it is the intersection of iron metabolism and oxygen reduction that needs to be the focus, with the 'iron'-catalysed production of hydroxyl radical being the nexus, with the standard redox potential of a redox couple per se being less significant in absolute terms, and the redox potential that a particular redox couple 'feels' being dependent in a complex manner on a variety of thermodynamic and kinetic factors 1229. Thus, although ascorbate is 'reducing' and an 'antioxidant', its reaction with O2, especially when catalysed by Fe(II), produces superoxide and thence OH radicals that may be pro-oxidant. It is this kind of stepwise multi-electron-transfer phenomenon that explains the otherwise possibly puzzling observation of the oxidant-induced reduction of respiratory chain components (see e.g. [1600, 1601]). Consequently, it is extremely unwise to make pronouncements on the role of 'ROSs' without being quite explicit about which ones are meant.

Thus anything – even an antioxidant – that e.g. by reaction with O2 produces superoxide, peroxide and hydroxyl radicals will turn out to be a pro-oxidant if the flux to superoxide and in particular to hydroxyl radicals is stimulated. Thermodynamically, the 1-electron reduction by ascorbate of dioxygen is disfavoured, with the 2-electron reduction to peroxide being the thermodynamically preferred route. However, such reactions are heavily restricted kinetically in the absence of any catalysts [130]. It is an unfortunate fact that the oxygen-mediated "autoxidation" of ascorbate does in fact occur at considerable rates when it is accelerated by the presence of iron or other transition metal ions [130, 16021606]. In a similar vein, 'free' or inadequately liganded Fe(II) catalyses the production of hydroxyl radicals from oxygen plus a variety of natural biomolecules, including adrenaline (epinephrine) 1607, haemin 1608, and even peptides such as the amyloid-β involved in the development of Alzheimer's disease [1009, 1027]. Dietary antioxidants (see below) can therefore act in complex and synergistic ways depending on iron status 1609. In this regard, the idea of using elemental iron plus ascorbate in food supplements 1610 does not seem a good one.

It should be noted that there are also occasions, e.g. in the decomposition of refractory polymers such as lignin, where such radical production is involved beneficially 1611.

Finally, a variety of molecules can trap hydroxyl radicals, including hippurate 1612, melatonin [1233, 1585, 1586, 16131631] and salicylate 1632.

Antioxidants as therapeutic agents? Should we be including iron chelators in such clinical trials?

Given the wide recognition of the importance of ROSs in a variety of diseases as described above, many investigators have considered the use of known antioxidants such as vitamins C (ascorbate) and E (α-tocopherol) in preventative therapy. Although there have been some successes (e.g. 1633), the results have generally been decidedly mixed, with little clinical benefit (or even actual disbenefit) following from their administration [692, 1588, 16341639], e.g. for ALS 1640, atherosclerosis [106, 764], cardiovascular disease [16411645], neuroprotection 1646, macular degeneration 1647, pre-eclampsia [16481652], critical care medicine 1653, aging [1165, 1168, 1654, 1655], lung disease 1656, elective surgery involving ischaemia-reperfusion 1657, all-cause mortality [1637, 1658], etc. One interpretation for these disappointing results, that is consistent with the general theme of this review, involves the recognition that a variety of antioxidants can in fact act as pro-oxidants and thus actually promote the production of OH radicals in the presence of inappropriately or inadequately liganded Fe(II) [130, 528, 1602, 1604, 1659, 1660]. (One might also comment that the intracellular location of the antioxidants may be an issue, and that the view that targeting them to mitochondria may well have considerable merit [16611663].) Thus any predictions about the utility or otherwise of antioxidants need to take into account the amount of 'free' iron present. In particular, we would suggest that future trials of this type might beneficially include appropriate iron chelators, whether alone or with anti oxidants.

Liganding and reactivity of Fe(n)

Given the damage that iron-mediated OH radical can create, the question arises as to whether appropriate chelators can inhibit this by inhibiting the production of OH, and while the answer is 'yes' the interpretation of the relevant experiments is not always as clear cut as one would wish [43]. This is because the OH radical is so reactive that its production is normally assessed by addition of the putative chelator and observation of its effect on the rate of reaction of a target molecule such as salicylate with the OH generated. The ability of a chelator to inhibit such a reaction can then occur not only via a reduction in the rate of OH production but by trapping the OH itself, as well as by other mechanisms 1664. This said, there is little doubt that iron chelators can be highly protective, and it is many ways very surprising that their use is not more widespread.

We begin by noting that the reactivity of iron does vary greatly depending upon its liganding environment [71]. Cheng et al. state [72] "Oxygen ligands prefer Fe(III); thus, the reduction potential of the iron is decreased. Conversely, nitrogen and sulfur ligands stabilize Fe(II); thus, the reduction potential of the iron is increased. Therefore, chelators with oxygen ligands, such as citrate, promote the oxidation of Fe(II) to Fe(III), while chelators that contain nitrogen ligands, such as phenanthroline, inhibit the oxidation of Fe(II). Many chelators, such as EDTA and Desferal (DFO), will bind both Fe(II) and Fe- (III); however, the stability constants are much greater for the Fe(III)-chelator complexes. Therefore, these chelators will bind Fe(II) and subsequently promote the oxidation of the Fe(II) to Fe(III) with the concomitant reduction of molecular oxygen to partially reduced oxygen species. Since the maximal coordination number of iron is six, the hexadentate chelators can provide more consistently inert complexes due to their ability to completely saturate the coordination sphere of the iron atom and, consequently, deactivate the "free iron" completely. For example, DFO is a very effective antioxidant in clinical application because of its potential to markedly decrease the redox activity of iron [137]." However, it is not easy to make hexadentate ligands orally active 1665.

Iron typically can coordinate 6 ligands in an octahedral arrangement. Preferential chelation of the Fe(II) or the Fe(III) form necessarily changes its redox potential as a result of Le Chatelier's principle, and from Marcus theory [16661669] the rate of outer-sphere electron transfer reactions is typically related to differences in the free energy change, i.e. the differences in redox potentials of the interacting partners. In addition, it widely recognised that [137] "The tight binding of low molecular {weight} chelators via coordinating ligands such as O, N, S to iron blocks the iron's ability to catalyze redox reactions. Since the maximal coordination number of iron is six, it is often argued that the hexadentate chelators can provide more consistently inert complexes due to their ability to completely saturate the coordination sphere of the Fe atom. Consequently, a chelator molecule that binds to all six sites of the Fe ion completely deactivates the "free iron". Such chelators are termed "hexidentate" {sic}, of which desferrioxamine is an example. There are many Fe chelators that inhibit the reactions of Fe, oxygen, and their metabolites. For example, desferrioxamine ... (DFO) markedly decreases the redox activity of Fe(III) and is a very effective antioxidant through its ability to bind Fe."

By contrast, bidentate or tridentate chelators that bind to only 2 or 3 of the available iron chelation sites, especially when they bind to both Fe(II) and Fe(III), can in fact catalyse redox cycling and thereby promote free radical generation [1437, 1665, 1670, 1671]. Thus, the most potent iron chelators will normally be hexadentate (but may consequently strip iron from iron-containing enzyme and thereby have deleterious side effects). Bi- or tri-dentate ligands should therefore be at saturating concentrations for maximum effect.

Generally, the harder ligands that favour Fe(III) involve O whereas softer ligands that bind Fe(II) involve N and S. The type of ligand also influences the absorption spectrum of the ferric form of the chelator, such that conclusions can be drawn about the types of group involved in the complex. These charge transfer bands that appear on ligand binding are at around 340 nm for carboxylates, around 425 nm for trishydroxamates, 470 nm for bis-hydroxamates, 515 nm for monohydroxamates, around 480 nm for tris-catecholates, 560 nm for bis-catecholates and 680 nm for mono-catecholates [173]. In addition, for tris-bidentate complexes the complex can, on an octahedral arrangement, have two different configurations, a left-handed propeller, termed the Λ-configuration, and a righthanded propeller, the Δ-configuration [173].

Iron chelators – those approved and used clinically

A number of reviews (e.g. [1437, 1438, 16721678]) cover aspects of iron chelators that have had or may have utility clinically.

Whitnall and Richardson 1062 list a number of useful features of an experimentally (and clinically) useful iron chelator. Thus, "A compound suitable for the treatment of neurodegenerative disease should possess a number of qualities, namely (1) strong affinity for FeIII, (2) low molecular weight, (3) lipophilicity high enough to accommodate permeation of cell membranes and the BBB, (4) oral activity, and (5) minimal toxicity 1062. Also, partly because there are few trivalent ions other than Fe(III) that the body actually needs, the major synthetic focus has been on the design of FeIII-selective chelators which feature "hard" oxygen donor atoms. Additionally, under aerobic conditions, high-affinity FeIII chelators will tend to chelate FeII to facilitate autoxidation, such that high-affinity FeIII-selective compounds will beneficially bind both FeIII and FeII under most physiological conditions" 1062. (Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity 1679.)

Desferrioxamines are nonpeptide hydroxamate siderophores composed of alternating dicarboxylic acid and diamine units. linked by amide bonds. They are produced by many Streptomyces species 1680. Desferrioxamine B is a linear (acyclic) substance produced (industrially) by the actinobacterium Streptomyces pilosus 1681, and is widely used as an iron chelator for the prevention and treatment of the effects of iron overload. It is commercially available as desferal (desferrioxamine methane sulphonate), also known as deferoxamine in the USA. It has been very effective in the treatment of a number of diseases, leading to the view that such molecules should have considerable therapeutic potential. A significant disadvantage of DFO is that it does not seem to cross the intestine intact (despite the rather catholic substrate specificity of intestinal peptide transporters [16821685]) and must therefore be given intravenously or subcutaneously. By contrast, another chelator known as Deferriprone or L1 does appear to cross cell membranes, but it is only bidentate.

Those with approval for clinical use are few in number and we deal with them first. Table 1 compares them with the 'ideal' properties of a clinically useful iron chelator, while Fig 7 gives the structure of the three most common, viz. desferal (deferoxamine), ferriprox (L1 or deferiprone) and exjade (ICL670 or deferasirox). (Dexrazoxane, a hexadentate chelator, is also marketed 1686.)
Figure 7

Some iron chelators that are in clinical use (left hand side) or that have been proposed.

Table 1

Comparison of the main available iron chelators to an ideal chelation drug (modified from 2469)


"Ideal chelator"




Route of administration


Parenteral, usually subcutaneous or intravenous



Plasma half-life

Long enough to give constant protection from labile plasma iron

Short (minutes); requires constant delivery

Moderate (< 2 hours). Requires at least 3-times-per-day dosing

Long, 8–16 hours; remains in plasma at 24 h

Therapeutic index


High at moderate doses in iron-overloaded subjects

Idiosyncratic side effects are most important

Probably high in iron overloaded subjects*

Molar iron chelating efficiency; charge of iron (III) complex

High, uncharged

High (hexadentate); charged

Low (bidentate); uncharged

Moderate (tridentate); uncharged

Important side effects

None or only in iron-depleted subjects

Auditory and retinal toxicity; effects on bones and growth; potential lung toxicity, all at high doses; local skin reactions at infusion sites

Rare but severe agranulocytosis; mild neutropenia; common abdominal discomfort; erosive arthritis

Abdominal discomfort; rash or mild diarrhoea upon initiation of therapy; mild increased creatinine level

Ability to chelate intracellular cardiac and other tissue iron in humans


Probably lower than deferiprone and deferasirox (it is not clear why)

High in clinical and in in vitro studies

Insufficient clinical data available; promising in laboratory studies

*Nephrotoxicity that has been observed in non-iron-loaded animals has been minimal in iron-overloaded humans, but effectiveness is demonstrated only at higher end of tested doses, as discussed in 1693.

Desferal (deferoxamine) is the most used chelator for historical reasons. It is hexadentate but is not orally bioavailable. Ferriprox (deferiprone) is a bidentate ligand (1,2-dimethyl, 3-hydroxypyridin-4-one). It is orally bioavailable although comparatively high doses are required, and it postdates desferal. "Deferiprone has high affinity for iron and interacts with almost all the iron pools at the molecular, cellular, tissue and organ levels. Doses of 50–120 mg/kg/day appear to be effective in bringing patients to negative iron balance" 1687. It can have somewhat better properties than desferal 1688. Finally, Exjade (ICL670) (deferasirox) [16891702] is the most recent chelator approved for clinical use, and is tridentate. It is orally active, and there is a large bibliography at The recommended initial daily dose of Exjade is 20 mg/kg body weight.

It is clear from Table 1 that in the time evolution from deferoxamine through deferiprone to deferasirox there has been a noticeable improvement in the general properties of iron chelators, although there are few published data on the quantitative structure-activity relationships of candidate molecules that might allow one to design future ones rationally. What is certainly clear is that there is a trade-off in properties, and that appropriate chelators will keep iron levels intermediate, i.e. not too low and not too high (a 'Goldilocks' strategy, if you will), and that hexadentate molecules may correspondingly be too tightly binding and strip iron from important molecules that need it. What is particularly important, as well as a good plasma half-life, is the ability to cross cell membranes, as this is necessary both for oral administration and for ensuring that the chelator in question actually accesses the intracellular 'free' iron pools of interest. Which carriers are used for this in humans in vivo is presently uncertain [18, 1703].

Drugs that have been approved for clinical use for other purposes, but that also happen to be iron chelators

The high investment of time, money and intellectual activity necessary to get a drug approved clinically has led to a number of strategies to exploit those that already have been approved and are thus considered 'safe'. One such strategy is the combination therapy of approved drugs that can yet serve for novel indications (e.g. [17041708]). Another strategy is to look for antioxidant or iron-binding chemical motifs in drugs that have already been approved for other purposes 1709 (or to measure such properties directly).

Clioquinol (CQ) [1062, 1674, 1710, 1711] (Fig 7) is one existing (anti-parasitic) drug that has been proposed for use as an iron chelator, as it contains the known iron-chelating 8-hydroxyquinoline moiety. It has indeed enjoyed some success in this role. However, clioquinol toxicity has been reported if it is used over an extended period 1712 and this may be due to the formation of a Zn-clioquinol chelate 1713.

A particular attraction of such existing drugs is that they are likely to have favourable pharmacokinetics and pharmacodynamics, and in particular are likely to be cell-permeable. Note that despite a widespread assumption that lipophilicity or log P is sufficient to account for drug distribution this is not in fact the case, as there are hundreds of natural transporters that drugs can use (e.g. [18, 1714]). For instance, the iron-chelating 8-hydroxy quinoline motif contained in molecules such as clioquinol is also present in the tryptophan catabolite xanthurenic acid (Fig 7), and it is likely that transmembrane transport of the synthetic drug molecule occurs via natural carriers whose 'normal' role is to transport endogenous but structurally related molecules [18, 1703].

Iron chelators that have been studied but not yet approved

Given the importance of the field, many academic investigators have sought to develop their own iron chelators that might exhibit the desirable properties listed above. One class of molecule includes isonicotinylhydrazones. Thus, pyridoxal isonicotinyl hydrazone (PIH) [1672, 17151720] is a promising molecule (also proposed in anti-cancer therapy), although it is hydrolysed both in vivo and in vitro 1721. Other analogues include salicylaldehyde (SIH) 1722 and 2-hydroxy-1-napthylaldehyde (NIH) isonicotinyl hydrazones. PIH was disclosed before being patented, and is thus seen as having no pharmaceutical (company) interest. Various other derivatives are therefore being considered [1035, 1462], including pyrazinylketone isonicotinoyl hydrazones 1723.

A variety of 8-hydroxyquinolines (8HQs) 1724 have been considered, although as with other bidentate and tridentate ligands that cannot necessarily effect complete liganding of iron there is always a danger that inadequate concentrations might be pro-oxidant (e.g. [1725, 1726]). One molecule, VK-28, combines various pertinent moieties and has shown some promise in the treatment of neurological disorders [17271730]. This strategy of combining drug elements that can hit multiple targets ('polypharmacology' [807, 17311734]) has much to commend it, including on theoretical grounds, and we discuss these in the section on systems biology below. Another 8HQ that has elicited interest is O-trensox [1431, 17351742].

Other ligands or motifs that might be considered include di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT), that has been shown to be effective against tumours 1743, 2,2'-dipyridyl, 1,10-phenanthroline [1744, 1745], 2-benzoylpyridine thiosemicarbazones 1746 and thiohydrazones 1747. HBED (Fig 7) (N,N'-bis-(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid) forms a 1:1 complex with Fe(III) but is probably only tetradentate 1748. It seems not to be very orally active 1749 but may be more effective than is DFO [17501752]. Poly-hydroxylated 1,4-naphthoquinones occur as sea urchin pigments and have shown protective effects 1753.

Continuing the theme of polypharmacology, R-(α)-lipoic acid [17541757] is also an antioxidant, that may in addition act by stimulating other anti-oxidant pathways 1758. Finally, one interesting area is that of prochelators (e.g. 1759) in which the oxidant itself triggers the formation of a chelator able to inhibit the Fenton reaction.

Utility of iron chelators in disease amelioration

Therapeutic uses of iron chelators have been widely and usefully reviewed (e.g. [1437, 1489, 1676, 17601767]). Many problems remain, such as bioavailability, mis-dosing 1768 (too little iron as well as too much of it can be bad), toxicity, selectivity and so on, and their design is consequently highly non-trivial [1665, 1670]. Nevertheless, iron chelators have demonstrated therapeutic benefits in Alzheimer's [1674, 1710, 17691771], Parkinson's [1037, 1729, 1772], cold-induced brain injury [1773, 1774], coronary disease [714, 797], renal diseases 1775, various kinds of infection 1763 and of course in iron overload diseases [1762, 1767].

As mentioned above, one interesting strategy is to devise chelators that are only activated by oxidative stress [1760, 17761779]. Another is to seek to combine different kinds of functionality in the same molecule. To this end, Youdim and colleagues in particular have developed a series of multifunctional 8-hydroxyquinoline 1740 derivatives that are effective bidentate iron chelators and that seem to show considerable promise in the treatment of a variety of neurodegenerative diseases [1037, 17271729, 17801784] (see also US Patent 20060234927). In this case the antioxidative mechanism is clearly via chelation since such (8-hydroxyquinoline) molecules are poor scavengers of radicals directly 1785, a fact that also makes them useful scientific tools. As bidentate ligands they cross both cell membranes and the BBB fairly easily (though lipophilicity per se seems not to be important for the biological activity of 8-hydroxyquinoline chelators [1737, 1739]). Importantly, the comparatively weak bidentate binders seem not to have major long-term effects if used carefully [1483, 1762, 1786, 1787]

Interaction of xenobiotics with iron metabolism

As Cherny and colleagues point out 1710, there are many US Pharmacopaeia-registered drugs that, while not being termed chelators, do in fact have both chelating properties and favourable toxicity profiles. Thus we need to recognise potentially both positive and negative interactions between drugs in general and iron metabolism. Any drug that can bind iron can also catalyse the formation of free radicals. Thus, gentamicin can form a gentamicin-iron complex that can lead to toxic symptoms such as hearing loss; this is reversed by iron chelators [1788, 1789]. Existing drugs other than iron chelators may also have effects on iron metabolism 1790, and iron can catalyse their oxidation 1791. It is not, of course, news that drugs have multiple effects. In this context, we reiterate that some statins, for instance, have chelating properties [893].

Other toxicants might also mediate their damaging effects through iron-catalysed radical formation [1792, 1793]. This in addition to the well-known iron-catalysed, radical-mediated mechanism of toxicity of the viologens such as diquat and paraquat [17941799] (whose herbicidal activity is in fact inhibited by iron chelators 1800) and of adriamycin [1801, 1802]. As mentioned above, the carcinogenic action of asbestos may also be due to the ability of the Fe(n) that it contains to catalyse hydroxyl radical production [1469, 1475], while carcinogenic mycotoxins such as aflatoxin may interact synergistically with iron 1803.

Dietary sources of iron chelators

There is also a considerable and positive role for nutrients in terms of their chelation of iron. Indeed, polyphenolic compounds, many of which have known health benefits [18041813], are widely used as food antioxidants [1814, 1815]. There is of course considerable epidemiological evidence for the benefits of consuming fruit and vegetables that are likely to contain such antioxidants (e.g. [18161819]), and – although possibly a minimum – this has been popularised as the 'five a day' message (e.g. and Even though elements of the 'Mediterranean' diet that are considered to be beneficial are usually assumed to be so on the basis of their antioxidant capabilities (but cf. 1820), many of the polyphenolic compounds (e.g. flavones, isoflavones, stilbenes, flavanones, catechins (flavan-3-ols), chalcones, tannins and anthocyanidins) [18211828] so implicated may also act to chelate iron as well [1073, 18291843]. This is reasonable given that many of these polyphenols and flavonoid compounds [1821, 18441853] have groups such as the catechol moiety that are part of the known iron-binding elements of microbial siderophores. Examples include flavones such as quercetin [914, 1813, 1829, 18541864], rutin [1829, 1857, 1858, 1865, 1866], baicalin [1860, 1867], curcumin [1813, 18681872], kolaviron 1873, flavonol 1874, floranol 1875, xanthones such as mangiferin [18761879], morin 1876, catechins [1073, 1807, 1838, 1854, 1880, 1881] and theaflavins 1882, as well as procyanidins [1835, 1883] and melatonin [1628, 18841887]. However, the celebrated (trans-)-resveratrol molecule [18881902] may act mainly via other pathways.

A considerable number of studies with non-purified dietary constituents containing the above polyphenolic components have also shown promise in inhibiting diseases in which oxidative stress is implicated [1825, 19031906]. For instance in stroke and related neuronal aging and stress conditions, preventative activity can be found in blueberries [19071913] (and see 1914), Ginkgo biloba extract (EGb 761) [1910, 1915, 1916], grapes 1917, green tea [1807, 19181921], Mangifera indica extract 1879, strawberries 1907, spinach 1907 and Crataegus [922], while combinations of some these components ('protandim') have been claimed to reduce ROS levels by stimulating the production of catalase and SOD 1922. As with pharmaceutical drugs [18, 19231925], there are significant problems with bioavailability [1926, 1927], although the necessary measurements are starting to come forward [1804, 1809, 19261932]. There is now increasing evidence for the mechanisms with which these dietary components and related natural products and derivatives (often with anti-inflammatory, anti-mutagenic or anti-carcinogenic properties) interact with well recognised cellular signalling pathways (e.g. [1402, 19351944, 1895, 19451952, 1896, 1410, 19531960, 1413, 19611981, 1913, 1982, 1900, 1933, 19831990]).

Role of iron-generated ROSs in cellular signalling and oxidative stress

Thus, although this is not the focus of the present more physiologically based review, we recognise that many of relationships between ROSs and oxidative stress and overt progressive diseases may be mediated via the inflammatory signalling pathways involved in 'innate immunity' [900, 19911993]. NF-κB is an important transcription factor, and the NF-κB system is intimately involved in this signalling [588, 672, 719, 1408, 1409, 1454, 19942019].

In the NF-κB system (e.g. [20202024]) (Fig 8), NF-κB is normally held inactive in the cytoplasm by binding to an inhibitor IκB (often IκBα). Pro-inflammatory cytokines such as TNF-α, LPS [20252030] and IL-1 2031 act by binding to receptors at the cell surface and initiating signalling pathways that lead to the activation of a particular kinase, IκB kinase or IKK. This kinase phosphorylates the IκB causing it to be released (and ubiquitinated and degraded by the proteasome), allowing the NF-κB to be translocated to the nucleus where it can activate as many as 300 genes. Simple models of the NF-κB system show the main control elements [2032, 2033] and their synergistic interaction 2034. The NF-κB system is implicated in apoptosis [2035, 2036], aging 1199, and in diseases such as cancer [1405, 1444, 1454, 1808, 20372040], arthritis [20402043] and a variety of other diseases 2044. Antioxidants such as vitamin E [552, 2017] and melatonin [20452049] are at least partially protective. Oxidative stress seems to act upstream of IKK 2014, on IκBα directly 2050 and in the p38 MAP kinase pathway [1993, 2014, 2051], and there is also evidence that at least some of the statins act on the PI3K-akt and NF-κB pathways too [819, 883, 20522060]. A considerable number of inhibitors of the NF-κB system exist 2055, many exhibiting cross-reactivity 1734.
Figure 8

An overview of cellular signaling using the NF-κB and p38 systems. Note that some of the extracellular effectors that mediate NF-κB activation are themselves produced and secreted as a result of the activation, potentially creating an autocatalytic system.

The induction of NF-κB by ROSs appears to involve a coupling via the glutathione system [2007, 2035, 2036, 20612078] (and see also [2079, 2080]).

A variety of studies have shown that iron is involved in these signalling processes [1839, 1996, 2015, 20812085], probably again acting upstream of the IKK [557, 2083, 2086, 2087].

Interestingly, there is interplay between the NF-κB pathway and the regulation of NGAL [404, 405, 2088, 2089], ferritin 2030 and hepcidin 2090, presumably acting as a negative feedback as the cell tries to control and ligand its free Fe(n) in the face of oxidative stress caused by the release of free iron 2091.

The systems biology of ROS generation and activity

It is not news that most major changes in physiological states have multigenic or multifactorial origins (e.g. [2092, 2093]). This means, as an inevitable consequence, that we need to recognize that their observation requires a systems approach, and that most diseases are therefore in fact to be seen as systems or network diseases [631, 20942102]. Changes in individual reaction steps (or even single manipulations) can change the levels of scores or hundreds of transcripts 2103, proteins 2104 or metabolites [725]. In this regard, small molecule (metabolomics) measurements have especial advantages for capturing network organisation, including on theoretical grounds [21052112].

If we consider just one variable of present relevance, the quantity of hydroxyl radical, the amount that is able to react with proteins, lipids and DNA is clearly determined by a huge number of reactions, whether directly or otherwise – not only the concentrations of reagents and enzyme that directly catalyse its formation and destruction but by everything else that affects their concentration and activity, and so on. This is of course well established in biology in the formalism of metabolic control analysis (MCA) (see e.g. [21132120]), and was recognized over 30 years ago in Morris' prescient review on anaerobes 2121. Modern systems theories of aging (e.g. [1175, 1180, 2120, 2122] and above) (Fig 9) also recognize physiological progression as being determined in terms of a balance between 'good' and 'bad' factors. MCA and related formalisms can be seen as theories of sensitivity analysis, which in many cases can be normalized such that an overall output function can be described quantitatively in terms of the relative contributions of each of its component steps (e.g. [21232127]). In MCA the normalized local sensitivities are known as control coefficients, and the sum of the concentration-control coefficients = 0, in other words in the steady state the rate of production and consumption of a particular entity is in balance and all reactions can contribute to it to some degree. The concentration-control coefficient describes this degree quantitatively. It is now possible to produce appropriate quantitative representations of metabolic networks using quite sparse kinds of information (in fact just the stoichiometry and network structure 2128), and thereby provide initial estimates for more sophisticated fitting algorithms (e.g. [21292132]. Indeed, the analysis of the properties and behaviour of networks is at the core of modern systems biology (e.g. [2095, 21332140]).
Figure 9

General view of the role of iron, antioxidants and ROSs in aging and degenerative processes. Some of the decay may be ameliorated by lifestyle and dietary means. Based in part on 1175.

A corollary of such considerations is that to decrease the amount of damage caused by OH (or any other) radicals we need both to decrease their production and increase their removal to harmless substances 2141, and that on general grounds [17061708, 2142] such a strategy (for instance of combining a cell-permeable iron chelator with a cell-permeable antioxidant) might be expected to give a synergistic response. Even determining the means of cell permeability and tissue distribution turns out to be a systems biology problem in which we need to know the nature and activity of all the carriers that are involved [18, 1703, 1714, 2143]. At all events, it is undoubtedly the case that the steady-state rate of production of a molecule such as the hydroxyl radical is controlled or affected by a considerable number of steps. These minimally include the multiple reactions of the mitochondrial respiratory chain and the various oxidases producing superoxide and peroxide, the activities of catalase and SOD enzymes that together can remove them, protective reactions such as heat-shock proteins, and most pertinently to the present review a large number of reactions involved in the metabolism and safe liganding of iron that help determine the rate at which OH is produced.

It is also pertinent to enquire as to why we are now seeing so many of these progressive diseases, and as to what may be their causes. Undoubtedly the simple fact of improved longevity is one [165] as damage accumulates. However, we note that anything that decreases the amount of unliganded iron, such as decreasing the total dietary iron intake e.g. from red meat, must be helpful [1156, 2144].

Anti-inflammatory cytokines; the example of erythropoietin

We have above adduced considerable evidence that decreasing the amount of hydroxyl radical by any means is valuable, whether by removing initially generated ROSs such as superoxide and peroxide or by chelating poorly liganded iron in a way that stops these ROSs forming the hydroxyl radical. While pro-inflammatory cytokines can themselves increase ROS production and modulate the activities of signaling pathways such as NF-κB and p38, there are also anti-inflammatory cytokines. A particularly interesting example is that of erythropoietin (also discussed above as being protective in a number of iron-mediated diseases).

Erythropoietin was originally recognized via its role in erythropoiesis [21452147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940, 942, 21482155]. These included cardiovascular disease [721, 722, 21562175], stroke and other related neurological diseases [924926, 928, 929, 933, 937, 938, 2155, 21762204], diabetic neuropathy 2205, kidney injury [2173, 22062212], intestinal injury 2213 and shock (both septic and non-septic) [1596, 1597, 2214].

The question then arises as to how it is doing this mechanistically, and the proximate answer is that it (and other anti-inflammatory agents, e.g. [1808, 2215, 2216]) seem to act via many of the same signalling pathways as do inflammatory agents [943, 2150, 22172226]. There is evidence that it can help maintain superoxide dismutase activity [2214, 2227], invoke haem oxygenase 2228, and in particular – from the perspective of this review – that it may remove poorly liganded iron 2229 and interact with hydroxyl radical directly [22302233].

It is notable that appropriate levels of erythropoietin appear not only to be efficacious but to be safe, even in pregnancy [22342241]. Erythropoietin may itself be a marker of hypoxia and oxidative stress in pregnancy [531, 22422245], consistent with a view that the body is attempting to deal with these problems by creating anti-inflammatory cytokines.

Hypoxia-inducible factor (HIF)

Although I am mainly not concentrating on genetic regulatory aspects in this review, the HIF [2246, 2247] does deserve some mention, since many of the syndromes described above are accompanied by hypoxia, and this causes levels of the HIF to increase. HIF is a transcription factor that can activate a considerable number of genes, including VEGF [1951, 22462250]. In contrast to the constitutive expression of HIF-1α, HIF-1β protein levels are regulated in response to the cellular oxygen concentration 2251. The active HIF is the HIF-1αβ heterodimer 2252. HIF couples anoxia to innate immunity via the NF-κB system 2253. In particular, HIF effects (via hepcidin) the mobilisation or iron and can cause the expression of inflammatory cytokines such as IL-1, IL-6 and TNF-α [22542256] under conditions (hypoxia) where superoxide and peroxide production are likely to be increased, and consequently increases sepsis (in that HIF-knockout mice are resistant to LPS-induced sepsis [2254, 2255]). By contrast, induction of HIF (and the genes that it activates) can effect neuroprotection [2252, 2257]. HIF also appears to have a significant role in placental development, and defective HIF expression may be involved in pre-eclampsia and intra-uterine growth retardation [435, 2246, 2258]. Qutub and colleagues provide useful models [2259, 2260] of HIF activation under a variety of conditions of iron, O2, 2-oxoglutarate and other factors.

Autocatalysis, positive feedback and Systems Biology

What has emerged in recent years is a recognition that the structure (i.e. topology) of the modules of metabolic and signalling networks, somewhat independent of the individual activities of their components, can have a profound controlling influence on their behaviour (e.g. [2107, 2134, 2135, 2261, 2262]). Classically, negative feedback structures are considered to confer stability, while positive feedbacks tend to have the opposite effect. However, negative feedbacks with delay loops can cause oscillations [2022, 2109] while some kinds of positive feedback loops can confer stability [2262, 2263]. However, there is no doubt that structures in which a damaging agent causes the production of a second damaging agent that itself catalyses the production of the first or a separate damaging agent can exhibit a runaway kind of damage. This is exactly what can happen with iron and superoxide since Fe(n) can be liberated from ferritin by superoxide radicals and then catalyse the production of further hydroxyl radical by increasing the amount of free iron (Fig 6). A similar effect can occur with Fe-S proteins in SOD-deficiency 1148, with the degradation of mitochondria by radical damage leading to further production of radicals [28, 30, 2264], and the effects of oxidative stress on iron storage 2265. This again illustrates the importance of acting at multiple points in a network to control these kinds of damage. Exactly the same is true of the IL-1 and TNF-α systems in which IL-1 or TNF-α (oxidative stress) acting on one cell can effect the secretion of further IL-1/TNF-α that can act on adjacent cells (Fig 8), of the hypoxia-dependent increase in both ROSs and serum iron mediated by hepcidin (Fig 3), the autocatalytic synergy between overfeeding, inflammation and (pre-)diabetes, and of the peroxide/iron pair that are liberated when frataxin is deficient (see above). It is these kinds of synergistic effects and autocatalytic cycles that are the hallmark of the major and progressive effects on human physiology that are seen in these kinds of system. Indeed, one might comment that such multi-site and autocatalytic effects are required to overwhelm normal defences precisely because human metabolic and signalling systems are 'robust' systems that have evolved topologies that are resistant or robust to parameter changes (see e.g. [22662291]).

Predictive biology

It is often considered (e.g. [2292, 2293]) that a desirable feature of a scientific idea is its ability to make useful predictions, and while this is not in fact a particularly well founded philosophical principle, it probably is of value to set out a couple of 'predictions' that follow from the present analysis. One prominent feature of the above is the primacy of the iron-catalysed production of the damaging hydroxyl radical, and thus a test of the involvement of these kinds of reactions in the various physiological and pathological states to which we allude is the prediction that they should be accompanied by markers of oxidative stress characteristic of reactions of endogenous metabolites with the hydroxyl radical. While it is not that easy to disentangle the complex reactions of ROSs with biomolecules [43, 1055], at least the following appear to be a result of reactions involving OH [2294, 2295]: 8-oxo-2'-deoxyguanosine (oxo8dG) [98, 2296, 2297], 8-oxo-7,8- dihydro-2'-deoxyguanosine [90, 92] and thymine glycol [92, 2294].

Another set of predictions from the systems biology perspective [17041708, 1731, 2138, 2291, 22982310] is that combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway 1906 or modulation of multiple gene products 2311, or both [2312, 2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents. Such combinations of 'causes' do not have to be guessed a priori but can be obtained via inferencing techniques (e.g. [23142320]) – for a recent example see 2321. The nonlinear behaviour of biochemical networks also serves to explain the bell-shaped dose-response curves underpinning the hormesis [23222326] often observed.

Iron-mediated oxidative stress is arguably the cause of much of the inflammation typically observed in biological systems, often further mediated via pro-inflammatory cytokines. Another major prediction that comes from the above then is that molecules that are anti-inflammatory, whether widely recognised as such or not, should have beneficial effects in syndromes for which they have not necessarily been tested. An obvious set of candidates in this regard are to be found among the statins, since it is now clear that they have important anti-inflammatory properties (see above). Thus, there are already indications that as well as their established benefits in cardiovascular disease (e.g. [804, 2327]) they may exert benefit in a huge variety of syndromes [838], including sepsis [839, 2060, 23282340], heart failure 2341, pain perception 2342, lupus and related diseases [1293, 2343], diabetes [877, 2344], rheumatoid arthritis [866, 869, 890, 23452350], kidney disease [23512353], inflammatory skin disease 2354, emphysema 2355, ischaemia-reperfusion injury 2356, stroke [864, 872, 23572364], traumatic brain injury [23652367], neurodegenerative diseases [860862, 920, 1294, 2059, 23682384], neurotoxicity 2385 and cancer [23862400].

Concluding remarks and quo vadis

"Actually, the orgy of fact extraction in which everybody is currently engaged has, like most consumer economies, accumulated a vast debt. This is a debt of theory and some of us are soon going to have an exciting time paying it back – with interest, I hope." 2401.

"But one thing is certain: to understand the whole you must look at the whole" 2402

"If you are not thinking about your experiments on a whole-genome level you are going to be a dinosaur". J. Stamatoyannopoulos, quoted in 2403.

While it is less common for scientists to publish 'negative' results ('there was no effect of some agent on some process'), and there has been a tendency to seek to falsify specific hypotheses rather than to paint a big picture 2404, there is no doubt that the sheer weight of positive evidence can be persuasive in leading one to a view. As Bertrand Russell put it 2405, "When one admits that nothing is certain one must, I think, also admit that some things are much more nearly certain than others." However, as mentioned above, the huge volume of scientific activity has in many ways led to a 'balkanisation' of the literature 2406 in which scientists deal with the problem of the deluge of published papers by necessarily ignoring most of them. This is no longer realistic (nor necessary) in an age of post-genomics, the internet, Web 2.0 and systems biology, and when we are starting to move to integrative (if distributed) models of organisms (including humans) at a whole organ, genome or whole organism scale [118, 2135, 24072416]. The 'digital human' is thus an important research goal [2410, 24152417]. Expression profiling atlases are becoming increasingly widespread (e.g. [24182423]), and one can anticipate using these straightforwardly to extend these 'generalised' (sub)cellular network models in a tissue-specific manner 2424. With the ability to exchange models of biochemical networks in a principled way [24252428], when they are marked up appropriately (e.g. [3, 4]), we can expect to begin to reason about them automatically [118, 2429], such that we may soon look forward to an era in which we can recognise the commonalities across a variety of different subfields – a specific message of the present overview. Thus, while iron and metabolism should be considered in the context of other processes that may be contributing to the disorders discussed, and it is evident that they are intimately involved in many disease processes, therapies derived for one of the inflammatory diseases listed above may well have benefit in some of the others where their underlying 'causes' are the same. The 'mass collaboration' agenda (e.g. [24302435]), in which dispersed agents contribute their different skills to the solution of a complex problem, may well help this happen effectively. Developments in distributed workflow technology, such as the Taverna [2226, 2436, 2437] and the myExperiment 2438 environments, represent an intellectually important approach. Important too to this endeavour will be Open Access initiatives [1, 2439, 2440] and institutional and other repositories [2441, 2442] of full-text papers. This will help to build an accurate picture of the biochemical networks operating in both normal and diseased states (and see 2443), preferably marked up semantically as in [118], and hence, by modelling them 2263, where best to consider interventions. In order to develop and exploit this distributed approach, it will also be necessary for those generating them to make their data and metadata available (preferably in a semantically marked up way), probably as Web Services (e.g. [24, 24442452]), and to give greater scientific weight to those involved in bio-curation [119] as they will be an increasingly important part of the scientific landscape. Modern sequencing instruments, for instance (e.g. [24532457]) are generating quality data at truly enormous rates 2458, and innovative but computationally demanding algorithms are required to deal with them (e.g. 2459). In particular, however, we need tools for manipulating and visualising biochemical models [2110, 2410, 2429, 2460]. As well as storing these models (e.g. as SBML or CellML 2461) in a file format, it is also convenient to store them in a database format, such as the B-net database developed by Mendes and colleagues [118, 2462]. Federated annotation protocols such as the Distributed Annotaton Scheme (see e.g. 2463) allow data from heterogeneous sources to be combined, while other integrative/distributed architectures such as ONDEX 2464 and Utopia [24652468] are similarly showing considerable promise for integrative systems biology.

Given the widely dispersed communities that have been referenced herein, and the future requirement for integrating knowledge generated throughput the world, a programme for understanding the combinatorial roles of poorly liganded iron and reactive oxygen species in the aetiology of many diseases, as set out in the above, appears to be prototypical for the kinds of new approaches to doing science that we may anticipate in the eras of Web 2.0 and the Semantic Web.



Acute Exacerbation of Chronic Obstructive Pulmonary Disorder


Acute Kidney Injury


Amyotrophic Lateral Sclerosis


Age-related Macular Degeneration


Blood-brain barrier


Chemical Entities of Biological Interest




Chronic Obstructive Pulmonary Disorder






Ethylenediamine-tetraacetic Acid


Friedrich's ataxia




N,N'-bis-(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid


Heme Carrier Protein-1


Hypoxia-Inducible Factor


Heme Oxygenase-1


Hydroxymethyl glutaryl Coenzyme A




A variety of 8-hydroxyquinolines


Inflammatory Bowel Disease


International Chemical Identifier


IκB kinase


Kyoto Encyclopedia of Genes and Genomes




Leukocyte Function Antigen-1


Labile Iron Pool


Long-Term Intervention with Pravastatin in Ischaemic Disease




Multiple organ failure


Nuclear Factor κB


Neutrophil Gelatinase-Associated Lipocalin (Also known as lipocalin-2 or siderocalin)


2-hydroxy-1-napthylaldehyde isonicotinyl hydrazone




Pyridoxal isonicotinyl hydrazone


Peroxisome Proliferator Activated Receptor


Rheumatoid Arthritis


Reactive Oxygen Species


Systems Biology Markup Language


Salicylaldehyde isonicotinyl hydrazone


Systemic Inflammatory Response Syndrome


Systemic Lupus Erythematosus


Simplified Molecular Input Line Entry Specification


Superoxide Dismutase




Tissue Necrosis Factor


Vascular Endothelial Growth Factor.



I thank Jon Barasch (Columbia University) for drawing my attention to the role of NGAL in human physiology, and Phil Baker, David Brough and Louise Kenny for many further useful and enjoyable discussions. I thank Katya Tarasova for considerable assistance with literature gathering and Julie Cowley for assistance with the proofs. Much of my work when this was written has been supported by the UK BBSRC and EPSRC, for which I am most grateful, and I am also a recipient of funding from the British Heart Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This is a contribution from the Manchester Centre for Integrative Systems Biology

Authors’ Affiliations

School of Chemistry and Manchester Interdisciplinary Biocentre, The University of Manchester, Manchester, UK


  1. Harnad S, Brody T, Vallieres F, Carr L, Hitchcock S, Gingras Y, Oppenheim C, Hajjem C, Hilf ER: The access/impact problem and the green and gold roads to open access: An update. Serials Review. 2008, 34: 36-40.Google Scholar
  2. Hull D, Pettifer SR, Kell DB: Defrosting the digital library: bibliographic tools for the next generation web. PLoS Comput Biol. 2008, 4: e1000204-doi:10.1371/journal.pcbi.1000204PubMedPubMed CentralGoogle Scholar
  3. Ananiadou S, McNaught J: Text mining in biology and biomedicine. 2006, Artech House, LondonGoogle Scholar
  4. Ananiadou S, Kell DB, Tsujii Ji: Text Mining and its potential applications in Systems Biology. Trends Biotechnol. 2006, 24: 571-579.PubMedGoogle Scholar
  5. Jensen LJ, Saric J, Bork P: Literature mining for the biologist: from information retrieval to biological discovery. Nat Rev Genet. 2006, 7: 119-29.PubMedGoogle Scholar
  6. Smalheiser NR: The Arrowsmith project: 2005 status report. LNCS. 2005, 3735: 26-43.Google Scholar
  7. Hristovski D, Peterlin B, Mitchell JA, Humphrey SM: Using literature-based discovery to identify disease candidate genes. Int J Med Inform. 2005, 74: 289-98.PubMedGoogle Scholar
  8. Kostoff RN: Systematic acceleration of radical discovery and innovation in science and technology. Technol Forecasting Soc Change. 2006, 73: 923-936.Google Scholar
  9. Yetisgen-Yildiz M, Pratt W: Using statistical and knowledge-based approaches for literature-based discovery. J Biomed Informatics. 2006, 39: 600-611.Google Scholar
  10. Kostoff RN: Validating discovery in literature-based discovery. J Biomed Inform. 2007, 40: 448-50. author reply 450–2.PubMedGoogle Scholar
  11. Kostoff RN, Briggs MB, Solka JL, Rushenberg RL: Literature-related discovery (LRD): Methodology. Technol Forecast Soc Change. 2008Google Scholar
  12. Cronin B: Bibliometrics and beyond: Some thoughts on web-based citation analysis. Journal of Information Science. 2001, 27: 1-7.Google Scholar
  13. Kasztler A, Leitner KH: Bibliometric analysis and visualisation of intellectual capital. J Universal Comp Sci. 2002, 8: 516-525.Google Scholar
  14. Tabah AN: Literature dynamics: Studies on growth, diffusion, and epidemics. Annu Rev Inf Sci Technol. 1999, 34: 249-286.Google Scholar
  15. Börner K, Chen CM, Boyack KW: Visualizing knowledge domains. Annual Review of Information Science and Technology. 2003, 37: 179-255.Google Scholar
  16. Errami M, Hicks JM, Fisher W, Trusty D, Wren JD, Long TC, Garner HR: Déjà vu: a study of duplicate citations in Medline. Bioinformatics. 2008, 24: 243-9.PubMedGoogle Scholar
  17. Kell DB: Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. 2008, []Google Scholar
  18. Dobson PD, Kell DB: Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat Rev Drug Discov. 2008, 7: 205-220.PubMedGoogle Scholar
  19. Smalheiser NR, Torvik VI, Bischoff-Grethe A, Burhans LB, Gabriel M, Homayouni R, Kashef A, Martone ME, Perkins GA, Price DL, Talk AC, West R: Collaborative development of the Arrowsmith two node search interface designed for laboratory investigators. J Biomed Discov Collab. 2006, 1: 8.PubMedPubMed CentralGoogle Scholar
  20. Smalheiser NR, Swanson DR: Using ARROWSMITH: a computer-assisted approach to formulating and assessing scientific hypotheses. Comput Methods Programs Biomed. 1998, 57: 149-53.PubMedGoogle Scholar
  21. Doms A, Schroeder M: GoPubMed: exploring PubMed with the Gene Ontology. Nucleic Acids Res. 2005, 33: W783-6.PubMedPubMed CentralGoogle Scholar
  22. Oinn T, Addis M, Ferris J, Marvin D, Senger M, Greenwood M, Carver T, Glover K, Pocock MR, Wipat A, Li P: Taverna: a tool for the composition and enactment of bioinformatics workflows. Bioinformatics. 2004, 20: 3045-54.PubMedGoogle Scholar
  23. Oinn T, Li P, Kell DB, Goble C, Goderis A, Greenwood M, Hull D, Stevens R, Turi D, Zhao J: Taverna/myGrid: aligning a workflow system with the life sciences community. Workflows for e-Science: scientific workflows for Grids. Edited by: Taylor IJ, Deelman E, Gannon DB, Shields M. 2007, Springer, Guildford, 300-319.Google Scholar
  24. Hull D, Wolstencroft K, Stevens R, Goble C, Pocock MR, Li P, Oinn T: Taverna: a tool for building and running workflows of services. Nucleic Acids Res. 2006, 34: W729-32.PubMedPubMed CentralGoogle Scholar
  25. Oinn T, Greenwood M, Addis M, Alpdemir MN, Ferris J, Glover K, Goble C, Goderis A, Hull D, Marvin D, Li P, Lord P, Pocock MR, Senger M, Stevens R, Wipat A, Wroe C: Taverna: lessons in creating a workflow environment for the life sciences. Concurrency and Computation: Practice & Experience. 2006, 18: 1067-1100.Google Scholar
  26. Goble C, Wolstencroft K, Goderis A, Hull D, Zhao J, Alper P, Lord P, Wroe C, Belhajjame K, Turi D, Stevens R, Oinn T, De Roure D: Knowledge discovery for biology with Taverna: producing and consuming semantics in the Web of Science. Semantic Web: revolutionising knowledge discovery in the life sciences. Edited by: Baker CJO, Cheung K-H. 2007, Springer, New YorkGoogle Scholar
  27. Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979, 59: 527-605.PubMedGoogle Scholar
  28. Lenaz G: Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta. 1998, 1366: 53-67.PubMedGoogle Scholar
  29. Barja G: Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. J Bioenerg Biomembr. 1999, 31: 347-66.PubMedGoogle Scholar
  30. Kowaltowski AJ, Vercesi AE: Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med. 1999, 26: 463-71.PubMedGoogle Scholar
  31. Cadenas E, Davies KJ: Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000, 29: 222-30.PubMedGoogle Scholar
  32. Lenaz G, D'Aurelio M, Merlo Pich M, Genova ML, Ventura B, Bovina C, Formiggini G, Parenti Castelli G: Mitochondrial bioenergetics in aging. Biochim Biophys Acta. 2000, 1459: 397-404.PubMedGoogle Scholar
  33. Raha S, Robinson BH: Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci. 2000, 25: 502-8.PubMedGoogle Scholar
  34. Lenaz G: The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life. 2001, 52: 159-64.PubMedGoogle Scholar
  35. Raha S, Robinson BH: Mitochondria, oxygen free radicals, and apoptosis. Am J Med Genet. 2001, 106: 62-70.PubMedGoogle Scholar
  36. Dröge W: Free radicals in the physiological control of cell function. Physiol Rev. 2002, 82: 47-95.PubMedGoogle Scholar
  37. Taylor ER, Hurrell F, Shannon RJ, Lin TK, Hirst J, Murphy MP: Reversible glutathionylation of complex I increases mitochondrial superoxide formation. J Biol Chem. 2003, 278: 19603-10.PubMedGoogle Scholar
  38. Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol. 2003, 552: 335-44.PubMedPubMed CentralGoogle Scholar
  39. Adam-Vizi V: Production of reactive oxygen species in brain mitochondria: Contribution by electron transport chain and non-electron transport chain sources. Antioxidants & Redox Signaling. 2005, 7: 1140-1149.Google Scholar
  40. Andreyev AY, Kushnareva YE, Starkov AA: Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc). 2005, 70: 200-14.Google Scholar
  41. Balaban RS, Nemoto S, Finkel T: Mitochondria, oxidants, and aging. Cell. 2005, 120: 483-495.PubMedGoogle Scholar
  42. Adam-Vizi V, Chinopoulos C: Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci. 2006, 27: 639-45.PubMedGoogle Scholar
  43. Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. 2006, Oxford University Press, Oxford, 4Google Scholar
  44. Orrenius S, Gogvadze A, Zhivotovsky B: Mitochondrial oxidative stress: Implications for cell death. Annual Review of Pharmacology and Toxicology. 2007, 47: 143-183.PubMedGoogle Scholar
  45. Fato R, Bergamini C, Leoni S, Strocchi P, Lenaz G: Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res. 2008, 33: 2487-501.PubMedGoogle Scholar
  46. Babior BM: Phagocytes and oxidative stress. Am J Med. 2000, 109: 33-44.PubMedGoogle Scholar
  47. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM: NADPH oxidases in cardiovascular health and disease. Antioxidants & Redox Signaling. 2006, 8: 691-728.Google Scholar
  48. Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007, 87: 245-313.PubMedGoogle Scholar
  49. Brown JM, Terada LS, Grosso MA, Whitmann GJ, Velasco SE, Patt A, Harken AH, Repine JE: Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts. J Clin Invest. 1988, 81: 1297-1301.PubMedPubMed CentralGoogle Scholar
  50. Granger DN: Role of xanthine oxidase and granulocytes in ischemia reperfusion injury. Amer J Physiol. 1988, 255: H1269-H1275.PubMedGoogle Scholar
  51. Linas SL, Whittenburg D, Repine JE: Role of xanthine oxidase in ischemia reperfusion injury. Amer J Physiol. 1990, 258: F711-F716.PubMedGoogle Scholar
  52. Thompson-Gorman SL, Zweier JL: Evaluation of the role of xanthine oxidase in myocardial reperfusion injury. J Biol Chem. 1990, 265: 6656-6663.PubMedGoogle Scholar
  53. Adkins WK, Taylor AE: Role of xanthine oxidase and neutrophils in ischemia-reperfusion injury in rabbit lung. J Appl Physiol. 1990, 69: 2012-2018.PubMedGoogle Scholar
  54. Müller MJ, Vollmar B, Friedl HP, Menger MD: Xanthine oxidase and superoxide radicals in portal triad crossclamping-induced microvascular reperfusion injury of the liver. Free Radic Biol Med. 1996, 21: 189-97.PubMedGoogle Scholar
  55. Imlay JA: Cellular defenses against superoxide and hydrogen peroxide. Annu Rev Biochem. 2008, 77: 755-76.PubMedPubMed CentralGoogle Scholar
  56. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T: Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995, 270: 296-9.PubMedGoogle Scholar
  57. Finkel T: Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003, 15: 247-54.PubMedGoogle Scholar
  58. Rhee SG: Cell signaling. H2O2, a necessary evil for cell signaling. Science. 2006, 312: 1882-3.PubMedGoogle Scholar
  59. Miller EW, Tulyathan O, Isacoff EY, Chang CJ: Molecular imaging of hydrogen peroxide produced for cell signaling. Nat Chem Biol. 2007, 3: 263-7.PubMedGoogle Scholar
  60. Forman HJ, Fukuto JM, Miller T, Zhang H, Rinna A, Levy S: The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal. Arch Biochem Biophys. 2008, 477: 183-95.PubMedPubMed CentralGoogle Scholar
  61. Halliwell B, Gutteridge JM: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 1984, 219: 1-14.PubMedPubMed CentralGoogle Scholar
  62. Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease – an overview. Meth Enzymol. 1990, 186: 1-85.PubMedGoogle Scholar
  63. Galaris D, Pantopoulos K: Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit Rev Clin Lab Sci. 2008, 45: 1-23.PubMedGoogle Scholar
  64. Buzan T: How to mind map. 2002, Thorsons, LondonGoogle Scholar
  65. Fridovich I: Superoxide radical and superoxide dismutases. Annu Rev Biochem. 1995, 64: 97-112.PubMedGoogle Scholar
  66. Wardman P, Candeias LP: Fenton chemistry: An introduction. Rad Res. 1996, 145: 523-531.Google Scholar
  67. Kehrer JP: The Haber-Weiss reaction and mechanisms of toxicity. Toxicology. 2000, 149: 43-50.PubMedGoogle Scholar
  68. Hershko C, Weatherall DJ: Iron-chelating therapy. Crit Rev Clin Lab Sci. 1988, 26: 303-45.PubMedGoogle Scholar
  69. Minotti G: Sources and role of iron in lipid peroxidation. Chem Res Toxicol. 1993, 6: 134-146.PubMedGoogle Scholar
  70. Rayman MP, Barlis J, Evans RW, Redman CW, King LJ: Abnormal iron parameters in the pregnancy syndrome preeclampsia. Am J Obstet Gynecol. 2002, 187: 412-8.PubMedGoogle Scholar
  71. Welch KD, Davis TZ, Van Eden ME, Aust SD: Deleterious iron-mediated oxidation of biomolecules. Free Radic Biol Med. 2002, 32: 577-83.PubMedGoogle Scholar
  72. Cheng Z, Li Y: What is responsible for the initiating chemistry of iron-mediated lipid peroxidation: an update. Chem Rev. 2007, 107: 748-66.PubMedGoogle Scholar
  73. Tsukahara H: Biomarkers for oxidative stress: Clinical application in pediatric medicine. Curr Med Chem. 2007, 14: 339-351.PubMedGoogle Scholar
  74. Evans MD, Dizdaroglu M, Cooke MS: Oxidative DNA damage and disease: induction, repair and significance. Mut Res. 2004, 567: 1-61.Google Scholar
  75. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J: Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004, 266: 37-56.PubMedGoogle Scholar
  76. David SS, O'Shea VL, Kundu S: Base-excision repair of oxidative DNA damage. Nature. 2007, 447: 941-50.PubMedPubMed CentralGoogle Scholar
  77. Stadtman ER, Oliver CN: Metal-catalyzed oxidation of proteins – physiological consequences. J Biol Chem. 1991, 266: 2005-2008.PubMedGoogle Scholar
  78. Davies MJ, Fu S, Wang H, Dean RT: Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med. 1999, 27: 1151-63.PubMedGoogle Scholar
  79. Davies MJ: The oxidative environment and protein damage. Biochim Biophys Acta. 2005, 1703: 93-109.PubMedGoogle Scholar
  80. Terman A, Brunk UT: Lipofuscin. Int J Biochem Cell Biol. 2004, 36: 1400-1404.PubMedGoogle Scholar
  81. Jung T, Bader N, Grune T: Lipofuscin: formation, distribution, and metabolic consequences. Ann N Y Acad Sci. 2007, 1119: 97-111.PubMedGoogle Scholar
  82. Halliwell B: Free radicals and antioxidants: a personal view. Nutr Rev. 1994, 52: 253-65.PubMedGoogle Scholar
  83. De Zwart LL, Meerman JHN, Commandeur JNM, Vermeulen NPE: Biomarkers of free radical damage applications in experimental animals and in humans. Free Rad Biol Med. 1999, 26: 202-226.PubMedGoogle Scholar
  84. Kohen R, Nyska A: Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol. 2002, 30: 620-50.PubMedGoogle Scholar
  85. Tarpey MM, Wink DA, Grisham MB: Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol. 2004, 286: R431-44.PubMedGoogle Scholar
  86. Halliwell B, Whiteman M: Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br J Pharmacol. 2004, 142: 231-55.PubMedPubMed CentralGoogle Scholar
  87. Cherubini A, Ruggiero C, Polidori MC, Mecocci P: Potential markers of oxidative stress in stroke. Free Radical Biology and Medicine. 2005, 39: 841-852.PubMedGoogle Scholar
  88. Shulaev V, Oliver DJ: Metabolic and proteomic markers for oxidative stress. New tools for reactive oxygen species research. Plant Physiol. 2006, 141: 367-72.PubMedPubMed CentralGoogle Scholar
  89. Serkova NJ, Reisdorph NA, van Patot MCT: Metabolic markers of hypoxia: Systems biology application in biomedicine. Toxicology Mechanisms and Methods. 2008, 18: 81-95.PubMedGoogle Scholar
  90. Aust AE, Eveleigh JF: Mechanisms of DNA oxidation. Proc Soc Exp Biol Med. 1999, 222: 246-52.PubMedGoogle Scholar
  91. Cooke MS, Lunec J, Evans MD: Progress in the analysis of urinary oxidative DNA damage. Free Radic Biol Med. 2002, 33: 1601-1614.PubMedGoogle Scholar
  92. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H: Free radical-induced damage to DNA: Mechanisms and measurement. Free Radical Biology and Medicine. 2002, 32: 1102-1115.PubMedGoogle Scholar
  93. Neeley WL, Essigmann JM: Mechanisms of formation, genotoxicity, and mutation of guanine oxidation products. Chem Res Toxicol. 2006, 19: 491-505.PubMedGoogle Scholar
  94. Hwang ES, Bowen PE: DNA damage, a biomarker of carcinogenesis: Its measurement and modulation by diet and environment. Crit Rev Food Sci Nutrition. 2007, 47: 27-50.Google Scholar
  95. Shin CS, Moon BS, Park KS, Kim SY, Park SJ, Chung MH, Lee HK: Serum 8-hydroxy-guanine levels are increased in diabetic patients. Diabetes Care. 2001, 24: 733-7.PubMedGoogle Scholar
  96. Loft S, Fischer-Nielsen A, Jeding IB, Vistisen K, Poulsen HE: 8-Hydroxydeoxyguanosine as a urinary biomarker of oxidative DNA damage. J Toxicol Environ Health. 1993, 40: 391-404.PubMedGoogle Scholar
  97. Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L: Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging. 2005, 26: 587-95.PubMedGoogle Scholar
  98. Bolin C, Cardozo-Pelaez F: Assessing biomarkers of oxidative stress: Analysis of guanosine and oxidized guanosine nucleotide triphosphates by high performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007Google Scholar
  99. Yamada S, Funada T, Shibata N, Kobayashi M, Kawai Y, Tatsuda E, Furuhata A, Uchida K: Protein-bound 4-hydroxy-2-hexenal as a marker of oxidized n-3 polyunsaturated fatty acids. J Lipid Res. 2004, 45: 626-634.PubMedGoogle Scholar
  100. Petersen DR, Doorn JA: Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med. 2004, 37: 937-45.PubMedGoogle Scholar
  101. Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, du Bois RM, Kharitonov SA, Barnes PJ: 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Amer J Resp Crit Care Med. 1998, 158: 1524-1527.Google Scholar
  102. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Amer J Resp Crit Care Med. 2000, 162: 1175-1177.Google Scholar
  103. Schwedhelm E, Boger RH: Application of gas chromatography-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease. Clin Chem Lab Med. 2003, 41: 1552-61.PubMedGoogle Scholar
  104. Davì G, Falco A, Patrono C: Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids. 2004, 128: 149-63.PubMedGoogle Scholar
  105. Montuschi P, Barnes PJ, Roberts LJ: Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004, 18: 1791-800.PubMedGoogle Scholar
  106. Morrow JD: Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol. 2005, 25: 279-86.PubMedGoogle Scholar
  107. Montuschi P, Barnes P, Roberts LJ: Insights into oxidative stress: the isoprostanes. Curr Med Chem. 2007, 14: 703-17.PubMedGoogle Scholar
  108. Mori TA, Croft KD, Puddey IB, Beilin LJ: Analysis of native and oxidized low-density lipoprotein oxysterols using gas chromatography mass spectrometry with selective ion monitoring. Redox Report. 1996, 2: 25-34.Google Scholar
  109. Murphy RC, Johnson KM: Cholesterol, reactive oxygen species, and the formation of biologically active mediators. J Biol Chem. 2008, 283: 15521-5.PubMedPubMed CentralGoogle Scholar
  110. Janero DR: Malondialdehyde and thiobarbituric acid reactivity as diagnostic indexes of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990, 9: 515-540.PubMedGoogle Scholar
  111. Gieseg SP, Crone EM, Flavall EA, Amit Z: Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis. Br J Pharmacol. 2008, 153: 627-35.PubMedGoogle Scholar
  112. Herce-Pagliai C, Kotecha S, Shuker DEG: Analytical methods for 3-nitrotyrosine as a marker of exposure to reactive nitrogen species: A review. Nitric Oxide-Biology and Chemistry. 1998, 2: 324-336.Google Scholar
  113. Bian K, Gao Z, Weisbrodt N, Murad F: The nature of heme/iron-induced protein tyrosine nitration. Proc Natl Acad Sci USA. 2003, 100: 5712-7.PubMedPubMed CentralGoogle Scholar
  114. Duncan MW: A review of approaches to the analysis of 3-nitrotyrosine. Amino Acids. 2003, 25: 351-361.PubMedGoogle Scholar
  115. Ryberg H, Caidahl K: Chromatographic and mass spectrometric methods for quantitative determination of 3-nitrotyrosine in biological samples and their application to human samples. J Chromatogr B. 2007, 851: 160-171.Google Scholar
  116. Cao EH, Wang JJ: Oxidative Damage to DNA – Levels of Thymine Glycol and Thymidine Glycol in Neoplastic Human Urines. Carcinogenesis. 1993, 14: 1359-1362.PubMedGoogle Scholar
  117. Makropoulos W, Kocher K, Heintz B, Schwarz ER, Mertens PR, Stefanidis I: Urinary thymidine glycol as a biomarker for oxidative stress after kidney transplantation. Renal Failure. 2000, 22: 499-510.PubMedGoogle Scholar
  118. Herrgård MJ, Swainston N, Dobson P, Dunn WB, Arga KY, Arvas M, Blüthgen N, Borger S, Costenoble R, Heinemann M, Hucka M, Le Novère N, Li P, Liebermeister W, Mo ML, Oliveira AP, Petranovic D, Pettifer S, Simeonidis E, Smallbone K, Spasić I, Weichart D, Brent R, Broomhead DS, Westerhoff HV, Kirdar B, Penttilä M, Klipp E, Palsson BØ, Sauer U, Oliver SG, Mendes P, Nielsen J, Kell DB: A consensus yeast metabolic network obtained from a community approach to systems biology. Nature Biotechnol. 2008, 26: 1155-1160.Google Scholar
  119. Howe D, Costanzo M, Fey P, Gojobori T, Hannick L, Hide W, Hill DP, Kania R, Schaeffer M, St Pierre S, Twigger S, White O, Yon Rhee S: Big data: The future of biocuration. Nature. 2008, 455: 47-50.PubMedPubMed CentralGoogle Scholar
  120. Brooksbank C, Cameron G, Thornton J: The European Bioinformatics Institute's data resources: towards systems biology. Nucleic Acids Res. 2005, 33: D46-53.PubMedGoogle Scholar
  121. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M: From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006, 34: D354-7.PubMedGoogle Scholar
  122. Weininger D: SMILES, a chemical language and information system .1. Introduction to methodology and encoding rules. J Chem Inf Comput Sci. 1988, 28: 31-36.Google Scholar
  123. Stein SE, Heller SR, Tchekhovski D: An open standard for chemical structure representation – the IUPAC chemical identifier. Proc 2003 Nimes Int Chem Info Conf. 2003, 131-143.Google Scholar
  124. Coles SJ, Day NE, Murray-Rust P, Rzepa HS, Zhang Y: Enhancement of the chemical semantic web through the use of InChI identifiers. Organic & Biomolecular Chemistry. 2005, 3: 1832-1834.Google Scholar
  125. Casher O, Rzepa HS: SemanticEye: a semantic web application to rationalize and enhance chemical electronic publishing. J Chem Inf Model. 2006, 46: 2396-411.PubMedGoogle Scholar
  126. Monge A, Arrault A, Marot C, Morin-Allory L: Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol Divers. 2006, 10: 389-403.PubMedGoogle Scholar
  127. Knox C, Shrivastava S, Sothard P, Eisner R, Wishart DS: Biospider: a web server for automating metabolome annotations. Pac Symp Biocomputing. 2007, 12: 145-156.Google Scholar
  128. Klinger R, Kolářik C, Fluck J, Hofmann-Apitius M, Friedrich CM: Detection of IUPAC and IUPAC-like chemical names. Bioinformatics. 2008, 24: i268-76.PubMedPubMed CentralGoogle Scholar
  129. Chavarria ME, Lara-Gonzalez L, Gonzalez-Gleason A, Garcia-Paleta Y, Vital-Reyes VS, Reyes A: Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol. 2003, 188: 986-92.PubMedGoogle Scholar
  130. Miller DM, Buettner GR, Aust SD: Transition metals as catalysts of "autoxidation" reactions. Free Radic Biol Med. 1990, 8: 95-108.PubMedGoogle Scholar
  131. Stohs SJ, Bagchi D: Oxidative mechanisms in the toxicity of metal ions. Free Rad Biol Med. 1995, 18: 321-336.PubMedGoogle Scholar
  132. Meneghini R: Iron homeostasis, oxidative stress, and DNA damage. Free Radical Biology and Medicine. 1997, 23: 783-792.PubMedGoogle Scholar
  133. Hubel CA: Dyslipidemia, iron, and oxidative stress in preeclampsia: assessment of maternal and feto-placental interactions. Semin Reprod Endocrinol. 1998, 16: 75-92.PubMedGoogle Scholar
  134. Aisen P, Enns C, Wessling-Resnick M: Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001, 33: 940-959.PubMedGoogle Scholar
  135. Reddy MB, Clark L: Iron, oxidative stress, and disease risk. Nutr Rev. 2004, 62: 120-4.PubMedGoogle Scholar
  136. Thompson KJ, Shoham S, Connor JR: Iron and neurodegenerative disorders. Brain Res Bull. 2001, 55: 155-64.PubMedGoogle Scholar
  137. Valko M, Morris H, Cronin MTD: Metals, toxicity and oxidative stress. Curr Med Chem. 2005, 12: 1161-1208.PubMedGoogle Scholar
  138. Carbonell T, Rama R: Iron, oxidative stress and early neurological deterioration in ischemic stroke. Current Medicinal Chemistry. 2007, 14: 857-874.PubMedGoogle Scholar
  139. Dunn LL, Rahmanto YS, Richardson DR: Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007, 17: 93-100.PubMedGoogle Scholar
  140. Weinberg ED: Exposing the hidden dangers of iron: what every medical professional should know about the impact of iron on the disease process. 2004, Cumberland HouseGoogle Scholar
  141. Brewer GJ: Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med. 2007, 232: 323-335.Google Scholar
  142. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007, 39: 44-84.PubMedGoogle Scholar
  143. Winterbourn CC: Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol. 2008, 4: 278-86.PubMedGoogle Scholar
  144. Qian SY, Buettner GR: Iron and dioxygen chemistry is an important route to initiation of biological free radical oxidations: an electron paramagnetic resonance spin trapping study. Free Radic Biol Med. 1999, 26: 1447-56.PubMedGoogle Scholar
  145. Brown GC, Borutaite V: Nitric oxide, mitochondria, and cell death. IUBMB Life. 2001, 52: 189-95.PubMedGoogle Scholar
  146. Gomes A, Fernandes E, Lima J: Use of fluorescence probes for detection of reactive nitrogen species: A review. J Fluorescence. 2006, 16: 119-139.Google Scholar
  147. Yokoyama H, Kuroiwa H, Yano R, Araki T: Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci. 2008, 29: 293-301.PubMedGoogle Scholar
  148. Moncada S, Palmer RMJ, Higgs EA: Nitric-Oxide – Physiology, Pathophysiology, and Pharmacology. Pharmacological Reviews. 1991, 43: 109-142.PubMedGoogle Scholar
  149. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990, 87: 1620-4.PubMedPubMed CentralGoogle Scholar
  150. Radi R, Cassina A, Hodara R, Quijano C, Castro L: Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med. 2002, 33: 1451-64.PubMedGoogle Scholar
  151. Rubbo H, O'Donnell V: Nitric oxide, peroxynitrite and lipoxygenase in atherogenesis: mechanistic insights. Toxicology. 2005, 208: 305-17.PubMedGoogle Scholar
  152. Zimmet JM, Hare JM: Nitroso-redox interactions in the cardiovascular system. Circulation. 2006, 114: 1531-44.PubMedGoogle Scholar
  153. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007, 87: 315-424.PubMedPubMed CentralGoogle Scholar
  154. Pavlovic R, Santaniello E: Peroxynitrite and nitrosoperoxycarbonate, a tightly connected oxidizing-nitrating couple in the reactive nitrogen-oxygen species family: new perspectives for protection from radical-promoted injury by flavonoids. J Pharm Pharmacol. 2007, 59: 1687-95.PubMedGoogle Scholar
  155. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA: Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci. 2001, 98: 15215-15220.PubMedPubMed CentralGoogle Scholar
  156. O'Donnell VB, Freeman BA: Interactions between nitric oxide and lipid oxidation pathways – Implications for vascular disease. Circulation Research. 2001, 88: 12-21.PubMedGoogle Scholar
  157. Lancaster JR: Protein cysteine thiol nitrosation: maker or marker of reactive nitrogen species-induced nonerythroid cellular signaling?. Nitric Oxide. 2008, 19: 68-72.PubMedGoogle Scholar
  158. Vaz SM, Augusto O: Inhibition of myeloperoxidase-mediated protein nitration by tempol: Kinetics, mechanism, and implications. Proc Natl Acad Sci USA. 2008, 105: 8191-6.PubMedPubMed CentralGoogle Scholar
  159. Brown GC, Bal-Price A: Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 2003, 27: 325-55.PubMedGoogle Scholar
  160. Kim YM, Chung HT, Simmons RL, Billiar TR: Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem. 2000, 275: 10954-61.PubMedGoogle Scholar
  161. Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation. Nature. 2008, 454: 445-54.PubMedPubMed CentralGoogle Scholar
  162. Finkel T: Radical medicine: treating ageing to cure disease. Nat Rev Mol Cell Biol. 2005, 6: 971-6.PubMedGoogle Scholar
  163. Finch CE: The biology of human longevity: inflammation, nutrition and aging in the evolution of lifespans. 2007, Academic Press, AmsterdamGoogle Scholar
  164. Serrano M, Blasco MA: Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol. 2007, 8: 715-22.PubMedGoogle Scholar
  165. Brown GM: The living end: the future of death, aging and immortality. 2008, Macmillan, LondonGoogle Scholar
  166. Renshaw JC, Robson GD, Trinci APJ, Wiebe MG, Livens FR, Collison D, Taylor RJ: Fungal siderophores: structures, functions and applications. Mycol Res. 2002, 106: 1123-1142.Google Scholar
  167. Haas H: Molecular genetics of fungal siderophore biosynthesis and uptake: the role of siderophores in iron uptake and storage. Applied Microbiology and Biotechnology. 2003, 62: 316-330.PubMedGoogle Scholar
  168. Haas H, Eisendle M, Turgeon BG: Siderophores in fungal physiology and virulence. Annu Rev Phytopathol. 2008, 46: 149-87.PubMedGoogle Scholar
  169. Johnson L: Iron and siderophores in fungal-host interactions. Mycol Res. 2008, 112: 170-83.PubMedGoogle Scholar
  170. Raymond KN, Muller G, Matzanke BF: Complexation of iron by siderophores – a review of their solution and structural chemistry and biological function. Top Curr Chem. 1984, 123: 49-102.Google Scholar
  171. Guerinot ML: Microbial iron transport. Annu Rev Microbiol. 1994, 48: 743-72.PubMedGoogle Scholar
  172. Jurado RL: Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997, 25: 888-95.PubMedGoogle Scholar
  173. Drechsel H, Jung G: Peptide siderophores. Journal of Peptide Science. 1998, 4: 147-181.PubMedGoogle Scholar
  174. Ratledge C, Dover LG: Iron metabolism in pathogenic bacteria. Annu Rev Microbiol. 2000, 54: 881-941.PubMedGoogle Scholar
  175. Boukhalfa H, Crumbliss AL: Chemical aspects of siderophore mediated iron transport. Biometals. 2002, 15: 325-339.PubMedGoogle Scholar
  176. Braun V, Braun M: Active transport of iron and siderophore antibiotics. Curr Opin Microbiol. 2002, 5: 194-201.PubMedGoogle Scholar
  177. Brown JS, Holden DW: Iron acquisition by Gram-positive bacterial pathogens. Microbes Infect. 2002, 4: 1149-56.PubMedGoogle Scholar
  178. Cornelis P, Matthijs S: Diversity of siderophore-mediated iron uptake systems in fluorescent pseudomonads: not only pyoverdines. Environ Microbiol. 2002, 4: 787-798.PubMedGoogle Scholar
  179. Crosa JH, Walsh CT: Genetics and assembly line enzymology of siderophore biosynthesis in bacteria. Microbiology and Molecular Biology Reviews. 2002, 66: 223.PubMedPubMed CentralGoogle Scholar
  180. Marx JJ: Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol. 2002, 15: 411-26.PubMedGoogle Scholar
  181. Winkelmann G: Microbial siderophore-mediated transport. Biochem Soc Trans. 2002, 30: 691-6.PubMedGoogle Scholar
  182. Andrews SC, Robinson AK, Rodriguez-Quinones F: Bacterial iron homeostasis. FEMS Microbiol Rev. 2003, 27: 215-37.PubMedGoogle Scholar
  183. Faraldo-Gómez JD, Sansom MSP: Acquisition of siderophores in Gram-negative bacteria. Nat Rev Mol Cell Biol. 2003, 4: 105-116.PubMedGoogle Scholar
  184. Raymond KN, Dertz EA, Kim SS: Enterobactin: an archetype for microbial iron transport. Proc Natl Acad Sci USA. 2003, 100: 3584-8.PubMedPubMed CentralGoogle Scholar
  185. Wandersman C, Delepelaire P: Bacterial iron sources: From siderophores to hemophores. Annual Review of Microbiology. 2004, 58: 611-647.PubMedGoogle Scholar
  186. Abergel RJ, Wilson MK, Arceneaux JE, Hoette TM, Strong RK, Byers BR, Raymond KN: Anthrax pathogen evades the mammalian immune system through stealth siderophore production. Proc Natl Acad Sci USA. 2006, 103: 18499-503.PubMedPubMed CentralGoogle Scholar
  187. Fischbach MA, Lin HN, Liu DR, Walsh CT: How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nature Chemical Biology. 2006, 2: 132-138.PubMedGoogle Scholar
  188. Grass G: Iron transport in Escherichia coli: All has not been said and done. Biometals. 2006, 19: 159-172.PubMedGoogle Scholar
  189. Miethke M, Marahiel MA: Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev. 2007, 71: 413-51.PubMedPubMed CentralGoogle Scholar
  190. Genco CA, Dixon DW: Emerging strategies in microbial haem capture. Molecular Microbiology. 2001, 39: 1-11.PubMedGoogle Scholar
  191. Loomis LD, Raymond KN: Solution equilibria of enterobactin and metal enterobactin complexes. Inorganic Chemistry. 1991, 30: 906-911.Google Scholar
  192. Stintzi A, Barnes C, Xu J, Raymond KN: Microbial iron transport via a siderophore shuttle: a membrane ion transport paradigm. Proc Natl Acad Sci USA. 2000, 97: 10691-6.PubMedPubMed CentralGoogle Scholar
  193. Braun V: Iron uptake mechanisms and their regulation in pathogenic bacteria. Int J Med Microbiol. 2001, 291: 67-79.PubMedGoogle Scholar
  194. Cendrowski S, MacArthur W, Hanna P: Bacillus anthracis requires siderophore biosynthesis for growth in macrophages and mouse virulence. Mol Microbiol. 2004, 51: 407-417.PubMedGoogle Scholar
  195. Schaible ME, Kaufmann SHE: Iron and microbial infection. Nat Rev Microbiol. 2004, 2: 946-953.PubMedGoogle Scholar
  196. Ong ST, Ho JZS, Ho B, Ding JL: Iron-withholding strategy in innate immunity. Immunobiology. 2006, 211: 295-314.PubMedGoogle Scholar
  197. Challis GL, Ravel J: Coelichelin, a new peptide siderophore encoded by the Streptomyces coelicolor genome: structure prediction from the sequence of its non-ribosomal peptide synthetase. FEMS Microbiol Lett. 2000, 187: 111-4.PubMedGoogle Scholar
  198. Fernandez-Pol JA: Isolation and characterization of a siderophore-like growth factor from mutants of SV40-transformed cells adapted to picolinic acid. Cell. 1978, 14: 489-99.PubMedGoogle Scholar
  199. Jones RL, Peterson CM, Grady RW, Cerami A: Low molecular weight iron-binding factor from mammalian tissue that potentiates bacterial growth. J Exp Med. 1980, 151: 418-28.PubMedGoogle Scholar
  200. Primosigh JV, Thomas ED: Studies on the partition of iron in bone marrow cells. J Clin Invest. 1968, 47: 1473-82.PubMedPubMed CentralGoogle Scholar
  201. Jacobs A: Low molecular weight intracellular iron transport compounds. Blood. 1977, 50: 433-9.PubMedGoogle Scholar
  202. Hershko C, Graham G, Bates GW, Rachmilewitz EA: Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978, 40: 255-63.PubMedGoogle Scholar
  203. Graham G, Bates GW, Rachmilewitz EA, Hershko C: Nonspecific serum iron in thalassemia: quantitation and chemical reactivity. Am J Hematol. 1979, 6: 207-17.PubMedGoogle Scholar
  204. Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J: Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci. 1987, 84: 3457-61.PubMedPubMed CentralGoogle Scholar
  205. Fontecave M, Pierre JL: Iron metabolism – the low molecular mass iron pool. Biology of Metals. 1991, 4: 133-135.PubMedGoogle Scholar
  206. Kaplan J: Mechanisms of cellular iron acquisition: another iron in the fire. Cell. 2002, 111: 603-6.PubMedGoogle Scholar
  207. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003, 102: 783-788.PubMedGoogle Scholar
  208. Finch C: Regulators of iron balance in humans. Blood. 1994, 84: 1697-702.PubMedGoogle Scholar
  209. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J: Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008, 88: 7-15.PubMedPubMed CentralGoogle Scholar
  210. Crichton RR, Ward RJ: Iron metabolism–new perspectives in view. Biochemistry. 1992, 31: 11255-64.PubMedGoogle Scholar
  211. Andrews NC: Medical progress: Disorders of iron metabolism. New England Journal of Medicine. 1999, 341: 1986-1995.PubMedGoogle Scholar
  212. Beard JL, Dawson H, Piñero DJ: Iron metabolism: a comprehensive review. Nutr Rev. 1996, 54: 295-317.PubMedGoogle Scholar
  213. Lieu PT, Heiskala M, Peterson PA, Yang Y: The roles of iron in health and disease. Mol Aspects Med. 2001, 22: 1-87.PubMedGoogle Scholar
  214. Chung JY, Wessling-Resnick M: Molecular mechanisms and regulation of iron transport. Crit Rev Clin Lab Sci. 2003, 40: 151-182.PubMedGoogle Scholar
  215. Frazer DM, Anderson GJ: The orchestration of body iron intake: how and where do enterocytes receive their cues?. Blood Cells Molecules and Diseases. 2003, 30: 288-297.Google Scholar
  216. Knutson M, Wessling-Resnick M: Iron metabolism in the reticuloendothelial system. Crit Rev Biochem Mol Biol. 2003, 38: 61-88.PubMedGoogle Scholar
  217. McArdle HJ, Danzeisen R, Fosset C, Gambling L: The role of the placenta in iron transfer from mother to fetus and the relationship between iron status and fetal outcome. Biometals. 2003, 16: 161-7.PubMedGoogle Scholar
  218. Hentze MW, Muckenthaler MU, Andrews NC: Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004, 117: 285-97.PubMedGoogle Scholar
  219. Andrews NC: Molecular control of iron metabolism. Best Pract Res Clin Haematol. 2005, 18: 159-69.PubMedGoogle Scholar
  220. Papanikolaou G, Pantopoulos K: Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005, 202: 199-211.PubMedGoogle Scholar
  221. Taketani S: Aquisition, mobilization and utilization of cellular iron and heme: Endless findings and growing evidence of tight regulation. Tohoku J Exp Med. 2005, 205: 297-318.PubMedGoogle Scholar
  222. Donovan A, Roy CN, Andrews NC: The ins and outs of iron homeostasis. Physiology (Bethesda). 2006, 21: 115-23.Google Scholar
  223. Ganz T, Nemeth E: Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta. 2006, 1763: 690-699.PubMedGoogle Scholar
  224. Huang XP, O'Brien PJ, Templeton DM: Mitochondrial involvement in genetically determined transition metal toxicity I. Iron toxicity. Chemico-Biological Interactions. 2006, 163: 68-76.PubMedGoogle Scholar
  225. Nairz M, Weiss G: Molecular and clinical aspects of iron homeostasis: from anemia to hemochromatosis. Wiener Klinische Wochenschrift. 2006, 118: 442-462.PubMedGoogle Scholar
  226. Anderson GJ: Mechanisms of iron loading and toxicity. Am J Hematol. 2007, 82: 1128-31.PubMedGoogle Scholar
  227. Andrews NC, Schmidt PJ: Iron homeostasis. Annu Rev Physiol. 2007, 69: 69-85.PubMedGoogle Scholar
  228. Harrison-Findik DD: Role of alcohol in the regulation of iron metabolism. World J Gastroenterol. 2007, 13: 4925-30.PubMedPubMed CentralGoogle Scholar
  229. Jones BC, Beard JL, Gibson JN, Unger EL, Allen RP, McCarthy KA, Earley CJ: Systems genetic analysis of peripheral iron parameters in the mouse. Am J Physiol Regul Integr Comp Physiol. 2007, 293: R116-24.PubMedGoogle Scholar
  230. Mithen R: Effect of genotype on micronutrient absorption and metabolism: a review of iron, copper, iodine and selenium, and folates. Int J Vitam Nutr Res. 2007, 77: 205-16.PubMedGoogle Scholar
  231. Vallerio LG: Mammalian iron metabolism. Toxicology Mechanisms and Methods. 2007, 17: 497-517.Google Scholar
  232. Andrews NC: Forging a field: the golden age of iron biology. Blood. 2008, 112: 219-30.PubMedPubMed CentralGoogle Scholar
  233. Beard J, Han O: Systemic iron status. Biochim Biophys Acta. 2008.Google Scholar
  234. Deugnier Y, Brissot P, Loréal O: Iron and the liver: update 2008. J Hepatol. 2008, 48 (Suppl 1): S113-23.PubMedGoogle Scholar
  235. Ganz T: Iron homeostasis: fitting the puzzle pieces together. Cell Metab. 2008, 7: 288-90.PubMedGoogle Scholar
  236. Handelman GJ, Levin NW: Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev. 2008, 13: 393-404.PubMedGoogle Scholar
  237. Hower V, Mendes P, Torti FM, Laubenbacher R, Akman S, Shulaev V, Torti SV: A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst. 2008Google Scholar
  238. Kemna EH, Tjalsma H, Willems HL, Swinkels DW: Hepcidin: from discovery to differential diagnosis. Haematologica. 2008, 93: 90-7.PubMedGoogle Scholar
  239. Kong W, Duan X, Shi Z, Chang Y: Iron metabolism in the mononuclear phagocyte system. Progr Nat Sci. 2008, 18: 1197-1202.Google Scholar
  240. Levi S, Rovida E: The role of iron in mitochondrial function. Biochim Biophys Acta. 2008.Google Scholar
  241. Wrighting DM, Andrews NC: Iron homeostasis and erythropoiesis. Red Cell Development. 2008, 82: 141-167.Google Scholar
  242. Frazer DM, Anderson GJ: Iron Imports. I. Intestinal iron absorption and its regulation. Amer J Physiol. 2005, 289: G631-G635.Google Scholar
  243. Mackenzie B, Garrick MD: Iron Imports. II. Iron uptake at the apical membrane in the intestine. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2005, 289: G981-G986.PubMedGoogle Scholar
  244. Wessling-Resnick M: Iron Imports. III. Transfer of iron from the mucosa into circulation. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006, 290: G1-G6.PubMedPubMed CentralGoogle Scholar
  245. Ganz T, Nemeth E: Iron imports. IV. Hepcidin and regulation of body iron metabolism. Amer J Physiol. 2006, 290: G199-G203.Google Scholar
  246. Fleming RE, Britton RS: Iron Imports. VI. HFE and regulation of intestinal iron absorption. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006, 290: G590-G594.PubMedGoogle Scholar
  247. Ma YX, Yeh M, Yeh KY, Glass J: Iron imports. V. Transport of iron through the intestinal epithelium. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006, 290: G417-G422.PubMedGoogle Scholar
  248. De Domenico I, Ward DM, Kaplan J: Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nature Reviews Molecular Cell Biology. 2008, 9: 72-81.PubMedGoogle Scholar
  249. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA: Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997, 388: 482-8.PubMedGoogle Scholar
  250. Forbes JR, Gros P: Divalent-metal transport by NRAMP proteins at the interface of host-pathogen interactions. Trends Microbiol. 2001, 9: 397-403.PubMedGoogle Scholar
  251. Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, Khan Y, Warley A, McCann FE, Hider RC, Frazer DM, Anderson GJ, Vulpe CD, Simpson RJ, McKie AT: Identification of an intestinal heme transporter. Cell. 2005, 122: 789-801.PubMedGoogle Scholar
  252. Ryter SW, Alam J, Choi AM: Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006, 86: 583-650.PubMedGoogle Scholar
  253. Vítek L, Schwertner HA: The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem. 2007, 43: 1-57.PubMedGoogle Scholar
  254. Abraham NG, Kappas A: Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008, 60: 79-127.PubMedGoogle Scholar
  255. Ponka P: Tissue-specific regulation of iron metabolism and heme synthesis: Distinct control mechanisms in erythroid cells. Blood. 1997, 89: 1-25.PubMedGoogle Scholar
  256. Linder MC, Mortya M, Whon A, Kassa A, Gilley C: Vesicular transport of Fe and interaction with other metal ions in polarized Caco2 Cell monolayers. Biological Research. 2006, 39: 143-156.PubMedGoogle Scholar
  257. Moriya M, Linder MC: Vesicular transport and apotransferrin in intestinal iron absorption, as shown in the Caco-2 cell model. Amer J Physiol. 2006, 290: G301-G309.Google Scholar
  258. Petrat F, de Groot H, Sustmann R, Rauen U: The chelatable iron pool in living cells: A methodically defined quantity. Biological Chemistry. 2002, 383: 489-502.PubMedGoogle Scholar
  259. Tenopoulou M, Kurz T, Doulias PT, Galaris D, Brunk UT: Does the calcein-AM method assay the total cellular 'labile iron pool' or only a fraction of it?. Biochem J. 2007, 403: 261-6.PubMedPubMed CentralGoogle Scholar
  260. Shvartsman M, Kikkeri R, Shanzer A, Cabantchik ZI: Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am J Physiol Cell Physiol. 2007, 293: C1383-94.PubMedGoogle Scholar
  261. Breuer W, Shvartsman M, Cabantchik ZI: Intracellular labile iron. Int J Biochem Cell Biol. 2008, 40: 350-4.PubMedGoogle Scholar
  262. Fakih S, Podinovskaia M, Kong X, Collins HL, Schaible UE, Hider RC: Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools. J Med Chem. 2008, 51: 4539-52.PubMedGoogle Scholar
  263. Arosio P, Ingrassia R, Cavadini P: Ferritins: A family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta. 2008Google Scholar
  264. Shi H, Bencze KZ, Stemmler TL, Philpott CC: A cytosolic iron chaperone that delivers iron to ferritin. Science. 2008, 320: 1207-10.PubMedPubMed CentralGoogle Scholar
  265. Hallberg L, Hulthen L: Perspectives on iron absorption. Blood Cells Molecules and Diseases. 2002, 29: 562-573.Google Scholar
  266. Arosio P, Levi S: Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. 2002, 33: 457-63.PubMedGoogle Scholar
  267. Lee DH, Zacharski LR, Jacobs DR: Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes. Am Heart J. 2006, 151: 1247 e1-7.PubMedGoogle Scholar
  268. McKie AT, Barlow DJ: The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1). Pflugers Arch. 2004, 447: 801-6.PubMedGoogle Scholar
  269. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC: The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metabolism. 2005, 1: 191-200.PubMedGoogle Scholar
  270. Ganz T: Cellular iron: ferroportin is the only way out. Cell Metab. 2005, 1: 155-7.PubMedGoogle Scholar
  271. Oates PS: The role of hepcidin and ferroportin in iron absorption. Histol Histopathol. 2007, 22: 791-804.PubMedGoogle Scholar
  272. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Anderson GJ: Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nature Genetics. 1999, 21: 195-199.PubMedGoogle Scholar
  273. Worwood M: Serum transferrin receptor assays and their application. Annals of Clinical Biochemistry. 2002, 39: 221-230.PubMedGoogle Scholar
  274. Mense SM, Zhang L: Herne: a versatile signaling molecule controlling the activities of diverse regulators ranging from transcription factors to MAP kinases. Cell Res. 2006, 16: 681-692.PubMedGoogle Scholar
  275. Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW, Balla G: Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrology Dialysis Transplantation. 2003, 18: 8-12.Google Scholar
  276. Choi AM, Alam J: Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol. 1996, 15: 9-19.PubMedGoogle Scholar
  277. Foresti R, Green CJ, Motterlini R: Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. Biochem Soc Symp. 2004, 71: 177-192.PubMedGoogle Scholar
  278. Poon HF, Calabrese V, Scapagnini G, Butterfield DA: Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol A Biol Sci Med Sci. 2004, 59: 478-93.PubMedGoogle Scholar
  279. Akagi R, Takahashi T, Sassa S: Cytoprotective effects of heme oxygenase in acute renal failure. Cellular Stress Responses in Renal Diseases, Contrib Nephrol. 2005, 148: 70-85.Google Scholar
  280. Fredenburgh LE, Perrella MA, Mitsialis SA: The role of heme oxygenase-1 in pulmonary disease. Amer J Resp Cell Mol Biol. 2007, 36: 158-165.Google Scholar
  281. Gueler F, Park JK, Rong S, Kirsch T, Lindschau C, Zheng W, Elger M, Fiebeler A, Fliser D, Luft FC, Haller H: Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol. 2007, 170: 1192-1199.PubMedPubMed CentralGoogle Scholar
  282. Koizumi S: Human heme oxygenase-1 deficiency: a lesson on serendipity in the discovery of the novel disease. Pediatr Int. 2007, 49: 125-32.PubMedGoogle Scholar
  283. Horváth I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, Barnes PJ: Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax. 1998, 53: 668-72.PubMedPubMed CentralGoogle Scholar
  284. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Skollermo A, Steen J, Stenvall M, Sterky F, Stromberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Walden A, Wan J, Wernerus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Ponten F: A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005, 4: 1920-32.PubMedGoogle Scholar
  285. Lee DW, Andersen JK: Role of HIF-1 in iron regulation: potential therapeutic strategy for neurodegenerative disorders. Curr Mol Med. 2006, 6: 883-893.PubMedGoogle Scholar
  286. Rouault TA: The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nature Chem Biol. 2006, 2: 406-414.Google Scholar
  287. Wallander ML, Leibold EA, Eisenstein RS: Molecular control of vertebrate iron homeostasis by iron regulatory proteins. Biochim Biophys Acta. 2006, 1763: 668-689.PubMedPubMed CentralGoogle Scholar
  288. Lee K, Roth RA, LaPres JJ: Hypoxia, drug therapy and toxicity. Pharmacology & Therapeutics. 2007, 113: 229-246.Google Scholar
  289. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001, 276: 7811-7819.PubMedGoogle Scholar
  290. Fleming RE, Sly WS: Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Nal Acad Sci. 2001, 98: 8160-8162.Google Scholar
  291. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci. 2001, 98: 8780-8785.PubMedPubMed CentralGoogle Scholar
  292. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC: Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002, 100: 3776-81.PubMedGoogle Scholar
  293. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DHG, Subramaniam VN, Powell LW, Anderson GJ, Ramm GA: Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003, 361: 669-673.PubMedGoogle Scholar
  294. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, Andrews NC, Vaulont S: Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nature Genetics. 2003, 34: 97-101.PubMedGoogle Scholar
  295. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C: Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nature Genetics. 2003, 33: 21-22.PubMedGoogle Scholar
  296. Deicher R, Horl WH: Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant. 2004, 19: 521-4.PubMedGoogle Scholar
  297. Leong WI, Lönnerdal B: Hepcidin, the recently identified peptide that appears to regulate iron absorption. J Nutr. 2004, 134: 1-4.PubMedGoogle Scholar
  298. Robson KJ: Hepcidin and its role in iron absorption. Gut. 2004, 53: 617-9.PubMedPubMed CentralGoogle Scholar
  299. Camaschella C: Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood. 2005, 106: 3710-7.PubMedGoogle Scholar
  300. Loréal O, Haziza-Pigeon C, Troadec MB, Detivaud L, Turlin B, Courselaud B, Ilyin G, Brissot P: Hepcidin in iron metabolism. Curr Protein Pept Sci. 2005, 6: 279-91.PubMedGoogle Scholar
  301. Roetto A, Camaschella C: New insights into iron homeostasis through the study of non-HFE hereditary haemochromatosis. Best Pract Res Clin Haematol. 2005, 18: 235-50.PubMedGoogle Scholar
  302. Roy CN, Andrews NC: Anemia of inflammation: the hepcidin link. Curr Opin Hematol. 2005, 12: 107-11.PubMedGoogle Scholar
  303. Beutler E: Hemochromatosis: Genetics and pathophysiology. Annu Rev Med. 2006, 57: 331-347.PubMedGoogle Scholar
  304. Deicher R, Hörl WH: New insights into the regulation of iron homeostasis. Eur J Clin Invest. 2006, 36: 301-309.PubMedGoogle Scholar
  305. Farnaud S, Patel A, Evans RW: Modelling of a metal-containing hepcidin. Biometals. 2006, 19: 527-533.PubMedGoogle Scholar
  306. Ganz T: Hepcidin – A peptide hormone at the interface of innate immunity and iron metabolism. Antimicrobial Peptides and Human Disease, Current Topics in Microbiology and Immunology. 2006, 306: 183-198.Google Scholar
  307. Harrison-Findik DD, Schafer D, Klein E, Timchenko NA, Kulaksiz H, Clemens D, Fein E, Andriopoulos B, Pantopoulos K, Gollan J: Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem. 2006, 281: 22974-22982.PubMedGoogle Scholar
  308. Hugman A: Hepcidin: an important new regulator of iron homeostasis. Clin Lab Haematol. 2006, 28: 75-83.PubMedGoogle Scholar
  309. Mena NP, Esparza AL, Núñez MT: Regulation of transepithelial transport of iron by hepcidin. Biol Res. 2006, 39: 191-193.PubMedGoogle Scholar
  310. Mok H, Mlodnicka AE, Hentze MW, Muckenthaler M, Schumacher A: The molecular circuitry regulating the switch between iron deficiency and overload in mice. J Biol Chem. 2006, 281: 7946-51.PubMedGoogle Scholar
  311. Nemeth E, Ganz T: Regulation of iron metabolism by hepcidin. Annual Review of Nutrition. 2006, 26: 323-342.PubMedGoogle Scholar
  312. Atanasiu V, Manolescu B, Stoian I: Hepcidin – central regulator of iron metabolism. European Journal of Haematology. 2007, 78: 1-10.PubMedGoogle Scholar
  313. Malyszko J, Mysliwiec M: Hepcidin in anemia and inflammation in chronic kidney disease. Kidney & Blood Pressure Research. 2007, 30: 15-30.Google Scholar
  314. Oates PS, Ahmed U: Molecular regulation of hepatic expression of iron regulatory hormone hepcidin. J Gastroenterol Hepatol. 2007, 22: 1378-87.PubMedGoogle Scholar
  315. Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, Meneveri R, Nemeth E, Ganz T, Piperno A: Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol. 2008, 49: 123-33.PubMedGoogle Scholar
  316. Camaschella C, Silvestri L: New and old players in the hepcidin pathway. Haematologica. 2008, 93: 1441-4.PubMedGoogle Scholar
  317. De Domenico I, Nemeth E, Nelson JM, Phillips JD, Ajioka RS, Kay MS, Kushner JP, Ganz T, Ward DM, Kaplan J: The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab. 2008, 8: 146-56.PubMedPubMed CentralGoogle Scholar
  318. Farnaud S, Rapisarda C, Bui T, Drake A, Cammack R, Evans RW: Identification of an iron-hepcidin complex. Biochem J. 2008, 413: 553-7.PubMedGoogle Scholar
  319. Kartikasari AE, Roelofs R, Schaeps RM, Kemna EH, Peters WH, Swinkels DW, Tjalsma H: Secretion of bioactive hepcidin-25 by liver cells correlates with its gene transcription and points towards synergism between iron and inflammation signaling pathways. Biochim Biophys Acta. 2008, 1784: 2029-37.PubMedGoogle Scholar
  320. Muckenthaler MU, Galy B, Hentze MW: Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr. 2008, 28: 197-213.PubMedGoogle Scholar
  321. Nemeth E: Iron regulation and erythropoiesis. Curr Opin Hematol. 2008, 15: 169-75.PubMedGoogle Scholar
  322. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I: Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008, 134: 226-38.PubMedGoogle Scholar
  323. Peeling P, Dawson B, Goodman C, Landers G, Trinder D: Athletic induced iron deficiency: new insights into the role of inflammation, cytokines and hormones. Eur J Appl Physiol. 2008, 103: 381-91.PubMedGoogle Scholar
  324. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE. 2008, 3: e2706.PubMedPubMed CentralGoogle Scholar
  325. Swinkels DW, Wetzels JF: Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant. 2008, 23: 2450-3.PubMedGoogle Scholar
  326. Toblli JE, Cao G, Rivas C, Kulaksiz H: Heart and iron deficiency anaemia in rats with renal insufficiency: The role of hepcidin. Nephrology (Carlton). 2008, 13: 636-645.Google Scholar
  327. Trinder D, Ayonrinde OT, Olynyk JK: HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology. 2008, 134: 348-51.PubMedGoogle Scholar
  328. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M: Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA. 2005, 102: 1324-8.PubMedPubMed CentralGoogle Scholar
  329. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004, 306: 2090-2093.PubMedGoogle Scholar
  330. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F: Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood. 2005, 106: 3979-84.PubMedGoogle Scholar
  331. Ganz T: Hepcidin – a regulator of intestinal iron absorption and iron recycling by macrophages. Best Practice & Research Clinical Haematology. 2005, 18: 171-182.Google Scholar
  332. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, Goldberg YP, Sakellaropoulos N, Ganz T, Nemeth E: Hepcidin in iron overload disorders. Blood. 2005, 105: 4103-4105.PubMedPubMed CentralGoogle Scholar
  333. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, Houbron C, Hamard G, Kahn A, Vaulont S: Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood. 2006, 108: 1402-1405.PubMedGoogle Scholar
  334. Anderson GJ, Frazer DM: Iron metabolism meets signal transduction. Nature Genetics. 2006, 38: 503-504.PubMedGoogle Scholar
  335. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W: Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut. 2004, 53: 735-743.PubMedPubMed CentralGoogle Scholar
  336. Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W: The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. Journal of Endocrinology. 2005, 184: 361-370.PubMedGoogle Scholar
  337. Tiker F, Celik B, Tarcan A, Kilicdag H, Ozbek N, Gurakan B: Serum pro-hepcidin levels and relationships with iron parameters in healthy preterm and term newborns. Pediatr Hematol Oncol. 2006, 23: 293-297.PubMedGoogle Scholar
  338. Roe MA, Spinks C, Heath ALM, Harvey LJ, Foxall R, Wimperis J, Wolf C, Fairweather-Tait SJ: Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying. HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr. 2007, 97: 544-549.PubMedGoogle Scholar
  339. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002, 110: 1037-1044.PubMedPubMed CentralGoogle Scholar
  340. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S: Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006, 108: 3730-5.PubMedPubMed CentralGoogle Scholar
  341. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003, 101: 2461-2463.PubMedGoogle Scholar
  342. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004, 113: 1271-1276.PubMedPubMed CentralGoogle Scholar
  343. Kemna E, Pickkers P, Nemeth E, Hoeven van der H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005, 106: 1864-1866.PubMedGoogle Scholar
  344. Fleming RE: Iron and inflammation: cross-talk between pathways regulating hepcidin. J Mol Med. 2008, 86: 491-4.PubMedGoogle Scholar
  345. Malyszko J, Malyszko JS, Pawlak K, Drozdowska-Rams L, Brzosko S, Mysliwiec M: Hepcidin is linked to anemia and inflammation in peritoneal dialysis patients. Perit Dial Int. 2008, 28: 418-21.PubMedGoogle Scholar
  346. Wang RH, Li CL, Xu XL, Zheng Y, Xiao CY, Zerfas P, Cooperman S, Eckhaus M, Rouault T, Mishra L, Deng CX: A role of SMAD4 in iron metabolism through the positive regulation of hepicidin expression. Cell Metabolism. 2005, 2: 399-409.PubMedGoogle Scholar
  347. Falzacappa MVV, Spasic MV, Kessler R, Stolte J, Hentze MW, Muckenthaler MU: STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007, 109: 353-358.Google Scholar
  348. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, Ernst M, Klein C, Trautwein C: STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterol. 2007, 132: 294-300.Google Scholar
  349. Choi SO, Cho YS, Kim HL, Park JW: ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBP alpha and STAT-3. Biochem Biophys Res Comm. 2007, 356: 312-317.PubMedGoogle Scholar
  350. Flanagan JM, Truksa J, Peng HF, Lee P, Beutler E: In vivo imaging of hepcidin promoter stimulation by iron and inflammation. Blood Cells Mols Dis. 2007, 38: 253-257.Google Scholar
  351. Détivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, Ropert M, Jacquelinet S, Courselaud B, Ganz T, Brissot P, Loréal O: Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood. 2005, 106: 746-748.PubMedGoogle Scholar
  352. Weizer-Stern O, Adamsky K, Amariglio N, Rachmilewitz E, Breda L, Rivella S, Rechavi G: mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Amer J Hematol. 2006, 81: 479-483.Google Scholar
  353. Weizer-Stern O, Adamsky K, Amariglio N, Levin C, Koren A, Breuer W, Rachmilewitz E, Breda L, Rivella S, Cabantchik ZI, Rechavi G: Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol. 2006, 135: 129-138.PubMedGoogle Scholar
  354. Weizer-Stern O, Adamsky K, Margalit O, Ashur-Fabian O, Givol D, Amariglio N, Rechavi G: Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol. 2007, 138: 253-62.PubMedGoogle Scholar
  355. Sullivan JL: Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood). 2007, 232: 1014-20.Google Scholar
  356. Adamsky K, Weizer O, Amariglio N, Breda L, Harmelin A, Rivella S, Rachmilewitz E, Rechavi G: Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol. 2004, 124: 123-124.PubMedGoogle Scholar
  357. Flower DR, North AC, Sansom CE: The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta. 2000, 1482: 9-24.PubMedGoogle Scholar
  358. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993, 268: 10425-32.PubMedGoogle Scholar
  359. Stoesz SP, Gould MN: Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. Oncogene. 1995, 11: 2233-41.PubMedGoogle Scholar
  360. Kjeldsen L, Cowland JB, Borregaard N: Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta. 2000, 1482: 272-83.PubMedGoogle Scholar
  361. Liu Q, Ryon J, Nilsen-Hamilton M: Uterocalin: a mouse acute phase protein expressed in the uterus around birth. Mol Reprod Dev. 1997, 46: 507-14.PubMedGoogle Scholar
  362. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002, 10: 1033-43.PubMedGoogle Scholar
  363. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004, 432: 917-21.PubMedGoogle Scholar
  364. Fluckinger M, Haas H, Merschak P, Glasgow BJ, Redl B: Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob Agents Chemother. 2004, 48: 3367-72.PubMedPubMed CentralGoogle Scholar
  365. Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK: Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure. 2005, 13: 29-41.PubMedGoogle Scholar
  366. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW: Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2006, 103: 1834-9.PubMedPubMed CentralGoogle Scholar
  367. Borregaard N, Cowland JB: Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals. 2006, 19: 211-215.PubMedGoogle Scholar
  368. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J: An iron delivery pathway mediated by a lipocalin. Mol Cell. 2002, 10: 1045-56.PubMedGoogle Scholar
  369. Coles M, Diercks T, Muehlenweg B, Bartsch S, Zolzer V, Tschesche H, Kessler H: The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol. 1999, 289: 139-57.PubMedGoogle Scholar
  370. Tschesche H, Zolzer V, Triebel S, Bartsch S: The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem. 2001, 268: 1918-1928.PubMedGoogle Scholar
  371. Yan L, Borregaard N, Kjeldsen L, Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001, 276: 37258-65.PubMedGoogle Scholar
  372. Devarajan P, Mishra J, Supavekin S, Patterson LT, Steven Potter S: Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab. 2003, 80: 365-76.PubMedGoogle Scholar
  373. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003, 14: 2534-43.PubMedGoogle Scholar
  374. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005, 365: 1231-8.PubMedGoogle Scholar
  375. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J: Endocytic delivery of lipoccalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. Journal of Clinical Investigation. 2005, 115: 610-621.PubMedPubMed CentralGoogle Scholar
  376. Herget-Rosenthal S: One step forward in the early detection of acute renal failure. Lancet. 2005, 365: 1205-1206.PubMedGoogle Scholar
  377. Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, Jain A, Bullington N, Devarajan P: Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatric Nephrology. 2006, 21: 989-994.PubMedGoogle Scholar
  378. Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P: Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Critical Care. 2007, 11: R127.PubMedPubMed CentralGoogle Scholar
  379. Devarajan P: Update on mechanisms of ischemic acute kidney injury. Journal of the American Society of Nephrology. 2006, 17: 1503-1520.PubMedGoogle Scholar
  380. Schmidt-Ott KM, Mori K, Kalandadze A, Li JY, Paragas N, Nicholas T, Devarajan P, Barasch J: Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens. 2006, 15: 442-9.PubMedGoogle Scholar
  381. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007, 18: 407-13.PubMedGoogle Scholar
  382. Mori K, Nakao K: Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 2007, 71: 967-70.PubMedGoogle Scholar
  383. Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury PR, Nickolas TL, Barasch J, Devarajan P: Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol. 2007, 22: 101-8.PubMedGoogle Scholar
  384. Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, Parikh CR, Goldstein SL: Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Critical Care. 2007, 11.Google Scholar
  385. Molitoris BA, Melnikov VY, Okusa MD, Himmelfarb J: Technology Insight: biomarker development in acute kidney injury–what can we anticipate?. Nat Clin Pract Nephrol. 2008, 4: 154-65.PubMedGoogle Scholar
  386. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J: Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008, 148: 810-9.PubMedPubMed CentralGoogle Scholar
  387. Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, Malyszko JS, Poniatowski B, Dobrzycki S: Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2–4 chronic kidney disease. Ren Fail. 2008, 30: 625-8.PubMedGoogle Scholar
  388. Devarajan P: NGAL in acute kidney injury: from serendipity to utility. Am J Kidney Dis. 2008, 52: 395-9.PubMedGoogle Scholar
  389. Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008, 241: 89-94.PubMedPubMed CentralGoogle Scholar
  390. Devireddy LR, Gazin C, Zhu X, Green MR: A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 2005, 123: 1293-305.PubMedGoogle Scholar
  391. Richardson DR: 24p3 and its receptor: dawn of a new iron age?. Cell. 2005, 123: 1175-7.PubMedGoogle Scholar
  392. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N: The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005, 579: 773-7.PubMedGoogle Scholar
  393. Roudkenar MH, Kuwahara Y, Baba T, Roushandeh AM, Ebishima S, Abe S, Ohkubo Y, Fukumoto M: Oxidative stress induced lipocalin 2 gene expression: Addressing its expression under the harmful conditions. Journal of Radiation Research. 2007, 48: 39-44.PubMedGoogle Scholar
  394. Roudkenar MH, Halabian R, Ghasemipour Z, Roushandeh AM, Rouhbakhsh M, Nekogoftar M, Kuwahara Y, Fukumoto M, Shokrgozar MA: Neutrophil Gelatinase-associated Lipocalin acts as a protective factor against H2O2 toxicity. Arch Med Res. 2008, 39: 560-6.PubMedGoogle Scholar
  395. Gueler F, Gwinner W, Schwarz A, Haller H: Long-term effects of acute ischemia and reperfusion injury. Kidney International. 2004, 66: 523-527.PubMedGoogle Scholar
  396. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A: The story so far: molecular regulation of the heme oxygenase-1 gene in renal injury. Am J Physiol. 2004, 286: F425-F441.Google Scholar
  397. Shah S: Role of iron in progressive renal disease. Am J Kidney Dis. 2001, 37: S30-3.PubMedGoogle Scholar
  398. Aigner F, Maier HT, Schwelberger HG, Wallnofer EA, Amberger A, Obrist P, Berger T, Mak TW, Maglione M, Margreiter R, Schneeberger S, Troppmair J: Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Amer J Transplantation. 2007, 7: 779-788.Google Scholar
  399. Abergel RJ, Moore EG, Strong RK, Raymond KN: Microbial evasion of the immune system: structural modifications of enterobactin impair siderocalin recognition. J Am Chem Soc. 2006, 128: 10998-9.PubMedPubMed CentralGoogle Scholar
  400. Fischbach MA, Lin H, Zhou L, Yu Y, Abergel RJ, Liu DR, Raymond KN, Wanner BL, Strong RK, Walsh CT, Aderem A, Smith KD: The pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2. Proc Natl Acad Sci USA. 2006, 103: 16502-7.PubMedPubMed CentralGoogle Scholar
  401. Abergel RJ, Clifton MC, Pizarro JC, Warner JA, Shuh DK, Strong RK, Raymond KN: The siderocalin/enterobactin interaction: a link between mammalian immunity and bacterial iron transport. J Am Chem Soc. 2008, 130: 11524-34.PubMedPubMed CentralGoogle Scholar
  402. Cowland JB, Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997, 45: 17-23.PubMedGoogle Scholar
  403. Xu S, Venge P: Lipocalins as biochemical markers of disease. Biochim Biophys Acta. 2000, 1482: 298-307.PubMedGoogle Scholar
  404. Cowland JB, Sorensen OE, Sehested M, Borregaard N: Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol. 2003, 171: 6630-9.PubMedGoogle Scholar
  405. Cowland JB, Muta T, Borregaard N: IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J Immunol. 2006, 176: 5559-66.PubMedGoogle Scholar
  406. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgarde F, Ohlsson K: Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke. 1996, 27: 1734-8.PubMedGoogle Scholar
  407. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K: Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis. 1997, 131: 79-84.PubMedGoogle Scholar
  408. Falke P, Elneihoum AM, Ohlsson K: Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis. 2000, 10: 97-101.PubMedGoogle Scholar
  409. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thoren P, Hansson GK: Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006, 26: 136-42.PubMedGoogle Scholar
  410. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN: Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer. 1998, 79: 565-72.PubMedGoogle Scholar
  411. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP: Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005, 391: 441-8.PubMedPubMed CentralGoogle Scholar
  412. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty A, Bresalier RS, Logsdon C, Aggarwal BB, Krishnan S, Guha S: Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008, 68: 6100-8.PubMedPubMed CentralGoogle Scholar
  413. Weinberg ED: Iron out-of-balance: a risk factor for acute and chronic diseases. Hemoglobin. 2008, 32: 117-22.PubMedGoogle Scholar
  414. CESDI: Confidential Enquiry into Stillbirths and Deaths in Infancy. 5th Annual Report. 1998, Maternal and Child Health Research ConsortiumGoogle Scholar
  415. LaMarca BD, Gilbert J, Granger JP: Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension. 2008, 51: 982-8.PubMedPubMed CentralGoogle Scholar
  416. Redman CW, Sargent IL: Placental debris, oxidative stress and pre-eclampsia. Placenta. 2000, 21: 597-602.PubMedGoogle Scholar
  417. DiFederico E, Genbacev O, Fisher SJ: Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol. 1999, 155: 293-301.PubMedPubMed CentralGoogle Scholar
  418. Leung DN, Smith SC, To KF, Sahota DS, Baker PN: Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2001, 184: 1249-50.PubMedGoogle Scholar
  419. Huppertz B, Kingdom JC: Apoptosis in the trophoblast–role of apoptosis in placental morphogenesis. J Soc Gynecol Investig. 2004, 11: 353-62.PubMedGoogle Scholar
  420. Harris LK, Keogh RJ, Wareing M, Baker PN, Cartwright JE, Aplin JD, Whitley GS: Invasive trophoblasts stimulate vascular smooth muscle cell apoptosis by a fas ligand-dependent mechanism. Am J Pathol. 2006, 169: 1863-74.PubMedPubMed CentralGoogle Scholar
  421. Heazell AE, Moll SJ, Jones CJ, Baker PN, Crocker IP: Formation of syncytial knots is increased by hyperoxia, hypoxia and reactive oxygen species. Placenta. 2007, 28 (Suppl A): S33-40.PubMedGoogle Scholar
  422. Keogh RJ, Harris LK, Freeman A, Baker PN, Aplin JD, Whitley GS, Cartwright JE: Fetal-derived trophoblast use the apoptotic cytokine tumor necrosis factor-alpha-related apoptosis-inducing ligand to induce smooth muscle cell death. Circ Res. 2007, 100: 834-41.PubMedGoogle Scholar
  423. Heazell AE, Lacey HA, Jones CJ, Huppertz B, Baker PN, Crocker IP: Effects of oxygen on cell turnover and expression of regulators of apoptosis in human placental trophoblast. Placenta. 2008, 29: 175-86.PubMedGoogle Scholar
  424. Combs CA, Katz MA, Kitzmiller JL, Brescia RJ: Experimental preeclampsia produced by chronic constriction of the lower aorta: validation with longitudinal blood pressure measurements in conscious rhesus monkeys. Am J Obstet Gynecol. 1993, 169: 215-23.PubMedGoogle Scholar
  425. Wisdom SJ, Wilson R, McKillop JH, Walker JJ: Antioxidant systems in normal pregnancy and in pregnancy-induced hypertension. Am J Obs Gynecol. 1991, 165: 1701-1704.Google Scholar
  426. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ: Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest. 1996, 97: 540-50.PubMedPubMed CentralGoogle Scholar
  427. Benyo DF, Miles TM, Conrad KP: Hypoxia stimulates cytokine production by villous explants from the human placenta. J Clin Endocrinol Metab. 1997, 82: 1582-8.PubMedGoogle Scholar
  428. Conrad KP, Benyo DF: Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol. 1997, 37: 240-9.PubMedGoogle Scholar
  429. Lefevre G, Berkane N, Uzan S, Etienne J: Preeclampsia and oxygen free radicals. Annales De Biologie Clinique. 1997, 55: 443-450.PubMedGoogle Scholar
  430. Conrad KP, Miles TM, Benyo DF: Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol. 1998, 40: 102-11.PubMedGoogle Scholar
  431. Davidge ST: Oxidative stress and altered endothelial cell function in preeclampsia. Semin Reprod Endocrinol. 1998, 16: 65-73.PubMedGoogle Scholar
  432. Mise H, Sagawa N, Matsumoto T, Yura S, Nanno H, Itoh H, Mori T, Masuzaki H, Hosoda K, Ogawa Y, Nakao K: Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. J Clin Endocrinol Metab. 1998, 83: 3225-9.PubMedGoogle Scholar
  433. Walker JJ: Antioxidants and inflammatory cell response in preeclampsia. Semin Reprod Endocrinol. 1998, 16: 47-55.PubMedGoogle Scholar
  434. Walsh SW: Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Seminars in Reproductive Endocrinology. 1998, 16: 93-104.PubMedGoogle Scholar
  435. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ: Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest. 1999, 103: 1641-50.PubMedPubMed CentralGoogle Scholar
  436. Hubel CA: Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999, 222: 222-35.PubMedGoogle Scholar
  437. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN, Bennett WA: Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol. 1999, 181: 915-20.PubMedGoogle Scholar
  438. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, Post M: Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest. 2000, 105: 577-87.PubMedPubMed CentralGoogle Scholar
  439. Kharb S: Total free radical trapping antioxidant potential in pre-eclampsia. Int J Gynaecol Obstet. 2000, 69: 23-6.PubMedGoogle Scholar
  440. Tálosi G, Endreffy E, Túri S, Németh I: Molecular and genetic aspects of preeclampsia: State of the art. Mol Genet Metab. 2000, 71: 565-572.PubMedGoogle Scholar
  441. Walsh SW, Vaughan JE, Wang Y, Roberts LJ: Placental isoprostane is significantly increased in preeclampsia. FASEB J. 2000, 14: 1289-96.PubMedGoogle Scholar
  442. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R: Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol. 2001, 98: 757-62.PubMedGoogle Scholar
  443. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP: Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab. 2001, 86: 2505-12.PubMedGoogle Scholar
  444. Hung TH, Skepper JN, Burton GJ: In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol. 2001, 159: 1031-43.PubMedPubMed CentralGoogle Scholar
  445. López-Jaramillo P, Casas JP, Serrano N: Preeclampsia: from epidemiological observations to molecular mechanisms. Braz J Med Biol Res. 2001, 34: 1227-35.PubMedGoogle Scholar
  446. Malek A, Sager R, Schneider H: Effect of hypoxia, oxidative stress and lipopolysaccharides on the release of prostaglandins and cytokines from human term placental explants. Placenta. 2001, 22 (Suppl A): S45-50.PubMedGoogle Scholar
  447. Gitto E, Reiter RJ, Karbownik M, Tan DX, Gitto P, Barberi S, Barberi I: Causes of oxidative stress in the pre- and perinatal period. Biology of the Neonate. 2002, 81: 146-157.PubMedGoogle Scholar
  448. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA: Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002, 9: 147-60.PubMedGoogle Scholar
  449. Roberts JM, Lain KY: Recent Insights into the pathogenesis of pre-eclampsia. Placenta. 2002, 23: 359-72.PubMedGoogle Scholar
  450. Vaughan JE, Walsh SW: Oxidative stress reproduces placental abnormalities of preeclampsia. Hypertens Preg. 2002, 21: 205-223.Google Scholar
  451. Burton GJ, Jauniaux E: Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig. 2004, 11: 342-352.PubMedGoogle Scholar
  452. Connors N, Merrill D: Antioxidants for prevention of preterm delivery. Clin Obs Gynecol. 2004, 47: 822-832.Google Scholar
  453. Raijmakers MT, Peters WH, Steegers EA, Poston L: Amino thiols, detoxification and oxidative stress in pre-eclampsia and other disorders of pregnancy. Curr Pharm Des. 2005, 11: 711-34.PubMedGoogle Scholar
  454. Redman CW, Sargent IL: Pre-eclampsia, the placenta and the maternal systemic inflammatory response–a review. Placenta. 2003, 24 (Suppl A): S21-7.PubMedGoogle Scholar
  455. Downing JW, Ramasubramanian R, Johnson RF, Minzter BH, Paschall RL, Sundell HW, Engelhardt B, Lewis R: Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia. Med Hypotheses. 2004, 63: 1057-64.PubMedGoogle Scholar
  456. Myatt L, Cui XL: Oxidative stress in the placenta. Histochem Cell Biol. 2004, 122: 369-382.PubMedGoogle Scholar
  457. Touyz RM, Schiffrin EL: Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004, 122: 339-52.PubMedGoogle Scholar
  458. Touyz RM: Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension. 2004, 44: 248-52.PubMedGoogle Scholar
  459. Tsukahara H, Ohta N, Sato S, Hiraoka M, Shukunami K, Uchiyama M, Kawakami H, Sekine K, Mayumi M: Concentrations of pentosidine, an advanced glycation end-product, in umbilical cord blood. Free Radic Res. 2004, 38: 691-5.PubMedGoogle Scholar
  460. Bdolah Y, Karumanchi SA, Sachs BP: Recent advances in understanding of preeclampsia. Croat Med J. 2005, 46: 728-36.PubMedGoogle Scholar
  461. Biondi C, Pavan B, Lunghi L, Florini S, Vesce F: The role and modulation of the oxidative balance in pregnancy. Curr Pharmaceut Design. 2005, 11: 2075-2089.Google Scholar
  462. Engin-Üstün Y, Üstün Y, Kamaci M, Şekeroğlu R: Maternal serum ceruloplasmin in preectampsia. Int J Gynecol Obs. 2005, 89: 51-52.Google Scholar
  463. Gupta S, Agarwal A, Sharma RK: The role of placental oxidative stress and lipid peroxidation in preeclampsia. Obstet Gynecol Surv. 2005, 60: 807-16.PubMedGoogle Scholar
  464. Noris M, Perico N, Remuzzi G: Mechanisms of disease: pre-eclampsia. Nature Clin Pract Nephrol. 2005, 1: 98-114.Google Scholar
  465. Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science. 2005, 308: 1592-1594.PubMedGoogle Scholar
  466. Roberts JM, Gammill HS: Preeclampsia: recent insights. Hypertension. 2005, 46: 1243-9.PubMedGoogle Scholar
  467. Rodrigo R, Parra M, Bosco C, Fernandez V, Barja P, Guajardo J, Messina R: Pathophysiological basis for the prophylaxis of preeclampsia through early supplementation with antioxidant vitamins. Pharmacology & Therapeutics. 2005, 107: 177-197.Google Scholar
  468. Scholl TO, Leskiw M, Chen X, Sims M, Stein TP: Oxidative stress, diet, and the etiology of preeclampsia. Am J Clin Nutr. 2005, 81: 1390-6.PubMedGoogle Scholar
  469. Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, Post M, Caniggia I: Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab. 2005, 90: 4299-4308.PubMedGoogle Scholar
  470. Spinnato JA, Livingston JC: Prevention of preeclampsia with antioxidants: Evidence from randomized trials. Clinical Obstetrics and Gynecology. 2005, 48: 416-429.PubMedGoogle Scholar
  471. Blackburn S: Free radicals in perinatal and neonatal care, part 2 – Oxidative stress during the perinatal and neonatal period. Journal of Perinatal & Neonatal Nursing. 2006, 20: 125-127.Google Scholar
  472. Borzychowski AM, Sargent IL, Redman CW: Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006, 11: 309-16.PubMedGoogle Scholar
  473. Hauguel-de Mouzon S, Guerre-Millo M: The placenta cytokine network and inflammatory signals. Placenta. 2006, 27: 794-8.PubMedGoogle Scholar
  474. Perkins AV: Endogenous anti-oxidants in pregnancy and preeclampsia. Aus New Zeal J Obs Gynaecol. 2006, 46: 77-83.Google Scholar
  475. Rogers MS, Wang CC, Tam WH, Li CY, Chu KO, Chu CY: Oxidative stress in midpregnancy as a predictor of gestational hypertension and pre-eclampsia. BJOG. 2006, 113: 1053-9.PubMedGoogle Scholar
  476. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST: Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med. 2006, 8: 1-20.PubMedGoogle Scholar
  477. Sargent IL, Borzychowski AM, Redman CW: Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2006, 13: 680-6.PubMedGoogle Scholar
  478. Sharma JB, Sharma A, Bahadur A, Vimala N, Satyam A, Mittal S: Oxidative stress markers and antioxidant levels in normal pregnancy and pre-eclampsia. Int J Gynecol Obs. 2006, 94: 23-27.Google Scholar
  479. Webster RP, Brockman D, Myatt L: Nitration of p38 MAPK in the placenta: association of nitration with reduced catalytic activity of p38 MAPK in pre-eclampsia. Molecular Human Reproduction. 2006, 12: 677-685.PubMedGoogle Scholar
  480. Burdon C, Mann C, Cindrova-Davies T, Ferguson-Smith AC, Burton GJ: Oxidative stress and the induction of cyclooxygenase enzymes and apoptosis in the murine placenta. Placenta. 2007, 28: 724-33.PubMedPubMed CentralGoogle Scholar
  481. Crocker I: Gabor Than Award Lecture 2006: pre-eclampsia and villous trophoblast turnover: perspectives and possibilities. Placenta. 2007, 28 (Suppl A): S4-13.PubMedGoogle Scholar
  482. Keelan JA, Mitchell MD: Placental cytokines and preeclampsia. Front Biosci. 2007, 12: 2706-27.PubMedGoogle Scholar
  483. Milczarek R, Sokolowska E, Hallmann A, Klimek J: The NADPH- and iron-dependent lipid peroxidation in human placental microsomes. Molecular and Cellular Biochemistry. 2007, 295: 105-111.PubMedGoogle Scholar
  484. Schiessl B: Inflammatory response in preeclampsia. Mol Aspects Med. 2007, 28: 210-9.PubMedGoogle Scholar
  485. Shah TJ, Walsh SW: Activation of NF-kappaB and expression of COX-2 in association with neutrophil infiltration in systemic vascular tissue of women with preeclampsia. Am J Obstet Gynecol. 2007, 196: 48 e1-8.PubMedGoogle Scholar
  486. Walsh SW: Obesity: a risk factor for preeclampsia. Trends Endocrinol Metab. 2007, 18: 365-70.PubMedGoogle Scholar
  487. Zamudio S: High-altitude hypoxia and preeclampsia. Frontiers in Bioscience. 2007, 12: 2967-2977.PubMedGoogle Scholar
  488. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP: Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008, 294: H541-50.PubMedGoogle Scholar
  489. Robinson NJ, Wareing M, Hudson NK, Blankley RT, Baker PN, Aplin JD, Crocker IP: Oxygen and the liberation of placental factors responsible for vascular compromise. Lab Invest. 2008Google Scholar
  490. Entman SS, Richardson LD, Killam AP: Elevated serum ferritin in the altered ferrokinetics of toxemia of pregnancy. AmJ Obs Gynecol. 1982, 144: 418-422.Google Scholar
  491. Entman SS, Richardson LD: Clinical applications of the altered iron kinetics of toxemia of pregnancy. Am J Obs Gynecol. 1983, 146: 568-574.Google Scholar
  492. Entman SS, Richardson LD, Killam AP: Altered ferrokinetics in toxemia of pregnancy – a possible indicator of decreased red cell survival. Clin Exp Hypertens B. 1983, 2: 171-178.PubMedGoogle Scholar
  493. Entman SS, Kambam JR, Bradley CA, Cousar JB: Increased levels of carboxyhemoglobin and serum iron as an indicator of increased red cell turnover in preeclampsia. Am J Obstet Gynecol. 1987, 156: 1169-73.PubMedGoogle Scholar
  494. Samuels P, Main EK, Mennuti MT, Gabbe SG: The origin of increased serum iron in pregnancy-induced hypertension. Am J Obstet Gynecol. 1987, 157: 721-5.PubMedGoogle Scholar
  495. Lindheimer MD, Katz AI: Preeclampsia – Patho-physiology, diagnosis, and management. Annual Review of Medicine. 1989, 40: 233-250.PubMedGoogle Scholar
  496. Raman L, Pawashe AB, Yasodhara P: Hyperferritinemia in pregnancy induced hypertension and eclampsia. J Postgrad Med. 1992, 38: 65-7.PubMedGoogle Scholar
  497. Das SS, Dhall GI, Dhall K, Dash S: Significance of serum iron levels as a biochemical marker in pregnancy-induced hypertension. Int J Gynecol Obs. 1994, 45: 3-9.Google Scholar
  498. Hubel CA, Kozlov AV, Kagan VE, Evans RW, Davidge ST, McLaughlin MK, Roberts JM: Decreased transferrin and increased transferrin saturation in sera of women with preeclampsia: implications for oxidative stress. Am J Obstet Gynecol. 1996, 175: 692-700.PubMedGoogle Scholar
  499. Sizoo BB, Paarlberg MM, Bouman AA, Dekker GA: The role of serum iron levels in diagnostic hypertensive disorders in pregnancy. Hypertension in Pregnancy. 1997, 16: 425-433.Google Scholar
  500. Vitoratos N, Salamalekis E, Dalamaga N, Kassanos D, Creatsas G: Defective antioxidant mechanisms via changes in serum ceruloplasmin and total iron binding capacity of serum in women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 1999, 84: 63-7.PubMedGoogle Scholar
  501. Lao TT, Tam KF, Chan LY: Third trimester iron status and pregnancy outcome in non-anaemic women; pregnancy unfavourably affected by maternal iron excess. Hum Reprod. 2000, 15: 1843-8.PubMedGoogle Scholar
  502. Waterstone M, Bewley S, Wolfe C: Incidence and predictors of severe obstetric morbidity: case-control study. BMJ. 2001, 322: 1089-93.PubMedPubMed CentralGoogle Scholar
  503. Mello G, Parretti E, Cioni R, Lagozio C, Mealli F, Pratesi M: Individual longitudinal patterns in biochemical and hematological markers for the early prediction of pre-eclampsia. J Matern Fetal Neonatal Med. 2002, 11: 93-9.PubMedGoogle Scholar
  504. Casanueva E, Viteri FE: Iron and oxidative stress in pregnancy. J Nutr. 2003, 133: 1700S-1708S.PubMedGoogle Scholar
  505. Hubel CA, Bodnar LM, Many A, Harger G, Ness RB, Roberts JM: Nonglycosylated ferritin predominates in the circulation of women with preeclampsia but not intrauterine growth restriction. Clin Chem. 2004, 50: 948-951.PubMedGoogle Scholar
  506. Norwitz ER, Tsen LC, Park JS, Fitzpatrick PA, Dorfman DM, Saade GR, Buhimschi CS, Buhimschi IA: Discriminatory proteomic biomarker analysis identifies free hemoglobin in the cerebrospinal fluid of women with severe preeclampsia. Amer J Obs Gynecol. 2005, 193: 957-964.Google Scholar
  507. Scholl TO: Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr. 2005, 81: 1218S-1222S.PubMedGoogle Scholar
  508. Serdar Z, Gür E, Develioğlu O: Serum iron and copper status and oxidative stress in severe and mild preeclampsia. Cell Biochem Funct. 2006, 24: 209-15.PubMedGoogle Scholar
  509. Smith TG, Robbins PA: Iron, pre-eclampsia and hypoxia-inducible factor. Bjog. 2007, 114: 1581-2.PubMedGoogle Scholar
  510. Ziaei S, Norrozi M, Faghihzadeh S, Jafarbegloo E: A randomised placebo-controlled trial to determine the effect of iron supplementation on pregnancy outcome in pregnant women with haemoglobin > or = 13.2 g/dl. BJOG. 2007, 114: 684-8.PubMedGoogle Scholar
  511. Guller S, Buhimschi CS, Ma YY, Huang ST, Yang L, Kuczynski E, Zambrano E, Lockwood CJ, Buhimschi IA: Placental expression of ceruloplasmin in pregnancies complicated by severe preeclampsia. Lab Invest. 2008, 88: 1057-67.PubMedPubMed CentralGoogle Scholar
  512. Gambling L, Danzeisen R, Gair S, Lea RG, Charania Z, Solanky N, Joory KD, Srai SKS, McArdle HJ: Effect of iron deficiency on placental transfer of iron and expression of iron transport proteins in vivo and in vitro. Biochem J. 2001, 356: 883-889.PubMedPubMed CentralGoogle Scholar
  513. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, Clark P, Walker ID, Sattar N, Greer IA: Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension. 2004, 44: 708-14.PubMedGoogle Scholar
  514. Bodnar LM, Ness RB, Harger GF, Roberts JM: Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol. 2005, 162: 1198-206.PubMedGoogle Scholar
  515. Braekke K, Holthe MR, Harsem NK, Fagerhol MK, Staff AC: Calprotectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia. Am J Obstet Gynecol. 2005, 193: 227-33.PubMedGoogle Scholar
  516. Hu W, Wang H, Wang Z, Huang H, Dong M: Elevated serum levels of interleukin-15 and interleukin-16 in preeclampsia. J Reprod Immunol. 2007, 73: 166-71.PubMedGoogle Scholar
  517. Keelan JA, Mitchell MD: Cytokines, hypoxia, and preeclampsia. J Soc Gynecol Investig. 2005, 12: 385-7.PubMedGoogle Scholar
  518. Elovitz MA: Anti-inflammatory interventions in pregnancy: now and the future. Semin Fetal Neonatal Med. 2006, 11: 327-32.PubMedGoogle Scholar
  519. Paternoster DM, Fantinato S, Stella A, Nanhorngue KN, Milani M, Plebani M, Nicolini U, Girolami A: C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost. 2006, 12: 330-7.PubMedGoogle Scholar
  520. Dorrepaal CA, Berger HM, Benders M, vanZoerenGrobben D, VanDeBor M, VanBel F: Nonprotein-bound iron in postasphyxial reperfusion injury of the newborn. Pediatrics. 1996, 98: 883-889.PubMedGoogle Scholar
  521. Goldenberg RL, Tamura T, DuBard M, Johnston KE, Copper RL, Neggers Y: Plasma ferritin and pregnancy outcome. Am J Obs Gynecol. 1996, 175: 1356-1359.Google Scholar
  522. Tamura T, Goldenberg RL, Johnston KE, Cliver SP, Hickey CA: Serum ferritin: A predictor of early spontaneous preterm delivery. Obs Gynecol. 1996, 87: 360-365.Google Scholar
  523. Buhimschi IA, Buhimschi CS, Weiner CP: Protective effect of N-acetylcysteine against fetal death and preterm labor induced by maternal inflammation. American Journal of Obstetrics and Gynecology. 2003, 188: 203-208.PubMedGoogle Scholar
  524. Ciccoli L, Rossi V, Leoncini S, Signorini C, Paffetti P, Bracci R, Buonocore G, Comporti M: Iron release in erythrocytes and plasma non protein-bound iron in hypoxic and non hypoxic newborns. Free Radical Research. 2003, 37: 51-58.PubMedGoogle Scholar
  525. Buhimschi IA, Saade GR, Chwalisz K, Garfield RE: The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Human Reproduction Update. 1998, 4: 25-42.PubMedGoogle Scholar
  526. Milman N: Iron and pregnancy – a delicate balance. Annals of Hematology. 2006, 85: 559-565.PubMedGoogle Scholar
  527. Milman N: Iron prophylaxis in pregnancy-general or individual and in which dose?. Annals of Hematology. 2006, 85: 821-828.PubMedGoogle Scholar
  528. Lachili B, Hininger I, Faure H, Arnaud J, Richard MJ, Favier A, Roussel AM: Increased lipid peroxidation in pregnant women after iron and vitamin C supplementation. Biol Trace Elem Res. 2001, 83: 103-10.PubMedGoogle Scholar
  529. Devrim E, Tarhan I, Ergüder IB, Durak I: Oxidant/antioxidant status of placenta, blood, and cord blood samples from pregnant women supplemented with iron. J Soc Gynecol Investig. 2006, 13: 502-5.PubMedGoogle Scholar
  530. Keyes LE, Armaza JF, Niermeyer S, Vargas E, Young DA, Moore LG: Intrauterine growth restriction, preeclampsia, and intrauterine mortality at high altitude in Bolivia. Pediatric Research. 2003, 54: 20-25.PubMedGoogle Scholar
  531. Teramo KA, Hiilesmaa VK, Schwartz R, Clemons GK, Widness JA: Amniotic fluid and cord plasma erythropoietin levels in pregnancies complicated by preeclampsia, pregnancy-induced hypertension and chronic hypertension. J Perinat Med. 2004, 32: 240-7.PubMedGoogle Scholar
  532. Liang ST, Wong VC, So WW, Ma HK, Chan V, Todd D: Homozygous alpha-thalassaemia: clinical presentation, diagnosis and management. A review of 46 cases. Br J Obstet Gynaecol. 1985, 92: 680-4.PubMedGoogle Scholar
  533. Tungwiwat W, Fucharoen S, Fucharoen G, Ratanasiri T, Sanchaisuriya K: Development and application of a real-time quantitative PCR for prenatal detection of fetal alpha(0)-thalassemia from maternal plasma. Ann N Y Acad Sci. 2006, 1075: 103-7.PubMedGoogle Scholar
  534. Senden IP, de Groot CJ, Steegers EA, Bertina RM, Swinkels DW: Preeclampsia and the C282Y mutation in the hemochromatosis (HFE) gene. Clin Chem. 2004, 50: 973-4.PubMedGoogle Scholar
  535. Quek L, Thein SL: Molecular therapies in beta-thalassaemia. British Journal of Haematology. 2007, 136: 353-365.PubMedGoogle Scholar
  536. Knox KS, Baker JC: Genome-wide expression profiling of placentas in the p57Kip2 model of pre-eclampsia. Mol Hum Reprod. 2007, 13: 251-63.PubMedGoogle Scholar
  537. Suire S, Stewart F, Beauchamp J, Kennedy MW: Uterocalin, a lipocalin provisioning the preattachment equine conceptus: fatty acid and retinol binding properties, and structural characterization. Biochem J. 2001, 356: 369-76.PubMedPubMed CentralGoogle Scholar
  538. Ryon J, Bendickson L, Nilsen-Hamilton M: High expression in involuting reproductive tissues of uterocalin/24p3, a lipocalin and acute phase protein. Biochem J. 2002, 367: 271-7.PubMedPubMed CentralGoogle Scholar
  539. Nilsen-Hamilton M, Liu Q, Ryon J, Bendickson L, Lepont P, Chang Q: Tissue involution and the acute phase response. Ann N Y Acad Sci. 2003, 995: 94-108.PubMedGoogle Scholar
  540. D'Anna R, Baviera G, Giordano D, Todarello G, Corrado F, Buemi M: Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand. 2008, 1-4.Google Scholar
  541. Coughlan MT, Permezel M, Georgiou HM, Rice GE: Repression of oxidant-induced nuclear factor-kappaB activity mediates placental cytokine responses in gestational diabetes. J Clin Endocrinol Metab. 2004, 89: 3585-94.PubMedGoogle Scholar
  542. Coughlan MT, Vervaart PP, Permezel M, Georgiou HM, Rice GE: Altered placental oxidative stress status in gestational diabetes mellitus. Placenta. 2004, 25: 78-84.PubMedGoogle Scholar
  543. King JC: Maternal obesity, metabolism and pregnancy outcomes. Annu Rev Nutrition. 2006, 26: 271-291.PubMedGoogle Scholar
  544. Mazar RM, Srinivas SK, Sammel MD, Andrela CM, Elovitz MA: Metabolic score as a novel approach to assessing preeclampsia risk. Am J Obstet Gynecol. 2007, 197: 411 e1-5.PubMedGoogle Scholar
  545. Rademacher TW, Gumaa K, Scioscia M: Preeclampsia, insulin signalling and immunological dysfunction: a fetal, maternal or placental disorder?. J Reprod Immunol. 2007, 76: 78-84.PubMedGoogle Scholar
  546. Hales CN, Ozanne SE: For Debate: Fetal and early postnatal growth restriction lead to diabetes, the metabolic syndrome and renal failure. Diabetologia. 2003, 46: 1013-1019.PubMedGoogle Scholar
  547. McMillen IC, Robinson JS: Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev. 2005, 85: 571-633.PubMedGoogle Scholar
  548. Williams PJ, Gumaa K, Scioscia M, Redman CW, Rademacher TW: Inositol phosphoglycan P-type in preeclampsia: a novel marker?. Hypertension. 2007, 49: 84-9.PubMedGoogle Scholar
  549. West IC: Radicals and oxidative stress in diabetes. Diabet Med. 2000, 17: 171-80.PubMedGoogle Scholar
  550. Lipinski B: Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications. 2001, 15: 203-10.PubMedGoogle Scholar
  551. Maddux BA, See W, Lawrence JC, Goldfine AL, Goldfine ID, Evans JL: Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid. Diabetes. 2001, 50: 404-10.PubMedGoogle Scholar
  552. Evans JL, Maddux BA, Goldfine ID: The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005, 7: 1040-52.PubMedGoogle Scholar
  553. Houstis N, Rosen ED, Lander ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006, 440: 944-8.PubMedGoogle Scholar
  554. Meigs JB, Larson MG, Fox CS, Keaney JF, Vasan RS, Benjamin EJ: Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care. 2007, 30: 2529-35.PubMedGoogle Scholar
  555. Shah S, Iqbal M, Karam J, Salifu M, McFarlane SI: Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: Pathophysiological insights. Antioxid Redox Signal. 2007, 9: 911-929.PubMedGoogle Scholar
  556. Choi SW, Benzie IF, Ma SW, Strain JJ, Hannigan BM: Acute hyperglycemia and oxidative stress: direct cause and effect?. Free Radic Biol Med. 2008, 44: 1217-31.PubMedGoogle Scholar
  557. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000, 404: 787-90.PubMedGoogle Scholar
  558. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocrine Reviews. 2002, 23: 599-622.PubMedGoogle Scholar
  559. Niedowicz DM, Daleke DL: The role of oxidative stress in diabetic complications. Cell Biochem Biophys. 2005, 43: 289-330.PubMedGoogle Scholar
  560. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002, 51: 2944-50.PubMedGoogle Scholar
  561. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, Komoda T: Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun. 1997, 235: 113-6.PubMedGoogle Scholar
  562. Fukui T, Noma T, Mizushige K, Aki Y, Kimura S, Abe Y: Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats. Life Sci. 2000, 66: 2043-9.PubMedGoogle Scholar
  563. Bao Y, Jia RH, Yuan J, Li J: Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology. 2007, 80: 57-64.PubMedGoogle Scholar
  564. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, Cha BS: Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci. 2007, 253: 53-60.PubMedGoogle Scholar
  565. Jung Y, Song S, Choi C: Peroxisome proliferator activated receptor gamma agonists suppress TNFalpha-induced ICAM-1 expression by endothelial cells in a manner potentially dependent on inhibition of reactive oxygen species. Immunol Lett. 2008, 117: 63-9.PubMedGoogle Scholar
  566. Allahtavakoli M, Shabanzadeh AP, Sadr SS, Parviz M, Djahanguiri B: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. Clin Exp Pharmacol Physiol. 2006, 33: 1052-8.PubMedGoogle Scholar
  567. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R: Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med. 2006, 41: 579-89.PubMedGoogle Scholar
  568. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R: Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol. 2006, 530: 70-80.PubMedGoogle Scholar
  569. Allahtavakoli M, Shabanzadeh A, Roohbakhsh A, Pourshanazari A: Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol. 2007, 101: 309-14.PubMedGoogle Scholar
  570. Wessel J, Moratorio G, Rao F, Mahata M, Zhang L, Greene W, Rana BK, Kennedy BP, Khandrika S, Huang P, Lillie EO, Shih PA, Smith DW, Wen G, Hamilton BA, Ziegler MG, Witztum JL, Schork NJ, Schmid-Schonbein GW, O'Connor DT: C-reactive protein, an 'intermediate phenotype' for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrenergic pathway loci. J Hypertens. 2007, 25: 329-43.PubMedGoogle Scholar
  571. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999, 48: 1-9.PubMedGoogle Scholar
  572. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004, 53: 693-700.PubMedGoogle Scholar
  573. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004, 27: 813-23.PubMedGoogle Scholar
  574. Kolb H, Mandrup-Poulsen T: An immune origin of type 2 diabetes?. Diabetologia. 2005, 48: 1038-50.PubMedGoogle Scholar
  575. Lee YH, Pratley RE: The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005, 5: 70-5.PubMedGoogle Scholar
  576. Tataranni PA, Ortega E: A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?. Diabetes. 2005, 54: 917-27.PubMedGoogle Scholar
  577. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest. 2005, 115: 1111-9.PubMedPubMed CentralGoogle Scholar
  578. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A: Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci. 2006, 1084: 89-117.PubMedGoogle Scholar
  579. Chen H: Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacol Res. 2006, 53: 469-77.PubMedGoogle Scholar
  580. Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, Lakka T, Ilanne-Parikka P, Eriksson JG, Hamalainen H, Keinanen-Kiukaanniemi S, Valle TT, Uusitupa M, Lindstrom J, Kolb H, Tuomilehto J: Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes. 2006, 55: 2340-6.PubMedGoogle Scholar
  581. Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444: 860-7.PubMedGoogle Scholar
  582. Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb H: Inflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucose. Ann N Y Acad Sci. 2006, 1084: 30-48.PubMedGoogle Scholar
  583. Neels JG, Olefsky JM: Inflamed fat: what starts the fire?. J Clin Invest. 2006, 116: 33-5.PubMedPubMed CentralGoogle Scholar
  584. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest. 2006, 116: 1793-801.PubMedPubMed CentralGoogle Scholar
  585. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW: CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006, 116: 115-24.PubMedGoogle Scholar
  586. Zozulinska D, Wierusz-Wysocka B: Type 2 diabetes mellitus as inflammatory disease. Diabetes Research and Clinical Practice. 2006, 74: S12-S16.Google Scholar
  587. Pradhan A: Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev. 2007, 65: S152-6.PubMedGoogle Scholar
  588. Shoelson SE, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology. 2007, 132: 2169-2180.PubMedGoogle Scholar
  589. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, Herder C: Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care. 2007, 30: 854-60.PubMedGoogle Scholar
  590. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, Sowers JR: Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol. 2008, 294: R673-80.PubMedGoogle Scholar
  591. Lao TT, Chan PL, Tam KF: Gestational diabetes mellitus in the last trimester – a feature of maternal iron excess?. Diabet Med. 2001, 18: 218-23.PubMedGoogle Scholar
  592. Lao TT, Tse KY, Chan LY, Tam KF, Ho LF: NBsAg carrier status and the association between gestational diabetes with increased serum ferritin concentration in Chinese women. Diabetes Care. 2003, 26: 3011-3016.PubMedGoogle Scholar
  593. Chen X, Scholl TO, Stein TP: Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: The Camden study. Diabetes Care. 2006, 29: 1077-82.PubMedGoogle Scholar
  594. Oberley LW: Free radicals and diabetes. Free Radic Biol Med. 1988, 5: 113-24.PubMedGoogle Scholar
  595. Wolff SP: Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull. 1993, 49: 642-52.PubMedGoogle Scholar
  596. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT: Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care. 1997, 20: 426-8.PubMedGoogle Scholar
  597. Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K: Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ. 1998, 317: 727.PubMedPubMed CentralGoogle Scholar
  598. Fernández-Real JM, López-Bermejo A, Ricart W: Cross-talk between iron metabolism and diabetes. Diabetes. 2002, 51: 2348-54.PubMedGoogle Scholar
  599. Fernández-Real JM, Ricart W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003, 24: 278-301.PubMedGoogle Scholar
  600. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF: Potential role of increased iron stores in diabetes. Am J Med Sci. 2003, 325: 332-9.PubMedGoogle Scholar
  601. Lee DH, Folsom AR, Jacobs DR: Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia. 2004, 47: 185-94.PubMedGoogle Scholar
  602. Kazi TG, Afridi HI, Kazi N, Jamali MK, Arain MB, Jalbani N, Kandhro GA: Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. Biol Trace Elem Res. 2008, 122: 1-18.PubMedGoogle Scholar
  603. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB: The role of iron in type 2 diabetes in humans. Biochim Biophys Acta. 2008.Google Scholar
  604. Adams PC, Kertesz AE, Valberg LS: Clinical presentation of hemochromatosis: a changing scene. Am J Med. 1991, 90: 445-9.PubMedGoogle Scholar
  605. Kaye TB, Guay AT, Simonson DC: Non-insulin-dependent diabetes mellitus and elevated serum ferritin level. J Diabetes Complic. 1993, 7: 246-249.Google Scholar
  606. Fernández-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J: Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998, 21: 62-68.PubMedGoogle Scholar
  607. Ford ES, Cogswell ME: Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999, 22: 1978-83.PubMedGoogle Scholar
  608. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB: Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004, 291: 711-7.PubMedGoogle Scholar
  609. Mojiminiyi OA, Marouf R, Abdella NA: Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2008, 18: 559-66.PubMedGoogle Scholar
  610. Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, Ballantyne CM, Hoogeveen RC, Harris ZL, Pankow JS: A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 2007, 165: 1047-54.PubMedGoogle Scholar
  611. Fernández-Real JM, Moreno JM, Chico B, Lopez-Bermejo A, Ricart W: Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care. 2007, 30: 616-21.PubMedGoogle Scholar
  612. Wang Y, Lam KSL, Kraegen EW, Sweeney G, Zhang JL, Tso AWK, Chow WS, Wat NMS, Xu JY, Hoo RLC, Xu AM: Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clinical Chemistry. 2007, 53: 34-41.PubMedGoogle Scholar
  613. van Dam RM, Hu FB: Lipocalins and insulin resistance: Etiological role of retinol-binding protein 4 and lipocalin-2?. Clinical Chemistry. 2007, 53: 5-7.PubMedGoogle Scholar
  614. Hua NW, Stoohs RA, Facchini FS: Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br J Nutr. 2001, 86: 515-9.PubMedGoogle Scholar
  615. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN: Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes. 2002, 51: 174-81.PubMedGoogle Scholar
  616. Ye G, Metreveli NS, Ren J, Epstein PN: Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes. 2003, 52: 777-83.PubMedGoogle Scholar
  617. Cai L, Wang J, Li Y, Sun X, Wang L, Zhou Z, Kang YJ: Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes. 2005, 54: 1829-37.PubMedGoogle Scholar
  618. Islam MS, Loots du T: Diabetes, metallothionein, and zinc interactions: a review. Biofactors. 2007, 29: 203-12.PubMedGoogle Scholar
  619. Li X, Cai L, Feng W: Diabetes and metallothionein. Mini Rev Med Chem. 2007, 7: 761-8.PubMedGoogle Scholar
  620. Zheng Y, Li XK, Wang Y, Cai L: The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. Hemoglobin. 2008, 32: 135-45.PubMedGoogle Scholar
  621. Lee DH, Liu DY, Jacobs DR, Shin HR, Song K, Lee IK, Kim B, Hider RC: Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care. 2006, 29: 1090-5.PubMedGoogle Scholar
  622. Chittum HS, Champney WS: Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells. Curr Microbiol. 1995, 30: 273-9.PubMedGoogle Scholar
  623. Facchini FS, Hua NW, Stoohs RA: Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002, 122: 931-9.PubMedGoogle Scholar
  624. Machado M, Cortez-Pinto H: Nash, insulin resistance and iron. Liver International. 2006, 26: 1159-1162.PubMedGoogle Scholar
  625. Allerson CR, Cazzola M, Rouault TA: Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome. Journal of Biological Chemistry. 1999, 274: 26439-26447.PubMedGoogle Scholar
  626. Beaumont C, Leneuve P, Devaux I, Scoazec JY, Berthier M, Loiseau MN, Grandchamp B, Bonneau D: Mutation in the Iron-Responsive Element of the L-Ferritin Messenger-Rna in a Family with Dominant Hyperferritinemia and Cataract. Nature Genetics. 1995, 11: 444-446.PubMedGoogle Scholar
  627. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome – A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005, 111: 1448-1454.PubMedGoogle Scholar
  628. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet. 2005, 365: 1415-28.PubMedGoogle Scholar
  629. Roberts CK, Barnard RJ: Effects of exercise and diet on chronic disease. J Appl Physiol. 2005, 98: 3-30.PubMedGoogle Scholar
  630. Nicolson GL: Metabolic syndrome and mitochondrial function: Molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. Journal of Cellular Biochemistry. 2007, 100: 1352-1369.PubMedGoogle Scholar
  631. Yudkin JS: Insulin resistance and the metabolic syndrome–or the pitfalls of epidemiology. Diabetologia. 2007, 50: 1576-86.PubMedGoogle Scholar
  632. Jehn M, Clark JM, Guallar E: Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care. 2004, 27: 2422-8.PubMedGoogle Scholar
  633. Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD, Hellerbrand C: Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol. 2006, 154: 333-340.PubMedGoogle Scholar
  634. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, Lotto V, Friso S, Pizzolo F, Corrocher R: Prevalence of body iron excess in the metabolic syndrome. Diabetes Care. 2005, 28: 2061-3.PubMedGoogle Scholar
  635. Choi KM, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH: Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism. 2005, 54: 1510-4.PubMedGoogle Scholar
  636. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005, 16: 2134-2140.PubMedGoogle Scholar
  637. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA: Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol. 2004, 24: 644-9.PubMedGoogle Scholar
  638. Mittra S, Bansal VS, Bhatnagar PK: From a glucocentric to a lipocentric approach towards metabolic syndrome. Drug Discov Today. 2008, 13: 211-8.PubMedGoogle Scholar
  639. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND: Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism. 2006, 55: 928-34.PubMedGoogle Scholar
  640. Booth FW, Gordon SE, Carlson CJ, Hamilton MT: Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol. 2000, 88: 774-87.PubMedGoogle Scholar
  641. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-53.PubMedGoogle Scholar
  642. Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006, 444: 840-6.PubMedGoogle Scholar
  643. Walker CG, Zariwala MG, Holness MJ, Sugden MC: Diet, obesity and diabetes: a current update. Clin Sci (Lond). 2007, 112: 93-111.Google Scholar
  644. Lecube A, Hernandez C, Pelegri D, Simo R: Factors accounting for high ferritin levels in obesity. Int J Obes (Lond). 2008Google Scholar
  645. Fricker J, Lemoel G, Apfelbaum M: Obesity and iron status in menstruating women. Am J Clin Nutrition. 1990, 52: 863-866.Google Scholar
  646. Farahani P, Chiu S, Bowlus CL, Boffelli D, Lee E, Fisler JS, Krauss RM, Warden CH: Obesity in BSB mice is correlated with expression of genes for iron homeostasis and leptin. Obesity Research. 2004, 12: 191-204.PubMedGoogle Scholar
  647. Das UN: Is obesity an inflammatory condition?. Nutrition. 2001, 17: 953-66.PubMedGoogle Scholar
  648. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002, 324: 127-37.PubMedGoogle Scholar
  649. Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004, 92: 347-55.PubMedGoogle Scholar
  650. Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005, 96: 939-49.PubMedGoogle Scholar
  651. Hukshorn CJ, Lindeman JH, Toet KH, Saris WH, Eilers PH, Westerterp-Plantenga MS, Kooistra T: Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab. 2004, 89: 1773-8.PubMedGoogle Scholar
  652. Toni R, Malaguti A, Castorina S, Roti E, Lechan RM: New paradigms in neuroendocrinology: relationships between obesity, systemic inflammation and the neuroendocrine system. J Endocrinol Invest. 2004, 27: 182-6.PubMedGoogle Scholar
  653. Koh KK, Han SH, Quon MJ: Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005, 46: 1978-85.PubMedGoogle Scholar
  654. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006, 17: 4-12.PubMedGoogle Scholar
  655. Kapiotis S, Holzer G, Schaller G, Haumer M, Widhalm H, Weghuber D, Jilma B, Roggla G, Wolzt M, Widhalm K, Wagner OF: A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol. 2006, 26: 2541-6.PubMedGoogle Scholar
  656. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006, 6: 772-83.PubMedGoogle Scholar
  657. Vincent HK, Taylor AG: Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2006, 30: 400-18.Google Scholar
  658. Wang B, Trayhurn P: Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch. 2006, 452: 418-27.PubMedGoogle Scholar
  659. Chandalia M, Abate N: Metabolic complications of obesity: inflated or inflamed?. J Diabetes Complications. 2007, 21: 128-36.PubMedGoogle Scholar
  660. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007, 117: 175-84.PubMedPubMed CentralGoogle Scholar
  661. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, Macneil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, Leonardson A, Castellini LW, Wang S, Champy MF, Zhang B, Emilsson V, Doss S, Ghazalpour A, Horvath S, Drake TA, Lusis AJ, Schadt EE: Variations in DNA elucidate molecular networks that cause disease. Nature. 2008, 452: 429-435.PubMedPubMed CentralGoogle Scholar
  662. Chung J, Nguyen AK, Henstridge DC, Holmes AG, Chan MH, Mesa JL, Lancaster GI, Southgate RJ, Bruce CR, Duffy SJ, Horvath I, Mestril R, Watt MJ, Hooper PL, Kingwell BA, Vigh L, Hevener A, Febbraio MA: HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA. 2008, 105: 1739-44.PubMedPubMed CentralGoogle Scholar
  663. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S, Mouy M, Steinthorsdottir V, Eiriksdottir GH, Bjornsdottir G, Reynisdottir I, Gudbjartsson D, Helgadottir A, Jonasdottir A, Jonasdottir A, Styrkarsdottir U, Gretarsdottir S, Magnusson KP, Stefansson H, Fossdal R, Kristjansson K, Gislason HG, Stefansson T, Leifsson BG, Thorsteinsdottir U, Lamb JR, Gulcher JR, Reitman ML, Kong A, Schadt EE, Stefansson K: Genetics of gene expression and its effect on disease. Nature. 2008Google Scholar
  664. Wärnberg J, Marcos A: Low-grade inflammation and the metabolic syndrome in children and adolescents. Curr Opin Lipidol. 2008, 19: 11-5.PubMedGoogle Scholar
  665. Rajala MW, Scherer PE: Minireview: The adipocyte–at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003, 144: 3765-73.PubMedGoogle Scholar
  666. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C: Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004, 12: 962-71.PubMedGoogle Scholar
  667. Arner P: Insulin resistance in type 2 diabetes – role of the adipokines. Curr Mol Med. 2005, 5: 333-9.PubMedGoogle Scholar
  668. Hutley L, Prins JB: Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005, 330: 280-9.PubMedGoogle Scholar
  669. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C: Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res. 2005, 126: 121-9.PubMedGoogle Scholar
  670. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005, 288: H2031-41.PubMedGoogle Scholar
  671. Rosen ED, Spiegelman BM: Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006, 444: 847-53.PubMedPubMed CentralGoogle Scholar
  672. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW: Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res. 2007, 100: 1589-96.PubMedGoogle Scholar
  673. Shah PK: Innate immune pathway links obesity to insulin resistance. Circ Res. 2007, 100: 1531-3.PubMedGoogle Scholar
  674. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004, 114: 1752-61.PubMedPubMed CentralGoogle Scholar
  675. Keaney JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ: Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003, 23: 434-9.PubMedGoogle Scholar
  676. Higdon JV, Frei B: Obesity and oxidative stress: a direct link to CVD?. Arterioscler Thromb Vasc Biol. 2003, 23: 365-7.PubMedGoogle Scholar
  677. Whitworth JA: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003, 21: 1983-92.PubMedGoogle Scholar
  678. Tuder RM, Voelkel NF: Pulmonary hypertension and inflammation. J Lab Clin Med. 1998, 132: 16-24.PubMedGoogle Scholar
  679. Intengan HD, Schiffrin EL: Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001, 38: 581-7.PubMedGoogle Scholar
  680. Grundy SM: Inflammation, hypertension, and the metabolic syndrome. JAMA. 2003, 290: 3000-2.PubMedGoogle Scholar
  681. Virdis A, Schiffrin EL: Vascular inflammation: a role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens. 2003, 12: 181-7.PubMedGoogle Scholar
  682. Boos CJ, Lip GY: Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension?. J Hum Hypertens. 2005, 19: 511-3.PubMedGoogle Scholar
  683. Varughese GI, Lip GY: Hypertension in patients with type-II diabetes: relation to urinary albumin excretion, endothelial function and inflammation. J Hum Hypertens. 2005, 19: 421-4.PubMedGoogle Scholar
  684. Li JJ: Inflammation in hypertension: primary evidence. Chin Med J (Engl). 2006, 119: 1215-21.Google Scholar
  685. Savoia C, Schiffrin EL: Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006, 15: 152-8.PubMedGoogle Scholar
  686. Savoia C, Schiffrin EL: Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond). 2007, 112: 375-84.Google Scholar
  687. Kannel WB, Brand N, Skinner JJ, Dawber TR, McNamara PM: The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967, 67: 48-59.PubMedGoogle Scholar
  688. Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG: State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension. 1999, 33: 537-41.PubMedGoogle Scholar
  689. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K: Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000, 105: 1243-52.PubMedPubMed CentralGoogle Scholar
  690. Hall JE: The kidney, hypertension, and obesity. Hypertension. 2003, 41: 625-33.PubMedGoogle Scholar
  691. Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N: The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008, 7: 10.PubMedPubMed CentralGoogle Scholar
  692. Vaziri ND, Rodriguez-Iturbe B: Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006, 2: 582-93.PubMedGoogle Scholar
  693. Yakobson MG, Antonov AR, Golovatyuk AV, Efremov AV, Markel AL, Yakobson GS: Iron content and parameters of blood antioxidant activity in rats with hereditary arterial hypertension during experimental myocardial infarction. Bull Exp Biol Med. 2001, 132: 1041-4.PubMedGoogle Scholar
  694. Peterson JR, Sharma RV, Davisson RL: Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep. 2006, 8: 232-41.PubMedGoogle Scholar
  695. Sullivan JL: Iron and the sex difference in heart-disease risk. Lancet. 1981, 1: 1293-1294.PubMedGoogle Scholar
  696. Sullivan JL: Misconceptions in the debate on the iron hypothesis. Journal of Nutritional Biochemistry. 2001, 12: 33-37.PubMedGoogle Scholar
  697. Sullivan JL: Stored iron and vascular reactivity. Arteriosclerosis Thrombosis and Vascular Biology. 2005, 25: 1532-1535.Google Scholar
  698. Sullivan JL: The big idea: the coxib crisis iron, aspirin and heart disease risk revisited. J R Soc Med. 2007, 100: 346-9.PubMedPubMed CentralGoogle Scholar
  699. Meyers DG: The iron hypothesis: does iron play a role in atherosclerosis?. Transfusion. 2000, 40: 1023-1029.PubMedGoogle Scholar
  700. Yuan XM, Li W: The iron hypothesis of atherosclerosis and its clinical impact. Ann Med. 2003, 35: 578-91.PubMedGoogle Scholar
  701. Zheng H, Dimayuga C, Hudaihed A, Katz SD: Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol. 2002, 22: E15-8.PubMedGoogle Scholar
  702. Zheng H, Huang X, Zhang Q, Katz SD: Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int. 2006, 69: 679-84.PubMedPubMed CentralGoogle Scholar
  703. Sullivan JL: Is homocysteine an iron-dependent cardiovascular risk factor?. Kidney Int. 2006, 69: 642-4.PubMedGoogle Scholar
  704. Clarke R: Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med. 2005, 5: 215-22.PubMedGoogle Scholar
  705. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT: Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998, 97: 1461-6.PubMedGoogle Scholar
  706. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003, 108: 2154-69.PubMedGoogle Scholar
  707. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004, 65: 1009-16.PubMedGoogle Scholar
  708. Vaziri ND: Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004, 13: 93-9.PubMedGoogle Scholar
  709. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003, 64: 610-5.PubMedGoogle Scholar
  710. Smith JK, Carden DL, Grisham MB, Granger DN, Korthuis RJ: Role of iron in postischemic microvascular injury. Am J Physiol. 1989, 256: H1472-7.PubMedGoogle Scholar
  711. Kukreja RC, Hess ML: The oxygen free radical system: from equations through membrane protein interactions to cardiovascular injury and protection. Cardiovasc Res. 1992, 26: 641-655.PubMedGoogle Scholar
  712. Lesnefsky E, Ye J: Exogenous intracellular, but not extracellular, iron augments myocardial reperfusion injury. Amer J Physiol. 1994, 266: H384-H392.PubMedGoogle Scholar
  713. Berenshtein E, Mayer B, Goldberg C, Kitrossky N, Chevion M: Patterns of mobilization of copper and iron following myocardial ischemia: Possible predictive criteria for tissue injury. J Mol Cell Cardiol. 1997, 29: 3025-3034.PubMedGoogle Scholar
  714. Horwitz LD, Sherman NA, Kong YN, Pike AW, Gobin J, Fennessey PV, Horwitz MA: Lipophilic siderophores Mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc Natl Acad Sci. 1998, 95: 5263-5268.PubMedPubMed CentralGoogle Scholar
  715. Horwitz LD, Rosenthal EA: Iron-mediated cardiovascular injury. Vasc Med. 1999, 4: 93-9.PubMedGoogle Scholar
  716. Pucheu S, Coudray C, Tresallet N, Favier A, Deleiris J: Effect of iron overload in the isolated ischemic and reperfused rat heart. Cardiovascular Drugs and Therapy. 1993, 7: 701-711.PubMedGoogle Scholar
  717. Amersi F, Dulkanchainun T, Nelson SK, Farmer DG, Kato H, Zaky J, Melinek J, Shaw GD, Kupiec-Weglinski JW, Horwitz LD, Horwitz MA, Busuttil RW: Novel iron chelator in combination with a P-selectin antagonist prevents ischemia/reperfusion injury in a rat liver model. Transplantation. 2001, 71: 112-118.PubMedGoogle Scholar
  718. Mamtani M, Kulkarni H: Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol. 2008, 141: 882-90.PubMedGoogle Scholar
  719. Ravati A, Ahlemeyer B, Becker A, Klumpp S, Krieglstein J: Preconditioning-induced neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor-kappa B. Journal of Neurochemistry. 2001, 78: 909-919.PubMedGoogle Scholar
  720. Berenshtein E, Vaisman B, Goldberg-Langerman C, Kitrossky N, Konijn AM, Chevion M: Roles of ferritin and iron in ischemic preconditioning of the heart. Mol Cell Biochem. 2002, 234: 283-292.PubMedGoogle Scholar
  721. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. ProcNatl Acad Sci. 2003, 100: 4802-4806.Google Scholar
  722. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003, 112: 999-1007.PubMedPubMed CentralGoogle Scholar
  723. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U: Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation. 2004, 110: 2175-9.PubMedGoogle Scholar
  724. Reyes AJ: Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003, 17: 397-414.PubMedGoogle Scholar
  725. Dunn WB, Broadhurst DI, Sasalu D, Buch M, McDowell G, Spasic I, Ellis DI, Brooks N, Kell DB, Neyses L: Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics. 2007, 3: 413-426.Google Scholar
  726. Hokamaki J, Kawano H, Yoshimura M, Soejima H, Miyamoto S, Kajiwara I, Kojima S, Sakamoto T, Sugiyama S, Hirai N, Shimomura H, Nagayoshi Y, Tsujita K, Shioji I, Sasaki S, Ogawa H: Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol. 2004, 43: 1880-5.PubMedGoogle Scholar
  727. Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003, 41: 1933-9.PubMedGoogle Scholar
  728. Felker GM, Adams KF, Gattis WA, O'Connor CM: Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004, 44: 959-66.PubMedGoogle Scholar
  729. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006, 48: 1225-7.PubMedGoogle Scholar
  730. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med. 2005, 352: 1011-23.PubMedGoogle Scholar
  731. Kunsch C, Medford RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999, 85: 753-66.PubMedGoogle Scholar
  732. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med. 1999, 340: 115-26.PubMedGoogle Scholar
  733. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res. 2001, 89: 763-71.PubMedGoogle Scholar
  734. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001, 21: 1876-90.PubMedGoogle Scholar
  735. Forrester JS: Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med. 2002, 137: 823-33.PubMedGoogle Scholar
  736. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62: 1524-38.PubMedGoogle Scholar
  737. Libby P: Inflammation in atherosclerosis. Nature. 2002, 420: 868-74.PubMedGoogle Scholar
  738. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-43.PubMedGoogle Scholar
  739. Young JL, Libby P, Schonbeck U: Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost. 2002, 88: 554-67.PubMedGoogle Scholar
  740. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL: Innate and acquired immunity in atherogenesis. Nat Med. 2002, 8: 1218-26.PubMedGoogle Scholar
  741. Altman R: Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thromb J. 2003, 1: 4.PubMedPubMed CentralGoogle Scholar
  742. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M: Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004, 350: 29-37.PubMedGoogle Scholar
  743. Forrester JS: Common ancestors: chronic progressive diseases have the same pathogenesis. Clin Cardiol. 2004, 27: 186-90.PubMedGoogle Scholar
  744. Paoletti R, Gotto AM, Hajjar DP: Inflammation in atherosclerosis and implications for therapy. Circulation. 2004, 109: III20-6.PubMedGoogle Scholar
  745. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL: Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004, 109 (Suppl 1): 6-19.Google Scholar
  746. van Oostrom AJ, van Wijk J, Cabezas MC: Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs. 2004, 64 (Suppl 2): 19-41.PubMedGoogle Scholar
  747. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation. 2004, 109: II2-10.PubMedGoogle Scholar
  748. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352: 1685-95.PubMedGoogle Scholar
  749. Madamanchi NR, Hakim ZS, Runge MS: Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost. 2005, 3: 254-67.PubMedGoogle Scholar
  750. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005, 25: 29-38.PubMedGoogle Scholar
  751. Mullenix PS, Andersen CA, Starnes BW: Atherosclerosis as inflammation. Ann Vasc Surg. 2005, 19: 130-8.PubMedGoogle Scholar
  752. Nigro J, Osman N, Dart AM, Little PJ: Insulin resistance and atherosclerosis. Endocr Rev. 2006, 27: 242-59.PubMedGoogle Scholar
  753. Taqueti VR, Mitchell RN, Lichtman AH: Protecting the pump: controlling myocardial inflammatory responses. Annu Rev Physiol. 2006, 68: 67-95.PubMedGoogle Scholar
  754. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006, 86: 515-81.PubMed